Valuing a reduction in the risk of asthma

A large scale multi-country stated preference approach

OECD ENVIRONMENT WORKING PAPERS NO. 218

Gildas Appéré
Damien Dussaux
Alan Krupnick
Muriel Travers

OECD
BETTER POLICIES FOR BETTER LIVES

Organisation for Economic Co-operation and Development

ENV/WKP(2023)10

Unclassified

English - Or. English

1 June 2023

ENVIRONMENT DIRECTORATE

Valuing a reduction in the risk and severity of asthma

A large scale multi-country stated preference approach

Environment Working Paper No. 218

By Gildas Appéré (1), Damien Dussaux (2), Alan Krupnick (3), Muriel Travers (4)

1) OECD Environment Directorate
2) Université d'Angers
3) Resource For the Future
4) Université de Nantes

Authorised for publication by Jo Tyndall, Director, Environment Directorate.

Keywords: asthma, health risk, economic valuation, health valuation, morbidity valuation, monetised benefits, chemicals regulation, non-market valuation, stated preferences, surveys, willingness-to-pay, value of a statistical case.

JEL codes: D61, I18, J17, K32, Q51, Q53, Q58

OECD Environment Working Papers are available at www.oecd.org/environment/workingpapers.htm

Damien Dussaux (Damien.Dussaux@oecd.org)

JT03520453

OECD ENVIRONMENT WORKING PAPERS

OECD Working Papers should not be reported as representing the official views of the OECD or of its member countries. The opinions expressed and arguments employed are those of the author(s). Working Papers describe preliminary results or research in progress by the author(s) and are published to stimulate discussion on a broad range of issues on which the OECD works.

This series is designed to make available to a wider readership selected studies on environmental issues prepared for use within the OECD. Authorship is usually collective, but principal author(s) are named. The papers are generally available only in their original language – English or French – with a summary in the other language.

Comments on Working Papers are welcomed, and may be sent to:

OECD Environment Directorate

2 rue André-Pascal, 75775 Paris Cedex 16, France

or by email: *env.contact@oecd.org*

OECD Environment Working Papers are published on
www.oecd.org/environment/workingpapers.htm as well as
on the OECD iLibrary (www.oecdilibrary.org)

The statistical data for Israel are supplied by and under the responsibility of the relevant Israeli authorities. The use of such data by the OECD is without prejudice to the status of the Golan Heights, East Jerusalem and Israeli settlements in the West Bank under the terms of international law.

Note by Republic of Türkiye: The information in this document with reference to "Cyprus" relates to the southern part of the Island. There is no single authority representing both Turkish and Greek Cypriot people on the Island. Türkiye recognises the Turkish Republic of Northern Cyprus (TRNC). Until a lasting and equitable solution is found within the context of the United Nations, Türkiye shall preserve its position concerning the "Cyprus issue".

Note by all the European Union Member States of the OECD and the European Union: The Republic of Cyprus is recognised by all members of the United Nations with the exception of Turkey. The information in this document relates to the area under the effective control of the Government of the Republic of Cyprus.

Abstract

Asthma is a non-communicable and non-curable lung disease that affects one in ten children and four in a hundred adults worldwide and that is associated with an array of environmental contaminants and chemicals. Many of these hazards are subject to regulation, or may be considered for regulation, in order to reduce exposures and prevent human health risks. However, valuation estimates for a reduction in the risk and severity of asthma that can be used in cost-benefit analyses are few, particularly willingness-to-pay estimates. In particular, the available information on willingness-to-pay (WTP) to avoid asthma or reduce its severity is incomplete and does not provide estimates compatible with welfare economic theory. This paper is part of the series of large scale WTP studies resulting from the Surveys to elicit Willingness to pay to Avoid Chemicals related negative Health Effects (SWACHE) project that intends to improve the basis for doing cost benefit analyses of chemicals management options and environmental policies in general. The present paper offers values suitable for use in cost-benefit analyses of the willingness to pay for reduced severity of asthma in adults and children and in reduced probability of getting asthma for these two population groups, all in the context of reducing chemical exposures, and covering populations in seven OECD countries: Canada, Czech Republic, France, Poland, Sweden, the United Kingdom and the United States. This paper applies two stated preference methods: the contingent valuation methods for eliciting willingness to pay (WTP) for reduced asthma severity and choice experiments for eliciting WTP for reduced probability of getting asthma of various severities. The context for such elicitations was a set of household products that contain fewer hazardous chemicals than what is currently available in supermarkets but are more expensive.

Asthma can be classified in five severity steps: mild, mild plus, moderate, moderate plus and severe depending on the intensity and frequency of symptoms, their impacts on the quality of life and the risk of hospitalisation and complications. The study finds that the WTP for reducing adult asthma severity by one step, e.g. from “moderate plus” to “moderate”, is USD_{2022} Purchasing Power Parity-adjusted 529 per year on average The parental WTP for reducing asthma severity in their children is on average 1.8 times higher than their WTP for themselves at USD_{2022} 948 per year. WTP for a reduction in asthma severity varies between USD_{2022} PPP 430 per year for Canada and USD_{2022} PPP 770 per year for Sweden for adult asthma, and between USD_{2022} PPP 740 for the United Kingdom and USD_{2022} PPP 1 300 for the United States for childhood asthma. The mean Value of a Statistical Case (VSC) of adult asthma which would be applied to predictions of new cases of asthma avoided by a regulation equals USD_{2022} 280 000 while the mean VSC of childhood asthma equals USD_{2022} 430 000. Country-specific VSC of asthma vary between USD_{2022} PPP 200 000 for the United Kingdom and USD_{2022} PPP 370 000 for Poland in the case of adult asthma and vary between USD_{2022} PPP 350 800 for Canada and USD_{2022} PPP 610 000 for the United States in the case of childhood asthma.

Keywords: asthma, health risk, economic valuation, health valuation, morbidity valuation, monetised benefits, chemicals regulation, non-market valuation, stated preferences, surveys, willingness-to-pay, value of a statistical case.

JEL Codes: D61, I18, J17, K32, Q51, Q53, Q58

Résumé

L'asthme est une maladie pulmonaire non transmissible et non curable qui touche un enfant sur dix et quatre adultes sur cent dans le monde et qui est associée à toute une série de contaminants présents dans l'environnement et de composés chimiques. Nombre de ces composés font l'objet d'une réglementation, ou sont susceptibles d'être réglementés, afin de réduire les expositions et de prévenir les risques pour la santé humaine. Toutefois, les estimations de la valorisation d'une réduction du risque et de la sévérité de l'asthme qui peuvent être utilisées dans les analyses coûts- bénéfices sont peu nombreuses, en particulier les estimations de consentement à payer. En particulier, les informations disponibles sur le consentement à payer (CAP) pour éviter l'asthme ou en réduire la sévérité sont incomplètes et ne fournissent pas d'estimations compatibles avec la théorie de l'économie du bien-être. Ce document fait partie d'une série d'études portant sur le consentement à payer et réalisées à grande échelle dans le cadre du projet SWACHE (Surveys to elicit Willingness to pay to Avoid Chemicals related negative Health Effects). Ce projet vise à améliorer la réalisation des analyses coûts-bénéfices des options de gestion des produits et composés chimiques et des politiques environnementales en général. Le présent document propose des valeurs, susceptibles d'être utilisées dans des analyses coûts-bénéfices, correspondant au consentement à payer pour une réduction de la sévérité de l'asthme chez les adultes et les enfants et pour une réduction de la probabilité d'être atteint d'asthme pour ces deux groupes de population. Ces valorisations sont effectuées dans le contexte d'une réduction de l'exposition aux produits et composés chimiques, et couvrent les populations de sept pays de l'OCDE: Canada, République tchèque, France, Pologne, Suède, Royaume-Uni et États-Unis. Ce document applique deux méthodes de préférences déclarées : les méthodes d'évaluation contingente pour obtenir le consentement à payer (CAP) pour une réduction de la sévérité de l'asthme et les expériences de choix pour obtenir le CAP pour une réduction de la probabilité de souffrir d'asthme de différentes sévérités. Le contexte dans lequel se sont déroulées ces valorisations est celui d'un ensemble de produits ménagers contenant moins de substances chimiques dangereuses que les produits actuellement disponibles dans les commerces, mais qui sont plus chers.

L'asthme peut être classé en cinq niveaux de sévérité : léger, léger plus, modéré, modéré plus et sévère, en fonction de l'intensité et de la fréquence des symptômes, de leur impact sur la qualité de vie et du risque d'hospitalisation et de complications. L'étude montre que le CAP pour réduire la sévérité de l'asthme chez l'adulte d'un cran, c'est-à-dire de "modéré plus" à "modéré", est de USD_{2022} 529 par an en moyenne en parité de pouvoir d'achat (PPA). Le consentement des parents à payer pour réduire la sévérité de l'asthme chez leurs enfants est en moyenne 1,8 fois plus élevée que la leur, soit USD2022 PPA 948 par an. Le CAP pour réduire la sévérité de l'asthme varie entre USD_{2022} PPA 430 par an pour le Canada et USD_{2022} PPA 770 par an pour la Suède dans le cas de l'asthme de l'adulte, et entre USD_{2022} PPA 740 pour le Royaume-Uni et USD_{2022} PPA 1 300 pour les États-Unis dans le cas de l'asthme de l'enfant. La valeur d'un cas statistique (VCS) d'asthme de l'adulte moyenne qui serait appliquée aux prévisions de nouveaux cas d'asthme évités par une réglementation est de USD_{2022} PPA 280 000, tandis que la VCS d'asthme de l'enfant moyenne est de USD_{2022} PPA 430 000. Les VCS d'asthme par pays varient entre USD_{2022} PPA 200 000 pour le Royaume-Uni et USD_{2022} PPA 370 000 pour la Pologne dans le cas de l'asthme de l'adulte, et entre USD_{2022} PPA 350 800 pour le Canada et USD_{2022} PPA 610 000 pour les États-Unis dans le cas de l'asthme de l'enfant.

Mots-clés : asthme, risque pour la santé humaine, valorisation économique, valorisation de la santé, valorisation de la morbidité, bénéfices monétisés, réglementation des composés chimiques, valorisation non marchande, préférences déclarées, enquêtes, consentement à payer, valeur d'un cas statistique.

Classification JEL : D61, I18, J17, K32, Q51, Q53, Q58

Acknowledgements

The paper was prepared in the context of the SWACHE project by Gildas Appéré, Damien Dussaux, Alan Krupnick and Muriel Travers. This work was undertaken under the guidance of Olof Bystrom, Team Lead at the Environment and Economy Integration Division and Eeva Leinala, Principal Administrator at the Environment, Health and Safety Division at the OECD Environment Directorate. The work benefited from the overall supervision of Shardul Agrawala, Head of the Environment and Economy Integration Division at the OECD Environment Directorate.

The SWACHE project is organised in co-operation between the OECD Working Party on Integrating Environmental and Economic Policies (WPIEEP) and the Working Party on Risk Management (WPRM) and with the support or the SWACHE advisory group including experts in chemicals regulation, toxicology and economic valuation that was set up for this project.

The authors are grateful to delegates of the WPIEEP, delegates of the WPRM and members of the expert advisory group for their helpful comments and valuable feedback. The authors are also thankful to Nicolina Lamhauge of the OECD Secretariat for review of the outputs and communication support. The authors would also like to thank Nils Axel Braathen for the initial coordination of the SWACHE project. Illias Mousse Iye and Ivan Babiy provided editorial assistance and Elizabeth Del Bourgo, Lea Stapper and Clara GaÏda provided communications support.

This paper was co-funded by the European Union. The views expressed herein do not necessarily reflect the official views of the OECD or of the governments of its member countries and can in no way be taken to reflect the official opinion of the European Union.

This paper has also been produced with the financial assistance of Canada, France, the Netherlands, Norway, Poland, Sweden, Switzerland, the United Kingdom and the United States. The authors wish to thank the European Chemicals Agency for its contributions throughout the SWACHE project. The views expressed herein do not necessarily reflect the official views of the OECD or of the governments of its member countries and can in no way be taken to reflect the official opinion of OECD member countries.

Table of contents

Tables

Figures

Boxes

Executive summary

Asthma is a non-communicable lung disease that affects 1 in 10 children and 4 in 100 adults worldwide. Asthmatics regularly experience various symptoms including wheeze, shortness of breath, chest tightness and cough that can in some cases prevent physical activities and sometimes lead to emergency visits and hospitalisations. There is ample evidence suggesting that chemicals increase the risk of an asthma diagnosis and asthma attacks.

OECD countries have laws and regulations to manage the health risks of chemicals by eliminating or reducing exposure. One key challenge for chemicals risk management relates to the monetisation of health benefits expected from actions to curb emissions of and exposure to such substances. Balancing the expected benefits against the costs of regulation is typically done using cost of illness (COI) estimates and willingness-to-pay (WTP) values as inputs to cost-benefit analysis. However, COI estimates alone underestimate the benefits of avoiding negative health outcomes because they do not account for the disutility of the disease unlike WTP estimates of stated preference studies. Moreover, the previous stated preference studies do not directly estimate the WTP to avoid asthma but focus on other pulmonary disease or on the WTP for an asthma cure even though asthma is not curable.

To improve the basis for doing cost benefit analysis of chemicals management options and environmental policies, this paper, reports on a new stated preference study valuing asthma that is part of the series of large scale WTP studies resulting from the Surveys to elicit Willingness to pay to Avoid Chemicals related Health Effects (SWACHE) project. Previous studies rely on small samples and either focus on WTP for a cure asthma, which is unrealistic or on other pulmonary diseases when valuing reduced risk. Moreover, studies deriving VSC of pulmonary diseases are based on methods that are sensitive to the value of a statistical life assumed. Finally, there is a dearth of studies valuing asthma severity reduction and asthma risk reduction for children.

The present paper reports on a new stated preference study that address these issues by estimating four policy relevant values: WTP to reduce asthma severity in adults and in children, the value per statistical case (VSC) of adult asthma and the VSC of childhood asthma. To that end, an online valuation survey was administered to 12 727 respondents from seven OECD countries representative of the respective general populations. The survey asked asthmatic adults (and parents of an asthmatic child) whether they would be willing to pay for a more expensive but safer set of household products over a period of 10 years to ensure a reduction in the severity of their (child's) asthma. The survey also asked non-asthmatic adults (and parents of a non-asthmatic child) whether they would be willing to pay for a more expensive but safer set of household products over a period of 10 years to ensure a reduction in their (their child's) risk to develop asthma.

The WTP values provided in this study are uniquely valuable for socio-economic analysis practitioners and policy makers since they are derived for different countries using the same methodology and are therefore internationally comparable. Furthermore, because the present study is part of the SWACHE project that provides an economic valuation of 10 health effects using the same general approach, the values provided by the present report are also comparable across health effects. This large scale and comprehensive valuation effort, that o our knowledge has not been attempted previously, will facilitate

quantitative analyses of chemicals management options and be helpful in formulating national and regional policy affecting health outcomes.

Asthma can be classified in five severity steps: mild, mild plus, moderate, moderate plus and severe depending on the intensity and frequency of symptoms, their impacts on the quality of life and the risk of hospitalisation and complications. Across the countries surveyed the survey results indicate a mean WTP of USD_{2022} Purchasing Power Parity (PPP) 529 per year over ten years for a one step reduction in adult asthma severity, e.g. from moderate plus to moderate, and a mean WTP of USD_{2022} PPP 529 per year over ten years for a one step reduction in childhood asthma severity. The study also derives country-specific mean WTP values, which vary between USD_{2022} PPP 430 per year for Canada and USD_{2022} PPP 770 per year for Sweden for adult asthma, and between USD_{2022} PPP 740 for the United Kingdom and USD_{2022} PPP 1 300 for the United States for childhood asthma. At the individual level, WTP for reduced severity both in adult and child asthma increases with income, baseline severity, being a male and having another chronic disease.

Across the countries surveyed the results indicate a VSC of adult asthma of USD_{2022} PPP 280 000 and a VSC of childhood asthma of USD_{2022} PPP 430 000, approximately 6 times higher than comparable COI estimates. Therefore, the report demonstrates that relying exclusively on COI estimates significantly underestimates the benefit of reducing asthma risk in cost-benefit analyses. The study also derives country-specific values per statistical case of asthma, which vary between USD_{2022} PPP 200 000 for the United Kingdom and USD_{2022} PPP 370 000 for Poland in the case of adult asthma and vary between USD_{2022} PPP 350 800 for Canada and USD_{2022} PPP 610 000 for the United States in the case of childhood asthma.

Various checks indicate that both the mean and the country-specific estimates derived in the present study are fairly robust towards different modelling, data cleaning and screening choices.

1 Introduction

1.1 Motivation

OECD countries have laws and regulations to manage the risks of chemicals by eliminating or reducing exposure. Examples include the European Union under REACH and the United States under the Lautenberg Chemical Safety Act. As part of these laws and regulations, governments are often required to perform cost-benefit analyses to inform the design of chemicals management options to maximise social welfare. To inform benefit estimates, governments need studies that value the suite of health effects that chemical exposure can cause or exacerbate. Current socio-economic analyses of chemical regulations use values for morbidity impacts that are often incomplete, in most cases covering only lost productivity or cost-of-illness (COI) and that disregard the disutility costs of pain and suffering from the illnesses (Navrud, 2018[1]).[1] Therefore, the benefits of reducing morbidity impacts due to chemical exposures are potentially underestimated in socio-economic analyses.

The only way to capture the full willingness-to-pay (WTP) to avoid illness is to conduct a stated-preference study, i.e., surveys where individuals are asked to report their WTP to reduce chemical pollution or risk or avoid the illness associated with exposure. Contingent valuation methods and discrete choice experiments do just that, and WTP figures based on these methods have been used in assessment efforts (irrespective of the payment vehicle used) (Alberini, 2017[2]). To improve the basis of doing cost benefit analyses of chemicals management options, the OECD coordinated a multi-country project to elicit internationally comparable willingness-to-pay values to avoid negative health endpoints due to chemical exposure, known as the SWACHE project (see Box 1.1 for an overview of the project). This paper provides results on the endpoints related to asthma, including the WTP for reducing the risk of asthma for non-asthmatics and the WTP to reduce asthma severity for asthmatics, covering both adults and children in seven countries, Canada, Czech Republic, France, Poland, Sweden, the United Kingdom and the United States.

Asthma affects people of all ages and has a prevalence estimated to be around 4% for adults and 10% for children worldwide but these figures are probably underestimated due to poor diagnosis in many countries (Global Burden of Disease Collaborative Network, 2021[3]; The Global Asthma Network, 2022[4]). In OECD countries, where data are more reliable, asthma prevalence is higher. For example, asthma prevalence in the United Kingdom and in the United States was around 10% in 2019 (Global Burden of Disease Collaborative Network, 2021[3]). Asthma is a lung disease with both genetic predisposition and environmental causes and exacerbations, such as from allergens, tobacco smoke, chemicals and more conventional air pollutants. Asthma attacks can be mild to severe, characterised by coughing, shortness of breath, wheezing and other respiratory symptoms, and in rare case can lead to death. Asthma attack severity and frequency can be mitigated with medication and avoidance of triggers, while the probability of getting asthma can be lowered by avoiding lung sensitisation agents. It cannot be cured.

[1] Cost-of-illness usually refers to direct medical cost and to indirect cost such as lost earning due to partial incapacity to work normally.

Box 1.1. The OECD SWACHE Project

Chemicals are part of our daily life and must be soundly managed to limit risks to human health and the environment. While countries around the world are setting up legal frameworks to address these risks, the cost of policy inaction is still poorly understood. Assessment of chemicals management options and environmental policies can be considerably improved by better estimating their costs and benefits. The resourcing of national chemicals management programmes also often requires economic justification of the benefits of such investment. However, current socio-economic analyses of chemical regulations use values for morbidity impacts that are often incomplete. In most cases, these values cover only lost productivity, lost earning or cost-of-illness and disregard the disutility costs of pain and suffering from the illnesses (Navrud, 2018[1]).

The OECD project Surveys on Willingness-to-Pay to Avoid Negative Chemicals-Related Health Impacts (SWACHE) brings together expertise on chemical safety and economic analysis to fill this gap. The project aims to establish internationally comparable values for the willingness-to-pay (WTP) to avoid negative health effects due to exposure to chemicals. Such values can be used to demonstrate and measure the economic benefits of minimising the impacts of chemicals on human health. Moreover, by using similar methodologies, survey design, approach to analyse survey data across 10 health impacts and implementing the surveys in parallel in a large number of countries, the SWACHE project offers a unique perspective that make it easier to compare the value of health impacts across health outcomes as well as across countries.

The only way to capture the full WTP to avoid illness is to conduct a stated-preference study, i.e., surveys where individuals are asked to report their WTP to reduce their risk of negative health impacts due to chemicals exposure. Contingent valuation methods and discrete choice experiments do just that, and WTP figures based on these methods have been used in assessment efforts (Alberini, 2017[2]). To derive WTP values, surveys of a large number of citizens of countries have therefore been conducted under the SWACHE project. Particularly, these stated preference surveys provide data that can shed light on the disutility in terms of symptoms and lower quality of life of a given disease or health effect, which is not captured by existing metrics such as those based on the cost of illness.

The SWACHE project is organised in two rounds, each focusing on 5 health effects each. The first round of health effects includes asthma, infertility, IQ loss, serious kidney impairment and very low birth weight. The first round of surveys was implemented in 2022 in at least five countries each where representative samples of at least 1 200 respondents each were collected. Overall, one to five of the surveys were implemented in 22 countries, totalling 46 surveys conducted. Survey responses are empirically analysed to estimate mean WTP for a given reduction in health risk for each country surveyed. The second round of surveys will include hypertension, miscarriage, skin sensitisation, thyroid dysfunction and non-fatal cancer and will be implemented in 2023-2024.

The results of this first round are presented in five working papers, one for each health effect. The research described in individual working papers makes a variety of empirical contributions to health valuation in particular in the context of chemicals exposure, although, by design, the approach was not to break new conceptual, theoretical or econometric ground. Moreover, the comparison of the estimated WTP across health effects and across countries will be carried out in a separate summary paper, which will also provide guidance for the transfer of WTP value over time and to non-surveyed countries.

Epidemiological studies link air pollutants, such as fine particulates (PM2.5) to asthma attacks and to increasing the likelihood of developing asthma. Relevant for this paper, several studies suggest that chemicals in cleaning products can increase the risk of an asthma diagnosis and asthma attacks (Rosenman et al., 2003[5]; Medina-Ramon et al., 2005[6]; Jaakkola and Jaakkola, 2006[7]; Nielsen et al., 2007[8]; Quirce and Barranco, 2010[9]; Zock, Vizcaya and Le Moual, 2010[10]). These studies in turn are used by governments around the world to estimate the effect of reduced air pollution and chemical exposure through policy interventions on reduced asthma prevalence and attacks. A relatively thin literature (discussed below) provides monetary values for avoiding asthma attacks and cases. This paper adds significantly to the latter literature by offering WTP values for asthma suitable for use in cost-benefit analyses (CBA) in the context of reducing chemical exposures and covering populations in seven OECD countries. More specifically, the study provides value of the WTP for reduced severity and frequency of asthma attacks in adults and children (called here reduced severity or RS), and in reduced probability of getting asthma for these two population groups (called here reduced probability or RP).

1.2 Previous work

The relevant literature for this paper provides economic (monetary) values for RS and RP in both adults and, through parental valuation, their children. This literature primarily uses COI methods to track expenses associated with the disease or its attacks. But such measures do not capture the monetised preferences of people for avoiding the disease and its consequences (i.e., they are not "welfare theoretic"). There are two welfare-theoretic approaches: survey-based research (termed stated preference studies) that put people in hypothetical situations to reveal their willingness to pay for health improvements, and revealed preference studies, which infer value from behaviour. Studies valuing asthma in welfare-consistent ways are generally based on stated preference studies, including the study presented in this paper.

1.2.1 Reduced probability (RP) valuation studies

Several studies have estimated the WTP to avoid asthma or reducing its probability in adults. Other studies that have estimated WTP to avoid similar conditions such as chronic bronchitis are also worth reviewing.

Priez and Jeanrenaud (1999[11]) employed a risk-based contingent valuation (CV) method to estimate the value of disutility of chronic bronchitis, a disease that has similar symptoms to asthma but different causes. More specifically, Priez and Jeanrenaud (1999[11]) surveyed 757 people representative of the population of Switzerland and elicited WTP using two methods: a payment card and a bidding game. Using a semi-logarithmic model, they found a mean WTP of CHF 38.5 cents (in CHF 1999) for a reduction of the risk equal to 1 in 100 000 over one year, which results in a value of statistical case of chronic bronchitis equal to CHF_{1999} 38 500.

Viscusi et al. (1991[12]) also valued chronic bronchitis but they used a risk-risk trade-off technique. Combining the observed risk-risk trade-offs with a statistical value of life, the annual value of a case of chronic bronchitis can be derived. Of course, this indirect approach is dependent on the value of a statistical life (VSL) chosen. Their median value was USD_{1991} 457 000 per case avoided. In a similar

vein, Krupnick and Cropper (1992[13]) surveyed relatives of persons with chronic bronchitis and estimated an average statistical case of chronic lung disease of USD_{1992} 1 438 000.[2]

It is instructive to consider the studies used to provide asthma values in government regulatory cost-benefit analyses. For the US Environmental Protection Agency (EPA)'s Regulatory Impact Analyses, the values appear in the BENMAP model and originate with Belova et al. (2020[14]) These are labelled "New Onset Asthma" and are based on the COI over a lifetime of asthma, including productivity loss at work, all discounted at 3%. While these values vary by age, as they should, the differences are insignificant (children showing a lower value per year but have more years with asthma), averaging around USD_{2015} 17 000.

There are some issues with these previous studies. At the highest level, COI estimates are not consistent with welfare economics, as they represent only the medical expenses, not pain and suffering, anxiety and other health outcomes associated with asthma. WTP estimates from stated preference surveys such as the one designed for this paper are more inclusive, although they do leave out expenses that are not explicit in the valuation scenario. Previous studies also generally use small sample sizes and focus solely on adults.

In contrast to earlier studies, the SWACHE project improves the approach by also valuing reductions in the probability of getting asthma (somewhat like Priez and Jeanrenaud (1999[11]) for chronic bronchitis) as well as for different levels of asthma severity. After proper screening, the SWACHE study analyses responses from 769 non-asthmatics per surveyed country who are representative of the general population adults and derives a value of a statistical case (VSC) of adult asthma. In addition, the paper derives a VSC of childhood asthma based on the responses of 222 parents of a non-asthmatic child obtained in each country.

1.2.2 Reduced asthma severity and frequency (RS) valuation studies

To value reduced asthma severity and frequency (RS), some studies use COI approaches and a few studies use stated preference surveys. As an example of the former, Lancsar et al. (2007[15]) interviewed 57 patients for their WTP for relief in different symptom categories. As an example of the latter, Lloyd et al. (2007[16]) surveyed 479 patients for their WTP to avoid asthma attacks and for days without symptoms using a discrete choice experiment (DCE) approach. O'Conor and Blomquist (1997[17]) estimated WTP of asthmatic adults for a set of drugs that have various effectiveness and involved different death risks and find a WTP equal to USD_{1997} 1 500 per year for a certain relief of asthma symptoms.

Similarly, Dickie and Messman (2004[18]) used a stated preference (choice experiment) approach based on 16 illness profiles. Dickie and Messman ask parents their WTP for themselves and for their children. They found that people are willing to pay USD_{2004} 125 to avoid 24 symptom days of mild adult asthma, USD_{2004} 238 to avoid 24 symptom days of mild childhood asthma, USD_{2004} 212 to avoid 24 symptom days of severe adult asthma and USD_{2004} 404 to avoid 24 symptom days of severe childhood asthma.

Lloyd et al. (2007[16]) surveyed a sample of 479 asthmatic patients in total across, the Netherlands, Spain and the United Kingdom. Using DCE, they found that asthma patients are willing to pay EUR_{2007} 94 per month for an asthma cure and EUR_{2007} 78 per month for a fully controlled asthma.

[2] According to the national cancer institute, chronic lung disease is a type of disorder that affects the lungs and other parts of the respiratory system. Types of chronic lung disease include asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, asbestosis, pneumonitis, and other lung conditions.

These previous studies focus on specific symptoms and frequencies while the study presented here elicits WTP to reduce the suite of symptoms associated with a severity level to the next less severe level.

Two other studies compare the current situation for asthma patients to a cure, even though no cure is possible and certainly not from a reduction in chemical exposure. Still this approach is closest to the present study. Blumenschein and Johannesson (1998[19]) used two different CV elicitation formats, the dichotomous choice method and a bidding game, to estimate mean willingness to pay for a cure for asthma from interviewing 69 patients. The mean WTP elicited from the bidding game was USD_{1996} 189 per month, or USD_{1996} 2 268 per year. The mean WTP elicited from the dichotomous choice approach was USD 343 per month, or USD_{1996} 4 116 per year.

The second study of this type, Zillich et al. (2002[20]), estimated the WTP for a cure from 100 asthmatic patients answering a double bounded dichotomous choice (DBDC) question in the United States. Patients were asked is they would pay an extra amount per month for a new treatment that would cure their asthma. They found mean monthly WTP of USD_{2002} 90 for curing mild asthma, USD 131 for curing moderate asthma, USD 331 for curing severe asthma.

Because VSC were previously not available, estimates from asthma COI studies have tended to be the ones used in government cost-benefit analyses. For example, the US EPA's Regulatory Impact Analyses rely on the BENMAP model for valuation. This model features values for several different types of RS endpoints. Two studies are cited for emergency visits costs. One is from Smith et al. (1997[21])) with a cost per visit of USD_{2015} 534 on average. The other is from Stanford et al. (1999[20]) who finds average costs of USD_{2015} 447. Belova et al. (2020[14]) find that asthma-related annual healthcare expenditures equal USD_{2010} 2 000 for asthmatic adults and USD_{2010} 1 200 for asthmatic children. They find that lost annual earnings of adult asthma equals USD_{2010} 2 000 on average across age group and that lost annual earnings for parents of childhood asthma equals USD_{2010} 3 000 on average. Finally, Table H-10 from BENMAP documentation (2022[22]) provides the values available to EPA analysts for their regulatory impact analyses (RIAs). For instance, it provides the value of USD_{2015} 70 for a day with minor restricted activity, which is known as a consequence of mild asthma symptoms.

1.3 Contribution

The research described in this paper makes a variety of empirical contributions to the health valuation literature although the approach was not designed to break new conceptual, theoretical or econometric grounds. Most importantly, this work contributes a consistently estimated welfare economics-based set of unit values for reducing the probability of getting asthma and, for asthmatics, for reducing asthma severity by "one step". An example of a one-step reduction is provided in Figure 2.4 where asthma is reduced from the self-described moderate severity level to "mild plus".[3]

These values were derived for populations in seven OECD countries including Canada, Czech Republic, Poland, Sweden, the United Kingdom and the United States and to both adults (asthmatic and non-asthmatic) and their children (asthmatics and non-asthmatic). As the context is reducing chemical exposure in the home and the payment vehicle is paying more for safer home cleaning and other products (termed SAFETYFIRST products), the resulting values apply to estimating the benefits of regulations to reduce chemical exposures. Nevertheless, these estimates are not only specific to

[3] The description of asthma severity is divided into mild, moderate and severe as described in Figure 2.2. However, in one-on-one tests, it was found that some respondents have trouble believing that buying greener products would reduce their asthma by a full step or, if mild to start, would make their asthma go away. So a finer severity scale was used ranging from very mild to severe, and including mild plus and moderate plus.

chemicals regulation and can be used for economic analysis of any policy that affects the prevalence and severity of this disease.

This paper is organised as follows. Section 2 presents the survey design. Section 3 shows data sources, sample representativeness and key descriptive statistics. The econometric strategy is presented in Section 4 and results are provided in Section 5. Finally, Section 6 provides recommended values for asthma severity and asthma risk to use in policy analysis and Section 7 concludes.

2 Survey design

2.1 Definition and description of asthma relevant to survey design

A general description of asthma was provided in Section 1. This subsection presents issues with asthma relevant to survey design.

Severity (frequency of attacks, severity of attacks, type of symptoms and impacts on daily living). The survey contains information explaining what various levels of severity entail (see subsection 0 on information treatment). This is shown to both asthmatics and non-asthmatics. The former are asked their WTP for a reduction in their own rating of their asthma severity by one step (e.g., from moderate to mild plus); the latter are asked their WTP for a reduction in their probability of getting asthma in total and for different levels of severity.

Groups affected. The population is divided into children and adults and asthmatics and non-asthmatics. The non-asthmatic adults and children are given the same baseline probabilities of getting asthma of different severity levels.

Incidence vs. Prevalence. Incidence is the number of new cases in a given time period and prevalence is the frequency of the disease in the population. Prevalence is reduced by reducing incidence. As an example, in the United States the incidence of childhood asthma in children at risk is 12.5 in 1 000 and the incidence of adult asthma in adults at risk is 4 in 1 000 (Winer et al., 2012[23]). As noted above, prevalence of asthma is about 80 in 1 000 in the US population and approximately the same for children and adults. Because the aim of the study is to elicit the value of a statistical case of asthma, the baseline risk presented to respondents in the survey was based on adult asthma incidence of at-risk adults. This ensures that the presented baseline risk, although overestimated, is a realistic approximation and therefore credible. However, smaller risk values such as 4 in 1 000 are generally more difficult to grasp for most respondents. Therefore, it was decided to present a baseline risk over 10 years equal to 40 in 1 000 or 4% and ask respondent what they are willing to pay per year over 10 years to reduce this risk. The baseline "total" risk is broken down by severity groups (mild, moderate and severe) in the population. Mild asthma is more prevalent than moderate asthma, which is more prevalent than severe asthma.

Duration. As noted, there is no cure for asthma although over time childhood asthma may become asymptomatic and asthma may develop in an adult, even though they were never an asthmatic as a child. In the survey, the baseline risk of developing asthma over a period of 10 years was presented to non-asthmatic adults and parents of non-asthmatic children, and in scenarios, small reductions to that probability if the non-asthmatic uses safer home cleaning and other "SAFETYFIRST" products. Asthma was presented as non-curable lifetime disease. In the survey, asthmatic adults and parents of an asthmatic child were asked their willingness to pay to reduce the severity of their asthma during a period of 10 years after which their severity would go back to its previous severity if they stop using SAFETYFIRST products.

Risk factors. The survey language recognises that chemicals in home products are risk factors for asthma onset and for asthma attacks. Persons buying and using reformulated products are told that these products can reduce their probability of getting the disease or, if they have the disease, its severity. In line with expert views, no scenarios take risks to zero or eliminate attacks for those with asthma, in contrast to some of the literature reviewed above.

2.2 Survey development

2.2.1 Non-asthmatic adults - differences

This branch was different from the asthmatic adults' branch in two main ways. First, the set up was a choice experiment where the respondent was asked to choose among the baseline scenario and two alternative, lower risk scenarios. Because asthma can be mild, moderate or severe, and the expected probabilities of getting asthma with different severities would likely influence WTP, the risks for the different severity levels were included as attributes. Specifically, the observed incidence rates over 10 years in the United States were used to define these three levels of severity for the baseline and reduced those probabilities for the scenarios. The questions were preceded by a practice choice screen, which made it clear, after working extensively with one-on-one interviewees, that the sum of the probabilities across severity levels is equal to the total probability of developing asthma. The choice screen is reproduced below in Table 2.1. Five consecutive choice screens were presented to respondents. Two sets of 5 choices were developed. One of two choice sets was randomly attributed to each non-asthmatic adult. If non-asthmatic adults have children who are not asthmatic, they responded to the discrete choice set that was not attributed to them.

Table 2.1. Example of choice in the discrete choice experiment to elicit WTP to avoid developing asthma

Over the next 10 years, risk of getting	Using original products	Using *SAFETYFIRST* products (Mix B)	Using *SAFETYFIRST* products (Mix C)
Mild asthma	25 in 1 000	**13** in 1 000	**23** in 1 000
Moderate asthma	10 in 1 000	**9** in 1 000	**7** in 1 000
Severe asthma	5 in 1 000	**3** in 1 000	**3** in 1 000
Total risk of getting adult asthma over the next 10 years	40 in 1 000	**25** in 1 000	**33** in 1 000
Added costs of *SAFETYFIRST* products you use for the next 10 years	$ 0	**$ 252 per year over 10 years** (**$ 21** per month over 120 months)	**$ 36 per year over 10 years** (**$ 3** per month over 120 months)
Your choice? (Check one box on this row)			

Because of the use of probabilities, the standard approach to teaching respondents about this concept was introduced at the beginning of this branch using a coin flip, a die cast, a grid with 100 and then 1 000 people in it coloured orange and blue, followed by two risk tests detailed in section 3.2.4.

2.2.2 General SWACHE approach to survey design

This sub-section discusses the survey development process and text of the final asthma survey. All surveys developed in the SWACHE project shared a common approach. As described in Box 2.1, this includes: development of a clear definition and description of the health effect (endpoint) to be valued, a risk reduction mechanism, a payment vehicle and an elicitation method developed in consultation with the SWACHE expert panel, harmonised approaches to risk communication, harmonised background and debriefing questions, and an agreed upon approach to adapting the survey for use in different countries and to pretesting and fielding.

2.2.3 Testing and piloting

Specific to the asthma survey, all the language, concepts, and visual aids were tested in one-on-one interviews administered to non-technical staff members at Resources for the Future (RFF)[4] in the US, then translated into French and piloted via an online survey to 52 adults (and their relatives) affiliated to either University of Angers or University of Nantes. Additional one-on-ones were conducted in both countries.

Late-stage piloting was used to set final cutpoints for bids in the survey seeking approximate equality in the proportion responding to the double-bounded dichotomous choice (DBDC) questions ("No-No", "No-Yes", "Yes-No", "No-No") and minimising "serial status quo responses" to the choice experiment (e.g., respondents making all status quo choices over the five choice questions). More precisely, a first pilot of 150 completed interviews was conducted in the United States and in France, followed by a second pilot in the United Kingdom and in Canada (150 interviews) and then a third pilot in Poland, Czech Republic and Sweden (225 interviews in total). Each pilot included a minimum number of asthmatic respondents to set final cutpoints for bids in the survey.

[4] RFF is an independent, non-profit research institution based in Washington, DC, United States, which mission is to improve environmental, energy, and natural resource decisions through impartial economic research and policy engagement.

Box 2.1. Development of SWACHE survey questionnaires and application of best practices

Each SWACHE survey questionnaire was drafted by a team of authors that includes recognised experts in the field of stated preference surveys related to health impacts as well as practitioners in the socio-economic analysis (SEA) of chemicals management options.

Each survey questionnaire was developed in several steps. First, a description of the health effect (endpoint) was drafted including information about the related quality-of-life health impact, a review of any prior stated preference studies on the same health effect and suggestions for how to characterise the endpoint in a new study. Second, various valuation scenarios were developed describing the target population, the risk reduction mechanism, the payment vehicle and the elicitation method. Third, a complete draft survey questionnaire was developed including the most appropriate valuation scenario.

A steering group of experts including internationally renowned academics, SEA practitioners, regulators and health professionals provided regular feedback throughout the process. The final working papers were reviewed by the expert group as well as by country delegations as per the OECD review process.

All SWACHE survey instruments featured a harmonised introduction that contains language to minimise non-response bias and comply with ethics principles:

> *Welcome!*
>
> *This survey is part of an international initiative coordinated by the Organisation for Economic Co-operation and Development (OECD) that aims to help design better policies.*
>
> *The survey asks for your views about a proposal to reduce the risk of [health effect] due to the exposure to chemicals and chemical products.*
>
> *Please read all the information and answer the questions carefully.* ***There are no right or wrong answers to the questions asked in this survey. It is your honest opinion that matters to us.*** *The survey can be completed on a mobile device, but we recommend doing it on a larger device, such as a tablet, laptop or desktop.*
>
> *We will ask some questions related to your health, habits and attitudes. Rest assured that a "Prefer not to answer" option will be available for you to select, at your discretion.*
>
> *Your answers throughout this survey will be kept* ***confidential****. Participation in the survey is* ***voluntary*** *and you may withdraw consent at any time by writing to support. Before agreeing, please also read this information sheet [hyperlink to information sheet screen].*

The informed consent of all participants to the surveys was collected by the internet panel provider. All survey response data are anonymised and participation in the survey was voluntary. In addition, best practices in terms of safe data storage are applied.

A description of the SWACHE project and the first five draft questionnaires were submitted to an institutional review board, the Inserm Ethics Evaluation Committee (CEEI), for an external, independent ethics review.[5] The submission process included a detailed description of the research project including type of data collected, measures to protect personal data, research objectives, research hypotheses and methodology. CEEI gave a favourable opinion on the project and had no significant concerns.

All survey questionnaires also include language to minimise non-response bias within the questionnaire. For example, the following language reduces the risk of "yea"-sayers:

> ***Please keep these things in mind***
>
> *In surveys such as this one, people sometimes say that they would pay for a reduction in risk even if they cannot afford it.*
>
> *Please treat the following questions as if they were a real-life situation, so that your answers are as accurate as possible.*
>
> *Don't agree to pay an amount that you cannot afford to pay or if you feel that there are more important ways to spend your money.*
>
> *When answering the next questions, please consider:*
>
> *your personal income and savings*
>
> *that the payment would reduce your spending on other things you may value.*

All surveys included harmonised debriefing questions to collect data on predictors of WTP such as income and age but also questions to control for non-response bias in empirical analysis. For instance, respondents were asked how much they agree with the following statements:

- I responded to the survey as I would have done in real life.
- The survey provided me with enough information to make informed choices.
- Did you agree or disagree with the description of [health effect] provided in this survey?

All survey questionnaires included a series of debriefing questions specific to the health effect valued in order to capture potential co-benefits or protests linked to the risk reduction mechanism. These survey specific questions are described in individual working papers.

Finally, all draft surveys questionnaires were tested in at least ten one-on-one interviews with people of various background and characteristics in an English-speaking country and in a non-English speaking country. The survey questionnaires were programmed and extensively tested. The translation into languages of target countries was verified by native speakers. Some surveys benefited from a pre-pilot to further revise the survey questionnaires.

Each survey questionnaire was piloted in all target countries with 50 survey responses per country. The pilots allowed for calibration of the bid levels that were presented to respondents to maximise the even distribution of responses across the four possible outcomes of the double bounded dichotomous choice.

2.3 Survey structure

2.3.1 Introductory statements and questions.

The first section includes an introduction to welcome respondents, provides information on the purpose of the survey, the confidentiality of responses, the voluntary nature of their participation, contact information, and the respondent's informed consent. The second section asks the respondent to describe themselves and their household. All of these questions were standardised for all surveys conducted under the OECD SWACHE project.

[5] See https://www.inserm.fr/en/ethics/ethics-evaluation-committee-ceei-irb/.

2.3.2 Branching questions

Additional questions were added for the asthma survey to determine the sequence of six branches of the survey that the respondent would take. The questions were about whether the respondent had been diagnosed with asthma, whether the respondent had children and whether any of those children had been diagnosed with asthma. The branches are shown in Figure 2.1.

Adults without children receive either the adult asthma section of the survey (A) or the adult non-asthmatic section (B). Adults with children receive A or B, as appropriate, and also receive one of two child sections of the survey – (C) if they had a child with asthma, (D) if they did not. Other things equal, respondents were asked to focus on the youngest child when questions were asked about their children. Information treatment - Asthmatics

Starting with the asthmatic adult branch, the survey defines how severity varies, as in Figure 2.2, and asks the respondent to rate their own asthma severity. Although only three levels are provided in the figure, respondents can also rate their asthma as very mild, mild plus (between mild and moderate) and moderate plus (between moderate and severe) to better capture their own severity.

Figure 2.1. Branching of the SWACHE asthma survey



Source: Authors' own elaboration.

Figure 2.2. Visual description of asthma severity levels



Source: Authors' own elaboration.

2.3.3 Risk reduction mechanism and payment vehicle

The risk reduction mechanism and payment vehicle are introduced next as a new line of household products specially formulated to contain fewer and safer chemicals, called SAFETYFIRST products. To avoid environmental and other health co-benefits identified in one-on-one interviews, the language specifies that SAFETYFIRST products are as effective as the original products, that both sets of products have the same amount and composition of packaging and that the only difference is on the risk of developing asthma (or in other branches, reducing attack severity and frequency). Below is the text and pictures used.

> *Assume that a new line of these common household products – called SAFETYFIRST -- is being developed by all the manufacturers. These products will provide all the benefits of the original products but have been reformulated to contain fewer and safer chemicals than the products you use now. The government has certified that these products work as good as the original products and reduce the risk of developing asthma.*
>
> *Specifically, if you substitute SAFETYFIRST products for the original products you can reduce your risk of developing asthma. However, these SAFETYFIRST products will be more expensive than those you use now (the original products). The amount and composition of packaging is the same for both sets of products. The only difference between original products and SAFETYFIRST products is their effect on the risk of developing asthma.*

Figure 2.3. Picture used to present original vs SAFETYFIRST household products

Notes: Labels on products were translated in each country.
Source: Authors' own elaboration.

2.3.4 Valuation questions set up

The next section used a "cheap talk" script, focused on the budget constraint and the pros and cons of buying the SAFETYFIRST line of products, and attempts to make the hypothetical situation more credible by having the respondent place themselves in a supermarket faced with making choices between the original and SAFETYFIRST products.

> *Below you will be asked to decide whether buying the SAFETYFIRST products is worth the added cost.*
>
> *In making this choice, we want you to consider the following:*
>
> • ***Some people may think a less risky set of products is worth buying, while others may not. We want to get the opinions of all kinds of people.***
>
> • ***How people respond in surveys is often not a reliable indication of how people will actually respond in the marketplace. In a survey, some people ignore the sacrifices they would need to make if their purchases actually meant they would have less money to spend on other things. Please, try to place yourself in the supermarket when making your choices in this survey.***

2.3.5 Valuation questions

For asthmatic adults, the valuation questions are formulated as double-bounded dichotomous choices, as follows. For clarity, the follow-up bid questions and open-ended question about why they made the choice they did is not shown below but were asked to respondents.

> *Please, only consider the benefit in terms of risk reduction for **yourself** when answering the next questions. You will be able to consider other adults and children in your immediate family later.*
>
> *Also, assume that all your financial expenses – medical costs, drugs, etc. – if you did get asthma would be covered by insurance. So, do not think about saving these costs through using SAFETYFIRST products. **Think only about the non-monetary benefits to you: having a lower risk of experiencing all the symptoms, the quality of life effects and other effects listed in the table you read**.*

Figure 2.4. Double bounded dichotomous choice to elicit WTP to reduce asthma severity

The following choice is between *the original products* and a collection (or mix) of various *SAFETYFIRST products* that reduces your asthma severity from Moderate to Mild Plus.

The *SAFETYFIRST* products will cost your household **an additional $144 per year over 10 years. This amount will come directly out of your household budget, so you will have less to spend on other things.** Please assume you will still purchase the same amount of products at the same frequency you did before, for the foreseeable future.

	Buy standard products	**Buy *SAFETYFIRST* products**
The severity of your asthma	Moderate	**Mild plus**
Extra expenditure	$0	**$144 per year over 10 years** (**$12** per month over 120 months)
Which option would you choose?	☐	☐

There are several elements to point out with this text. First, the language used throughout the survey aims to focus people away from valuations for their household and towards valuation for only themselves and (separately) for their youngest child. Thus the $12 per month in figure 2.4 is the WTP of the respondent out of their household budget for reducing their asthma severity. The second issue is to focus the respondent away from any savings in medical expenditures from their asthma being less severe, so that the estimated WTP will capture the utility associated with a reduced severity. This is easier to assume for European respondents as most do not pay out of pocket costs and thus would not think about these savings. However, for countries where patients pay for medical care out of pocket, respondents would think about the savings from reduced asthma severity. Thus, the language telling the respondent to think only of their non-monetary benefits from less severe asthma allows the estimates to be comparable between European countries and other countries. Third, the language stresses the importance that respondents assume they would still buy the same amount of products whether SAFETYFIRST or original products. One-on-one interviews revealed that some people will think they can cut down on these purchases so they can switch to SAFETYFIRST products at no additional cost. This type of thinking would bias WTP estimates downward. This problem was checked by using a debriefing question and respondents could also signal their thinking using the open-ended question following their choice.

Respondents were presented a first bid randomly chosen among 5 potential values. Table 2.2 shows the first bid values presented to respondents by country. To enable the comparison of WTP across countries, these values are the same across countries but they were shown in local currencies. Bid values were converted using Purchasing Power Parity for actual individual consumption provided by the OECD (Section 3.4). The first bid values were tested and updated during survey piloting to aim towards achieving an average of 50% of yes response to the first dichotomous choice. There is a factor two steps between each first bid value to avoid getting too many “yes”-“yes” responses that do not allow to pin down individual WTP. For example, respondents in the United States were presented with first bid values ranging from USD 36 per year to USD 576 USD per year. Bid values were purposely not rounded to give the impression to respondents that the added costs for SAFETYFIRST products were more realistic.

To avoid too many “no”-“no” and “yes”-“yes” responses and tend towards a balance across the four potential outcomes of the dichotomous choice questions, follow up bids were multiplied by 3 when people responded “yes” to the first dichotomous question and multiplied by 1/3 when people responded

"no" to the first dichotomous question. Table 2.3 provides the bid values that were presented to respondents in the United States.

Table 2.2. Bid values for the first dichotomous choice

Canada	Czech Republic	France	Poland	Sweden	United Kingdom	United States
$ 44	444 Kč	25 €	61 zł	kr. 348	£26	$36
$ 89	888 Kč	52 €	120 zł	kr. 696	£54	$72
$ 180	1 776 Kč	103 €	240 zł	kr. 1 380	£108	$144
$ 360	3 552 Kč	204 €	492 zł	kr. 2 772	£216	$288
$ 720	7 116 Kč	408 €	984 zł	kr. 5 544	£432	$576

Note: Bid values as seen by respondents. They were later converted in USD PPP using Purchasing Power Parities for actual individual consumption data for 2019 from the PPPs and exchange rates OECD database. The PPP data was extracted on 22 Feb 2021 08:44 UTC (GMT) from OECD.Stat, but has subsequently been revised. The exact series can be provided upon request.

Table 2.3. Bid values for reduced asthma severity

Bids presented to respondents in the United States, in USD PPP per year

First bid value	Follow up bid if respondent chose "No"	Follow up bid if respondent chose "Yes"
36	12	108
72	24	216
144	48	432
288	96	864
576	192	1 728

2.3.6 Parents of an asthmatic child

This branch was identical to the adult asthmatic branch except for minor changes such as replacing the language so that respondents would think about the non-monetary benefits for their asthmatic child and not for themselves.

2.3.7 Parents of a non-asthmatic child

This branch is substantially identical to the non-asthmatic adults' branch except for some minor wording changes.

2.3.8 Debriefing questions and final questions and information

The debriefing section was identical for all pathways through the survey. It contained questions on respondent: (i) attitudes towards the information provided in the survey e.g. did they believe it or act as if they did, was there enough information to make a choice; (ii) behaviour in answering the choice questions e.g. did the respondent consider the probabilities and the cost, (iii) considerations when answering the choice questions e.g. did the respondent think about financial consequences to his or her wages or medical bills, understand that the payments for SAFETYFIRST products carried indefinitely into the future to gain the added protection; (iv) yea-saying and protests, and (v) attitudes towards chemicals e.g., frequency of exposure and adequacy of government regulation.

The final questions covered the respondent's health status, their socioeconomic characteristics and their experience with COVID-19 following Mourato and Shreedhar (2021[24]). These questions were followed by a statement correcting any wrong impressions the survey may have caused and giving all the facts about the ideas in the survey e.g. there is actually a high degree of uncertainty about the role of chemicals in asthma.

3 Survey data

3.1 Data source and sampling

The survey was administered to a sample drawn from a large panel of individuals, maintained by Ipsos, who volunteer to participate in research surveys. The internet panels used for all SWACHE surveys are described in detail in Box 3.1. The SWACHE expert group and teams of survey authors helped to develop the common protocols that Ipsos would follow.

3.1.1 Data source and quality check

The Asthma Valuation Survey was carried out by Ipsos in seven countries: Canada, the Czech Republic, France, Poland, Sweden, the United Kingdom and the United States. Fieldwork took place between 11 November 2021 and 16 March 2022 (pilot and main stage fieldwork).

The target population for the asthma survey was males and females aged 18 or older. However, asthmatic adults and parents of an asthmatic child were oversampled because the prevalence rate of asthma is low. Oversampling allowed for a sufficiently high number of observations to get satisfactory statistical power for the econometric estimation of the WTP for a reduction in asthma severity in adults and children. Therefore, hard quotas were set for the number of adults who have been diagnosed with asthma by a health care professional (n = 300) and for the number of parents who have asthmatic children (n = 200) for each country.

A total of 17 526 individuals started the survey and 12 727 finished the survey. This is a break-off rate of 27.4%, with a substantial amount of break-off occurring at the risk test questions and less importantly at the various valuation questions.

As noted in Box 3.1, the online survey data were evaluated by Ipsos using automated checks. After these checks, an additional 79 interviews were suspected as unreliable due to having duplicate answers to the open-ended questions or specifying unrealistic numbers of children. In total 601 interviews were removed from the online survey data.

A total of 12 126 interviews were complete and valid, with a minimum of 1 600 in each of the countries surveyed. The target of 1 600 was exceeded due to oversampling to meet the hard quota for the number of parents with asthmatic children. The selection of respondents was based on quotas matching four key demographic characteristics: gender, age group, level of education and geographic region to help ensure representativeness. Additional screening based on speeding and understanding of the probability concept was required and is described in the next section.

Box 3.1. Quality of the internet panels used in SWACHE

The field implementation of the SWACHE surveys was carried out in all surveyed countries by Ipsos European Public Affairs (hereafter Ipsos), selected after a careful call for tender process. Ipsos has significant experience in multi-country projects and maintains panels of respondents in many countries. Fieldwork, pilot and main stage, took place between June 2021 and June 2022 for the first round of surveys. The surveys were conducted via Computer-Assisted Web Interviewing (CAWI). Random samples of at least 1 200 respondents matching the target population were drawn for each country from a high-quality network of online access (non-probability) panels. Some surveys had specific requirements regarding the target population due to the endpoint under consideration. This is elaborated in survey-specific information.

Online panels are databases of potential participants who declare that they will cooperate for future data collection if selected, generally in exchange for a reward or incentive. Loyalty card and subscription databases are included here if there is a continuous relationship with members who understand the commitment asked of them. Ipsos has its own supply of sample through its globally managed i-Say (IIS) panels and some locally owned Ipsos panels. In addition, Ipsos partners with many different types of external suppliers to source sample when needed to fulfil project requirements. This includes other traditional research panels, reward or loyalty communities, intercept or offer wall providers, and sample exchanges. Ipsos can also leverage its Direct-to-Survey channel which accesses respondents directly through social media platforms. To reach respondents, Ipsos has a proprietary project management and workflow system that controls access to their panel assets and where necessary, external respondent sources.

Importantly, Ipsos implements procedures to make sure that respondents to surveys are real, unique, engaged and fresh. To ensure that their respondents are real, i.e. they are who they claim to be, Ipsos uses country geo-IP validation and digital fingerprinting to check if the respondent used a device that is truly located or if it is evading detection and also if the respondent's device has any past history of fraud. These tools used in combination with cookies can make sure that each respondent is unique and has not already accessed the survey. To guarantee respondents are engaged, their survey taking behaviour is evaluated in real time, through standard self-adjusting algorithms involving speeding and straight-lining detection (i.e., always choosing the first (or nth) answer in multiple choice). The worst offenders are automatically removed from the data deliverables and are not counted against quotas. Finally, Ipsos invited members of their panels that were fresh, i.e., that have not taken part in any of the other SWACHE surveys and were not overburdened with surveys in general.

After the main stage was completed, the online survey data were evaluated by Ipsos using several quality markers that feed into an overall quality score for each respondent: survey length and speeding, straight lining and proportion of "don't know" answers.

3.1.2 Representativeness of the samples

Finally, to verify the representativeness of the sample, the achieved quotas were compared to target quotas set for the four groups of interest: (i) asthmatic adults, (ii) parents with an asthmatic child, (iii) non-asthmatic adults and (iv) parents with a non-asthmatic child. Target quotas for non-asthmatic adults were set based on statistics from the general population of each country surveyed. Gender ratio were taken from World Bank (2019[25]). The distribution of ages across four categories (18–29-year-olds, 30–44-year-olds, 45–60-year-olds, and greater than 60 years old was taken from UN data (United Nations Statistics Division, 2021[26]). Data on education come from the OECD data from "Education at a glance: Educational attainment and labour-force status" (OECD, 2020[27]).

Target quotas for asthmatic adults were set using various data on the key demographics of people diagnosed with asthma. For example, 63% of asthmatic adults in the United States are female according to the most recent national asthma data from the Centers for Disease Control and Prevention (CDC) (2020[28]) drawing from 2020 National Health Interview Survey (NHIS) Data. The CDC also provides the distribution by age and education attainment. For all countries, data were available on gender ratio of asthmatics. For 5 countries, the distribution across age categories was also available.[6] The distribution across education attainment was only available for the United States. However, there is no significant difference between asthmatic and non-asthmatic adults in terms of education. Missing target quotas for asthmatic adults were imputed by the target quotas used for the general population.

Target quotas for parents of an asthmatic or non-asthmatic child were set based on statistics on age of parents at birth from Eurostat (2022[29]) and the United Nations Statistics Division (2022[30]). The target quotas for gender ratio and education used for the parents were the same as the general population.

The difference between achieved quotas and target quotas varies across key demographics and groups of respondents. Table 3.1 shows average deviation from target quotas across surveyed countries for each demographic and group of respondents. For non-asthmatic adults, there is little deviation from the target quota meaning that the sample is representative of the general population overall. For other groups of respondents, the deviation is larger but is never very high.

Average deviation from target quotas set for age categories varies from -9.6% to 13.2%. In the sample of asthmatic adults, people aged 30-44 tend to be slightly overrepresented while people aged above 45 tend to be slightly underrepresented. For parents of an asthmatic child, young respondents aged 18-29 tend be somewhat overrepresented while people aged 30-60 are slightly underrepresented. For parents of a non-asthmatic child, people aged 18-29 are marginally overrepresented at the expense of people aged 30-44.

Regarding education quotas, people with low or medium education tend to be somewhat underrepresented in all groups of respondents. This deviation is relatively more important for surveyed parents. This underrepresentation of people with lower education is not specific to this survey. It is notoriously harder to survey people with lower education for several reasons. First, the asthma survey is long due to its complexity and ambition, especially for parents who not only have to provide their own WTP but also their WTP for their child. It took between 15 and 23 minutes on average for respondents to complete the survey depending on which group they were assigned to. The longer the survey, the more likely respondents will leave before finishing the survey. People with lower education tend to leave more often than people with higher education for different reasons. The deviation for gender quotas is less important than the one observed for age or education overall. The largest deviation equal 4.3% for parents of an asthmatic child and 5.3% for asthmatic adults.

[6] Various sources were used to set target quotas for asthmatic adults: Statistics Canada. Table 13-10-0096-08 Asthma, by age group DOI: https://doi.org/10.25318/1310009601-eng; Institute of Health Information and Statistics of the Czech Republic. 6.2.21 Prevalence of asthma (J45 – J46); Santé Publique France citing the study of Delmas et al. (2021[49]); Śliwczyński et al. (2015[50]); Folkhälsomyndigheten,National public health, national and regional results, Diseases and disorders (self-reported) by age, sex and year. Percentage; British Lung Foundation, asthma statistics; Centers for Disease Control and Prevention, national asthma data.

Table 3.1. Average deviation from target quotas across surveyed countries

	Asthmatic adults	Parents of an asthmatic child	Non-asthmatic adults	Parents of non-asthmatic child
Age				
18-29	2.4%	13.2%	-2.2%	5.7%
30-44	12.0%	-6.8%	1.1%	-8.8%
45-60	-4.8%	-6.7%	-0.8%	0.8%
60+	-9.6%	0.3%	1.9%	2.3%
Gender				
Female	-5.3%	-4.3%	0.0%	1.3%
Male	5.3%	4.3%	0.0%	-1.3%
Education				
Low + Medium	-7.6%	-13.2%	-3.5%	-9.1%
High	7.6%	13.2%	3.5%	9.1%

Table 3.2 shows the average absolute deviation from target quotas across key demographics by country and by group of respondents. The deviation from target quotas is higher for asthmatic adults and parents of an asthmatic child. This is explained by the smaller sample size of these two groups but also by the fact that it's more difficult to recruit asthmatic respondents and even more difficult to recruit parents of an asthmatic child. The deviation from target quotas is highest for the United States, France and Poland. Post-stratification weights are used in the estimation of WTP to take these deviations into account.

Table 3.2. Average absolute deviation from target quotas across key demographics

Country	Asthmatic adults	Parents of an asthmatic child	Non-asthmatic adults	Parents of non-asthmatic child	Average
Canada	7.6%	6.7%	6.5%	5.3%	6.5%
Czech Republic	7.6%	11.7%	1.6%	4.2%	6.3%
France	10.6%	11.4%	6.6%	8.1%	9.2%
Poland	5.8%	12.9%	6.8%	7.1%	8.2%
Sweden	7.0%	8.4%	3.2%	4.1%	5.7%
United States	19.3%	17.8%	7.9%	6.3%	12.8%
United Kingdom	5.7%	5.5%	2.0%	7.4%	5.2%
Average	9.1%	10.6%	4.9%	6.1%	

3.2 Screening strategy

The survey builds in a variety of checks that can flag problematic responses for possible deletion or treatment econometrically. Nearly all of these are common to the two major parts of the survey: the estimation of WTP for reduced asthma severity and the WTP for a reduced risk of getting asthma. These checks include: speeders, very slow respondents and debriefing questions. The vast majority of the screening criteria are based on core principles for empirical analysis agreed upon by the SWACHE project (see Box 3.2). For the groups of respondents who were asked their WTP for a reduced risk of getting asthma, three additional screening criteria were applied. First, respondents who failed to respond correctly to the "understanding probabilities" tests were screened out. Second, non-attendant

respondents who indicated that they did not take into account *any* attributes while making their five consecutives choices for the DCE are also screened out. Third, respondents who were part of the pilot are excluded because the parameters of the DCE in the pilot are too different from the final parameters.

Box 3.2. Consistent analysis of survey responses across SWACHE health effects

Each focused on a single health effect, the SWACHE working papers will ultimately feed into an OECD summary paper that will gather the recommended estimates for WTP values and Value of a Statistical Case (VSC) for all endpoints, compare them across countries and offer comprehensive guidance for practical use by practitioners including guidance on benefit transfer that is the transfer of value over time and toward non-surveyed countries. Consequently, the different teams involved in the SWACHE project adopted a similar core strategy on how datasets would be cleaned and analysed empirically to allow the proper comparison of WTP values across countries and endpoints. A series of consensus meetings with the teams of survey authors led to the adoption of a set of Core Principles of Survey Analysis that are applied but adapted, when necessary, to survey specificities and data. As indicated in Box 1.1, the idea is not to break new conceptual, theoretical or econometric ground but set up core principles that are consistent with the economic valuation literature and are widely recognised in the field. These shared principles ensure that all the working papers apply the same empirical strategy in terms of data cleaning, screening of respondents, specification, estimators, robustness checks and guidance on which central WTP or VSC value should be used in regulatory impact analysis. The final version of these Core Principles of Survey Analysis is presented in Annex B.

3.2.1 Very slow respondents

Very slow respondents were identified as taking an inordinately long time to finish the survey and therefore may forget part of it and lose the logic presented. Sometimes, respondents leave the survey to do other things. In the extreme, they may start one day and finish the next. There is no consensus on the definition of a very slow responder. A definition was agreed to be a respondent taking more than 12 hours to complete the survey. 2% of the non-asthmatic adults (182) and 2.3% of non-asthmatic children (61) were screened out as a result of eliminating parents that were determined to be very slow responders. None of the asthmatic adults or parents of an asthmatic child had to be eliminated from the sample.

3.2.2 Speeders

Speeders are respondents who run through the survey so quickly that they couldn't possibly be reading the questions. Speeders cannot provide informed responses so they need to be screened out. Two types of speeders were defined in this analysis. First were speeders who completed the entire survey too quickly. Second were speeders who completed the valuation questions too quickly. Respondents who belong to either of these categories were screened out.

A standard recommendation from Survey Sampling International (2013[31]) and Mitchell (2014[32]) is to filter out respondents that took 48% less time than the median respondent. However, depending on their circumstances, some respondents answered only one section of the survey rather than two – one for themselves and one for their child. Therefore, respondents' completion time was re-computed and the median taken for each of the four valued health effects based on similar sets of survey items. This allows, for example, for the comparison of completion time for childhood asthma risk of non-asthmatic adults to the completion time for childhood asthma risk of asthmatic adults. A unique median per group

was computed for each country to take into account difference in language, IT proficiency, and other cross-country differences. The median values were computed based on the sample that excludes very slow respondents.

The speeder criteria screened out 12.3% of non-asthmatic adults (1 123), 10.2% of non-asthmatic children (270), 15.6% of asthmatic adults (406) and 5.3% of parents of an asthmatic child (75). In an informal literature search of speeding in online surveys, 10% was a common finding (Rao, Wells and Luo, 2014[33]).

3.2.3 Non-attendance of all the attributes of DCE

Following the five consecutive choices in the DCE, non-asthmatic respondents were asked whether they took into account or neglected some of the attributes during their choices. Respondents that indicated they never considered any attribute during their 5 choices were removed from the sample. This criterion screens out 4.5% of non-asthmatic adults (407) and 3.4 % of non-asthmatic children (90).

3.2.4 Not understanding probability

As non-asthmatics are presented with choices about their risk of developing asthma and parents of non-asthmatic children to reduce their child's risk of developing asthma, the concept of probability was introduced at the beginning of the questionnaire. Then, these respondents were asked two questions to test their understanding of probability. The first test question showed two grids, each with 100 persons, with most coloured in blue and a few coloured in orange indicating the probability of getting asthma. The two grids had different numbers of "orange people" and respondents were asked which grid showed the highest number of asthmatics. Figure 3.1 shows the probability test taken by respondents.

Figure 3.1. Question to test respondents understanding of probability using visuals



The second test question was formulated as follows: "Which of these two probabilities (risk) of developing asthma is higher? 40 in 1 000 or 30 in 1 000". The selection criteria used consists of keeping only respondents who passed both tests. This rather strict screening strategy can be justified for two main reasons. First, the initial test measures the ability to understand the concept of probability (from a frequency approach) while the second test measures the ability to read a probability as it is then used

in the Discrete Choice Experiment tables. The second reason is the choice to be strict in deleting respondents who incorrectly miss one test. Since a random response could result in a correct answer, this aimed to minimise risks of falsely accepting responses from an individual that really did not understand probabilities.

This screening criteria exclude 31.6% (2 882) of the non-asthmatic adults and 33% (872) of parents of non-asthmatic children. Most of them failed the first test, which was more difficult. For example, in the case of non-asthmatic adults, 25.6% failed this first test, while 11.2% of them failed the second test. As a consequence, only 5.3% of non-asthmatic adults failed both tests. There is a significant difference at the 1% level of risk in the average risk test failure rate between countries for non-asthmatic adults and for parents of non-asthmatic children. Table 3.3 summarises the difference between the full and screened samples in terms of number of survey responses.

Table 3.3. Full and screened sample composition

	Provided by Ipsos	Very slow Responders	Speeders	Failed probability	Full nonattendance	Final sample
Asthmatic adults	2 600	0	406			2 194
Parents of an asthmatic child	1 414	0	75			1 339
Non-asthmatic adults*	9 132	182	1 123	2 882	407	5 384
Parents of a non-asthmatic child*	2 645	61	270	872	90	1 556

Note: * Observations from the pilot were not used because the discrete choice experiment varied too significantly between the pilot and the main stage. Asthmatics adults and parent of an asthmatic child were not presented a probability test and did not participate in the discrete choice experiment.

3.2.5 Open-ended responses

Respondents had multiple opportunities to give open-ended (OE) answers to explain why they chose to pay for a reduction in asthma severity. The responses to open-ended questions in English and in French from the screened sample were analysed in two steps for Canada, France, the United Kingdom and the United States. First, the number of characters of OE responses were computed to get a sense of how seriously respondents were taking this opportunity. A minimal number of characters typically indicates that the respondent did not care much about providing an open-ended answer.

Second, all of the open-ended responses for adult and childhood asthma severity in English and in French were analysed to find a set of keywords that could indicate a problematic response, such as protest, altruism, people who thought they could save on their current medication and people who would pay anything to reduce their risk even by a small amount.

Table 3.4 provides examples of responses for the different categories for asthmatic adults and parents of an asthmatic child.

For asthmatic adults, 4.3% of responses were related to altruism, 0.8% to protest, 2.4% to people who thought that they would save on asthma medication, and 0.6% related to people saying they would pay anything (Table 3.5). The remaining 91.8% being short, normal or excellent responses.[7] For parents of an asthmatic child, 4.3% of responses were protest, 1.1% related to altruism, 1% related to people

[7] In this context, an excellent response is a response presenting a logical argumentation that proves that the respondent completely understood the trade-off between lower risk and higher cost.

saying they would pay anything and 0.3% who though they could save on asthma medication by choosing reduced asthma severity. The remaining 93.3% being short, normal or well aligned responses.

Overall, there were very few problematic responses to open ended questions. Therefore, respondents were not screened out on this basis. The next section describes how responses to closed-ended debriefing questions were used in the analysis.

Table 3.4. Examples of responses to open-ended from English speaking asthmatic adults and parent of asthmatic child

Type of OE responses	Asthmatic adult	Parent of an asthmatic child
Excellent	I would gladly reduce other "pleasure" spending to spend more on products that would reduce my asthma and give me better health. my health is much more important to me than dining out several time a week.	i would like to try the products but i also cant afford to pay that price every year due to financial issues i have incurred recently.
Altruism	I prefer things that work and are also good for me, my kids and the environment	Very important to reduce a number of people suffering whit this [disease]
Protest	Because I would rather reduce chemical usage and find natural ways to alleviate symptoms of asthma.	I can buy items that are natural DIY cleaning solutions that would be cheaper
Reduce med	If these products are not going to affect me like the regular products do, I will spend less on medications and suffer much less, so it would make sense to try the new products.	$6 per month would be worth the cost of the peace of mind of knowing she is well and possibly can be on less medicine for her asthma. In the long run this will actually save me money because her medicine is more than $6 per month.
Would Pay Anything	Health is wealth and money is nothing	I would I go broke if it meant keeping my children much more healthy

Table 3.5. Share of problematic responses to open-ended for asthmatic adults and children

	Altruism	Protest	Reduce medical cost	Would pay anything
Asthmatic adult	4.3%	0.8%	2.4%	0.6%
Parent of an asthmatic child	1.1%	4.3%	0.3%	1.0%

Note: computed on all responses from Canada, France, the United States and the United Kingdom after the screen out.

3.2.6 Closed-ended debriefing questions

The questionnaire included 14 debriefing questions at the end of the survey. Table 3.6 illustrates the questions for asthmatic adults and parents of an asthmatic child. No respondents were dropped based on their responses to close-ended debriefing question. This avoids being too conservative by preserving degrees of freedom. It also allows keeping a representative sample since responses to these debriefing questions could be correlated with gender, age and education. However, responses to these questions were analysed to check if the results were sensitive to this methodological choice.

Debriefing questions are grouped into three groups – those whose problematic response would lead to an overestimation of WTP e.g. “I would pay anything” … (8 questions), those that would lead to an underestimation, e.g. “I though the probabilities were lower than those presented” (4 questions), and those that were neutral or with an undetermined directional bias e.g. “I did not have enough information

to make an informed choice" (4 questions). The number of overestimating, underestimating, and non-directional problematic responses were computed for each respondent.

Table 3.6. Bias direction of problematic responses to debriefing questions for asthma severity

Debriefing questions	Bias direction of poor responses
Do you understand that to continue to get the benefits you have to keep using the SAFETYFIRST products?	Overestimation if responded "no"
Do you understand that to continue to get the benefits for your child, you have to keep using the SAFETYFIRST products?	Overestimation if responded "no"
I responded to the survey as I would have done in real life. :	Non-directional if responded "disagree"
…think that by reducing your (your child) risk of getting asthma (asthma severity) you also reduced your medical bills.	Overestimation if responded "yes"
…think that by reducing your (your child) risk of getting asthma (asthma severity) you also reduced the risk that your wages decrease because of being sick with asthma {#Q68_insert2}.	Overestimation if responded "yes"
Did you understand that your household would be required to pay the additional amount every month for 10 years if you chose to buy SAFETYFIRST products to reduce the severity of asthma or the risk to develop asthma?	Overestimation if responded "no"
When you chose between the original and SAFETYFIRST products, were you thinking you could just lower consumption of these products to reduce your costs?	Underestimation if responded "yes"
Do you already purchase household products that you feel reduce risks of asthma or its severity?	Underestimation if responded "yes"
Please consider the statement: "I would pay almost anything necessary to improve my children's health even a small amount". Do you…*	Overestimation if responded "agree"
The survey provided me with enough information to make informed choices.	Non-directional if "disagree"
Do you think the survey tried to PUSH you to choose one answer or another, or did it let you freely make up your own mind?	Overestimation if responded "pushed me to choose spending more" Underestimation if responded "pushed me to choose spending less or nothing"
How confident are you that the information that has been provided in this survey is correct?	Non-directional if "not confident"
How confident are you in the ability of experts to provide reliable information?	Non-directional if "not confident"
Regarding the reduction of asthma risks and severity, did you think using the SAFETYFIRST products would…	Overestimation if responded "be more effective than described in the survey" Underestimation if responded "be less effective than described in the survey" or "have no effect on asthma risks or its severity"

Note: *Only parents of an asthmatic child were asked this question.

The utilisation of these variables is illustrated with asthmatic adults and parents of an asthmatic child. For asthmatic adults, 13 debriefing questions were analysed: 4 can indicate poor non-directional responses, 7 help the identification of potential overestimation of WTP and 4 help the identification of potential underestimation of WTP. The frequencies of poor answers to these debriefing questions from asthmatic adults are included in Table 3.7.

Table 3.7. Frequency of poor answers to debriefing questions, asthmatic adults

Number of poor responses	Poor non-directional answers to debrief		Answers potentially indicating overestimation of WTP		Answers potentially indicating underestimation of WTP	
	Number of respondents	Share of respondents	Number of respondents	Share of respondents	Number of respondents	Share of respondents
0	1 755	80.0%	733	33.4%	453	20.6%
1	289	13.2%	826	37.6%	889	40.5%
2	116	5.3%	420	19.1%	758	34.5%
3	22	1.0%	171	7.8%	92	4.2%
4	12	0.5%	42	1.9%	2	0.1%
5	0	0%	2	0.1%	0	0.0%

It was found that 20% of asthmatic adults respond “poorly” at least once to the non-directional debriefs. 77% of asthmatic adults have at least one response that could indicate overestimation of WTP and 79% have at least one response that could indicate underestimation of WTP. However, these high percentages are not necessarily problematic considering the large number of debriefing questions. For example, 826 asthmatic adults responded poorly to only 1 out of the 7 debriefing questions that can help identify overestimation of WTP.

For parents of an asthmatic child, 14 debriefing questions were analysed: 4 can indicate poor non-directional responses, 8 help the identification of potential overestimation of WTP and 4 help the identification of potential underestimation of WTP. The frequencies of poor answers to these debriefing questions from parents of an asthmatic child are included in Table 3.8

It was found that 24% of parents of an asthmatic child respond “poorly” at least once to the non-directional debriefs. However, 91% of them have at least one response that could indicate overestimation of WTP and 84% have at least one response that could indicate underestimation of WTP. Similar to the asthmatic adults, it is not necessarily problematic considering the large number of debriefing questions considered. For example, 62% of parents of an asthmatic child responded poorly to less than 3 out of the 8 debriefing questions that can help identifying overestimation of WTP. Comparing with the frequencies reported in Table 3.7 for asthmatic adults, it was found that there are slightly more poor responses for parents of an asthmatic child.

To make sure that these “poor” answers do not unduly influence the results, robustness checks were performed, where the model was augmented to include the number of poor responses in these three categories: non-directional, overestimation, underestimation as additional control variables.

Table 3.8. Frequency of poor answers to debriefing questions, parents of an asthmatic child

Number of poor responses	Poor non-directional answers to debrief		Answers potentially indicating overestimation of WTP		Answers potentially indicating underestimation of WTP	
	Number of respondents	Share of respondents	Number of respondents	Share of respondents	Number of respondents	Share of respondents
0	1 018	76.0%	117	8.7%	218	16.3%
1	199	14.9%	324	24.2%	493	36.8%
2	84	6.3%	385	28.8%	563	42.0%
3	23	1.7%	300	22.4%	63	4.7%
4	15	1.1%	158	11.8%	2	0.1%
5	0	0.0%	55	4.1%	0	0.0%

3.3 Key descriptive statistics

3.3.1 Composition of the final sample

After screening, there are 2 194 asthmatic respondents, between 288 and 343 per country (Table 3.9). There are fewer parents of an asthmatic child, 1 339 in total, between 188 and 194 per country. The final sample includes 5 384 non-asthmatic adults, between 620 and 849 per country, and 1 556 parents of non-asthmatic children, from 168 to 321 per country.

3.3.2 Asthmatic respondents

After applying the screening criteria described in the previous section, the number of asthmatic adults is 2 194, i.e., 85% of the initial sample and the number of parents of an asthmatic child is 1 339, i.e., 95% of the initial database. Table A.1 and Table A.2 of Annex A show the respective descriptive statistics for the key demographics by country.

Table 3.9. Number of respondents in the screened sample by country and by group

	Asthmatic adults	Parents of an asthmatic child	Non-asthmatic adults	Parents of non-asthmatic children
Canada	288	188	849	168
Czech Republic	343	192	620	248
France	294	192	818	227
Poland	293	188	783	321
Sweden	334	193	793	190
United Kingdom	323	194	819	205
United States	319	192	702	197
All countries	2 194	1 339	5 384	1 556

3.3.3 Non-asthmatic respondents

After applying the screening criteria described in the previous section, the number of non-asthmatic adults is 5 384, i.e., 59% of the initial sample without the pilot surveys, and the number of parents of non-asthmatic children is 1 556, i.e., 58.8% of the initial sample excluding respondents included in the pilot surveys.

A large majority of non-asthmatic adults (70.5%) do not have children under 18 living with them (Table A.3). Respondents from Czech Republic account for the lowest share of respondents (11.5%) because many are screened out due to the risk tests criterion. The percentage of adults aged between 18 and 29 is higher in Poland reflecting a younger population. The percentage of non-asthmatic adults surveyed with a low level of education is much higher in the Czech Republic than in other countries (Table A.4). This difference is only due to the way education achievement have been classified for the Czech Republic and not due to lower education achievement in the Czech Republic.

A very large majority of parents of non-asthmatic children are themselves non-asthmatic (86.4%) (Table A.5). Regarding the parents of non-asthmatic children, the proportion of people over 60 is (as expected) much lower compared to that of non-asthmatic adults (Table A.6).

Finally, the issue of serial status quo is explored for choice experiments. A serial status quo respondent is defined as a respondent who for their 5 discrete choices systematically chooses the status quo, i.e., the original products. While such responses may be legitimate, there is reason to question them. The share of serial status quo respondents is on average 21.5% for adults and 17.8% for children (Table A.7). These magnitudes are close to those observed in the literature. In terms of countries, important differences emerge, especially between respondents from the United Kingdom and those from the Czech Republic There are 11.6% of serial status quo adults in the Czech Republic sample and 33.1% for the United Kingdom. There are 13.3% of serial status quo respondents for parents of non-asthmatic children in the Czech Republic sample against 24.9% in the United Kingdom.

3.4 Purchasing power parity adjustments

When responding to the surveys, people from various countries saw the extra cost of the set of SAFETYFIRST products and ranges of income in the currency of the country they live in. These amounts where derived from the set of bid values expressed in USD using data from 2019 on Purchasing Power Parities for actual individual consumption provided by the OECD. For the econometric analyses detailed below, all bid levels and incomes were converted to USD PPP. For clarity, USD PPP is simply written USD in the next sections of this paper. Tables of recommended values at the end of the paper are both in USD and the local currency.

4 Empirical strategy

4.1 Valuing a reduction in asthma severity

As described in Box 3.2, the different teams involved in the SWACHE project adopted a similar core strategy on how the survey data would be cleaned and analysed empirically to allow the proper comparison of WTP values across countries and endpoints. The final version of this core strategy is presented in Annex B. The application of this strategy for the asthma survey is detailed below.

4.1.1 Baseline estimation strategy

4.1.1.1 Estimating WTP using contingent valuation

The first aim of this paper is to derive mean and median WTP for a reduction in asthma severity from severity s_0 to s_1 where s_0 denotes baseline asthma severity using standard products and s_1 the reduced asthma severity level using *SAFETYFIRST* products, such that $s_1 \succ s_0$, other things equal. Denote y the income and $V(s, y)$ the indirect utility. Assuming a Random Utility Model, one can write indirect utility of individual i as follows:

$$v(s, y_i) + \epsilon_i$$

where ϵ_i is the idiosyncratic error term. The WTP corresponds to the maximum monetary amount that a person is willing to spend in order to have at least the same utility level as the situation with the baseline severity and unchanged disposable income.

$$V(s_1, y - WTP) = V(s_0, y)$$

To estimate WTP, it is possible to ask a sample of the population if they would pay a certain amount of money to reduce their asthma severity. This contingent valuation method is called a single-bounded dichotomous choice approach. An individual who responds yes when asked if he is willing to pay the amount b for reducing asthma severity from s_0 to s_1 implies that

$$v(s_1, y_i - b) + \epsilon_{i1} \geq v(s_0, y_i) + \epsilon_{i0}$$

and that $b \leq WTP_i$. Therefore, the probability that individual i chooses yes when presented b can be written as follows

$$Pr\{Yes_i|b\} = Pr\{b \leq WTP_i\}$$
$$= Pr\{\epsilon_{i0} - \epsilon_{i1} \leq v(s_0, y_i) - v(s_1, y_i - b)\}$$
$$= Pr\{\epsilon_{i0} - \epsilon_{i1} \leq g(b, y_i, s_0, s_1, \theta)\}$$
$$= 1 - F(b, y_i, s_0, s_1, \theta)$$

where F is the cumulative distribution function of the error term $\epsilon_{i1} - \epsilon_{i0}$ and θ the parameter of the distribution. Assuming that the n observations are independent and identically distributed, θ can be estimated by finding the maximum likelihood, which is the joint probability that respondents choose the reduced risk option.

$$L(b, y, s_0, s_1, \theta) = Pr\{Yes_1, \dots, Yes_i, \dots, Yes_n|b\} = \prod_{i=1}^{n} Pr\{Yes_i|b\}$$

The mean WTP can then be estimated by integrating the probability of choosing the reduced severity option over the interval from 0 to infinite cost.

$$E(WTP) = \int_0^{\infty} Pr\{\text{Yes}|b\}db$$

The median WTP is the bid level for which the $Pr\{\text{Yes}|b\}$ equals 50%.

4.1.1.2 Double-bounded dichotomous choice (DBDC) estimation

In this questionnaire, people were asked if they were willing to pay for a reduced asthma severity using a DBDC. This elicitation method allows several of the estimated individual WTP to be bounded between two values, which is not possible using a single bounded dichotomous choice. Denote b_i as the first bid level proposed to respondent i. Denote $b_i^U = 3b_i$ the follow up bid level proposed to respondent i if he responded yes to the first valuation question. $b_i^L = \frac{b_i}{3}$ is the follow up bid level proposed to respondent i if he responded no to the first valuation question.[8]This elicitation provides four outcomes per respondent: d_i^{YY}, d_i^{YN}, d_i^{NY} and d_i^{NN}. Denote d_i^{YY} a dummy variable equal to one when respondent i chooses yes to both valuation questions. When d_i^{YY} equals 1, $WTP_i \geq b_i^U > b_i$ where b_i is the first bid level proposed to respondent i and b_i^U is the higher follow up bid level proposed to respondent i. Denote d_i^{YN} a dummy variable equal to one when respondent i chooses yes to the first valuation question and no to the follow up valuation question. When d_i^{YN} equals 1, $b_i \leq WTP_i < b_i^U$. Denote d_i^{NY} a dummy variable equal to one when respondent i chooses no to the first valuation question and yes to the follow up valuation question. When d_i^{NY} equals 1, $b_i^L \leq WTP_i < b_i$. Finally, denote d_i^{NN} a dummy variable equal to one when respondent i chooses no for both valuation questions. When d_i^{NN} equals 1, $WTP_i < b_i^L$.

Based on the previous section, the probability of these four outcomes can be written as follows:

$$Pr\{YesYes|b^u\} = Pr\{b^u \leq WTP\} = 1 - F(b^u, \theta)$$

$$Pr\{YesNo|b, b^u\} = Pr\{b \leq WTP < b^u\} = F(b^u, \theta) - F(b, \theta)$$

$$Pr\{NoYes|b^L, b\} = Pr\{b^L \leq WTP < b\} = F(b, \theta) - F(b^L, \theta)$$

$$Pr\{NoNo|b^L\} = Pr\{WTP < b^L\} = F(b^L, \theta)$$

In this setting, the log-likelihood function for the sample of n respondents can be written as follows

$$\ln L(b, \theta) = \sum_{i=1}^{n} [d^{YY} Pr\{YesYes|b^u\} + d^{YN} Pr\{YesNo|b, b^u\} + d^{NY} Pr\{NoYes|b^L, b\} + d^{NN} Pr\{NoNo|b^u\}]$$

Maximising $\ln L(b, \theta)$ permits an estimate θ and derives the mean WTP and median WTP more efficiently than with a single bounded dichotomous choice approach, although the professional literature debates the incentive compatibility of the double-bounded approach and its empirical significance (Bateman, Langford and Jones, 2001[34]).

4.1.1.3 Spike configuration with Weibull distribution of the error

So far, it has been assumed that people will always choose the reduced severity option when it costs them nothing or almost nothing. In other words that $Pr\{Yes|b = 0\} = 1$. In reality, a small share of the population might still choose the status quo because they do not care enough about reducing their

[8] See Section 2.3.5 for more details about the bid levels.

asthma severity. This creates a spike near zero that could be significant in the case of people having mild asthma that can be more easily controlled. Carson and Hanneman (2005[35]) argue that failing to include a spike parameter can in some cases lead to an overestimate of WTP.

This spike near zero can be measured using the responses to the open-ended question that followed the double-bounded dichotomous choice: "What would be the most you would be willing to pay, for the *SAFETYFIRST* products?". Denote d_i^{NNY} a dummy variable equal to one when respondent i chooses no to both valuation questions but provides a positive value to the open-ended questions and d_i^{NNN} a dummy variable equal to one when respondent i chooses no to both valuation questions and responded 0 to the open-ended questions. The probability of these two events are:

$$Pr\{NoNoYes|b^L\} = Pr\{0 < WTP < b^L\} = F(b^L, \theta) - F(0, \theta)$$

$$Pr\{NoNoNo|0\} = Pr\{WTP \leq 0\} = F(0, \theta)$$

These two events can be added to the likelihood function to improve information as follows:

$$\ln L(b, \theta) = \sum_{i=1}^{n} [d^{YY} Pr\{YesYes|b^u\} + d^{YN} Pr\{YesNo|b, b^u\} + d^{NY} Pr\{NoYes|b^L, b\} + d^{NN} Pr\{NoNo|b^u\} + d^{NNY} Pr\{NoNoYes|b^L\} + d^{NNN} Pr\{NoNoNo|0\}]$$

To derive the mean WTP and median WTP, it is necessary to estimate θ and therefore to be able to compute the log-likelihood for various values of θ. Hence, it is necessary to assume a distribution F for the utility error. In this paper, a Weibull distribution is assumed as the baseline because it generally has a shorter right tail than the log-normal and, in its "spike" configuration, usually performs well (Kriström, 1997[36]; Carson and Hanemann, 2005[35]).

4.1.1.4 Control variables and use of post-stratification weights

A Weibull distribution $\theta = \{k, \lambda\}$ is characterised by a shape parameter k that measures the slope of the function and a scale parameter λ that measures the spread of the distribution. All estimations assume a shape parameter equal to 1. In the baseline, specification of the scale parameter when $b > 0$ is

$$\lambda_{ic}(b) = \alpha_0 + \alpha_1 MediumSev_i + \alpha_2 HighSev_i + \alpha_3 \ln b_i + \sum_c \delta_c (d_{ic} \times \omega_i) \quad (1)$$

And the spike parameter when $b = 0$ is

$$\eta_{ic} = \alpha_0 + \alpha_1 MediumSev_i + \alpha_2 HighSev_i + \sum_c \delta_c (d_{ic} \times \omega_i) \quad (2)$$

where $MediumSev_i$ is a dummy variable equal to 1 when respondent i has mild plus or moderate asthma, $HighSev_i$ is a dummy variable equal to 1 when respondent i has moderate plus or severe asthma, $\ln b_i$ is the logged cost or bid proposed to respondent i, d_{ic} is a country dummy equal to 1 when respondent i lives in country c and ω_i is the post-stratification weight of respondent i. Including ω_i as a control captures the fact that some categories of people were slightly under or over represented in the sample compared to the actual population. The greater respondent i is underrepresented in the sample, the higher their weight ω_i. It is necessary to interact country dummies with the weight because weights are defined at the country level.

The model is also estimated when the scale parameter includes additional explanatory variables as follows:

$$\lambda_{ic}(b) = \alpha_0 + \alpha_1 MediumSev_i + \alpha_2 HighSev_i + \alpha_3 \ln b_i + \sum_c \delta_c (d_{ic} \times \omega_i) + \alpha_4 Female_i + \\ + \sum_a \tau_a Age_{ia} + \alpha_5 \ln y_i + \alpha_6 HighEduc_i \quad (3)$$

where $Female_i$ is a dummy variable equal to 1 when respondent i identifies as a female, Age_{ia} is a country dummy equal to 1 when respondent i belongs to age category a, $\ln y_i$ is the logged monthly income for the household of respondent i and $HighEduc_i$ is a dummy variable equal to 1 when respondent i achieved high education outcome.

The model is also estimated when the scale parameters include information on whether respondents have to pay health costs out of pocket, whether they perceive their health below or above average people of their gender and age, whether they are diagnosed with any other chronic disease and whether they or a relative was diagnosed with COVID-19.

4.1.1.5 Deriving mean and median WTP based on individual WTP

The mean WTP for a one half-step reduction in asthma severity is computed as a simple average of the individual mean WTP as follows:

$$\widehat{WTP} = \frac{1}{n}\sum_{i=1}^{n} \widehat{WTP_i}$$

The individual mean WTP are computed by integrating the probability of responding yes to the valuation question over the interval from 0 to maximum bid with adjustment:

$$\widehat{WTP_i} = \int_0^{b_{max}} \frac{f(\lambda_{ic}(b), k)}{1 - f(\lambda_{ic}(b_{max}), k)} db$$

where f is the density function of the Weibull distribution. Truncation at maximum bid level b_{max} is necessary since the right tail is not null when the cost goes to infinity. The adjustment of the denominator compensates for the fact that the support of $f(\lambda_{ic}(b), k)$ does not stop at b_{max}. The median WTP is also computed as a simple average of individual median WTP, computed as follows:

$$\widehat{WTP_i} = \frac{\ln 2}{|\alpha_2|} e^{\eta_{ic}\left(\frac{1}{|\alpha_2|}\right)}$$

where α_2 is the parameter for the logged bid value as indicated in equation (1).

4.1.2 Robustness checks

Several robustness checks were performed. Overall, the baseline estimation results are robust to various methodological choices. First, the model was estimated assuming different distributions for the utility error including lognormal or log-logistic. Second, the model was estimated without allowing for a spike. Third, the model was estimated without post stratification weights to see if rare respondents have an outsized impact on the estimates. Finally, the model was augmented with counts of problematic response to debriefing question to examine the sensitivity of the estimated coefficients to respondents who likely underestimated or overestimated their WTP.

4.2 Valuing a reduction in the risk of developing asthma

In addition to deriving WTP values for a reduction in asthma severity, this paper also derives mean and median marginal WTP for a reduction in the risk of developing asthma, based on the choices of respondents in the context of a discrete choice experiment. The econometric strategy to analyse data from the DCE differs in some points from the core principles of surveys analysis presented in Annex B that mostly apply to WTP elicited using a DBDC.

Due to the structure of the choices, two types of specification were estimated. For the first specification, the risk of having asthma is broken down into 3 levels of severity: mild, moderate and severe:

$$U(Alternative_j) = ASC + \beta_1 MildRisk_j + \beta_2 ModerateRisk_j + \beta_3 SevereRisk_j + \beta_4 AddedCost_j \quad (4)$$

Where $Alternative_j$ is using original products or using SAFETYFIRST products (Mix B) or using SAFETYFIRST products (Mix C), ASC is the Alternative Specific Constant, the coefficient associated with the Status Quo which corresponds to not choosing the SAFETYFIRST products, $MildRisk_j$ is the risk of getting mild asthma under $Alternative_j$ and $AddedCost_j$ is the additional cost that the respondent chooses to pay to reduce its risks under $Alternative_j$.

The second specification estimates the reduction in the total probability of getting asthma that is the sum of risk for mild, moderate and severe asthma and the added cost.

$$U(Alternative_j) = ASC + \beta_5 TotalRisk_j + \beta_6 AddedCost_j \quad (5)$$

For these two specifications, estimates are made separately for non-asthmatic adults and for parents of non-asthmatic children and analyses are conducted from data for all countries. Three types of econometric estimation techniques are used: the Multinomial Logit model (MNL), the Random Parameter Logit model (RPL) and the Latent Class model (LCM).

4.2.1 Overview of the different econometric models

Regarding the Multinomial Logit (MNL) model, individuals are assumed to assign the same value to an attribute entering into their utility function. The coefficient associated with this attribute is considered to be identical for all individuals (McFadden, 1974[37]), which is a very strong assumption.

The Random Parameter Logit model (RPL) makes it possible to take into account the heterogeneity of individuals' preferences by allowing coefficients associated with the different attributes to vary randomly according to a specified distribution $f(\beta|\Omega)$. The coefficient associated with the status quo is assumed to be normally distributed and therefore it can be positive or negative depending on whether the individual has utility or disutility from not using SAFETYFIRST products. The non-monetary attributes associated with reductions in the risk of developing asthma follow an exponential Weibull distribution because their coefficients would naturally be positive. The coefficient associated with the added cost is assumed to be deterministic. In the case where individual i makes T choices[9], it is assumed that their preferences for a given attribute do not vary over their choices. The probability for an individual i choosing alternative j for choice t is then calculated as follows:

$$P_i(y_{it} = j \mid \Omega) = \int_{\beta} P_i(y_{it} = j \mid \beta)\, f(\beta \mid \Omega) d\beta \quad (6)$$

Where $y_{it} = j$ corresponds to the alternative chosen by individual i for the choice t and where

$$P_i(y_{it} = j \mid \beta) = \frac{exp(\alpha_i + \beta_i' X_{ijt})}{\sum_{j=1}^{J} exp(\alpha_i + \beta_i' X_{ijt})} \quad (7)$$

[9] Here, the number of choices by individual is 5.

Where α is the constant associated with the status quo and X corresponds to the different attributes. Consequently, the log-likelihood function associated with the various coefficients to be estimated is defined as follows:

$$\ln L\,(\Omega) = \sum_{i=1}^{N} \ln\left(\int_{\beta}\left(\prod_{t=1}^{T} P_i(y_{it} = j \mid \beta)\right) f(\beta \mid \Omega) d\beta\right) \tag{8}$$

Since the integral of the log-likelihood must be approximated through simulations, the different parameters of the estimate are calculated from different random samples.[10]

Nevertheless, in the model presented above, the sources of heterogeneity are assumed to be random. A refinement of this model following Hensher and Greene (2003[38]) is to allow the means of the parameter distributions to be heterogeneous according to the country of individuals.

Alternatively, the heterogeneity of individuals' preferences can be modelled through a discrete distribution using the Latent Class model. This type of model assumes that each individual belongs to a class c, and his membership can be linked to his geographic origin. This model simultaneously divides individuals into classes and estimates the different coefficients β_c of the utility function conditional on class membership (Greene and Hensher, 2003[39]). The probability that individual i chooses alternative j for choice t is then calculated as follows:

$$P(y_{it} = j) = \sum_{c=1}^{C}\big(P(class = c) \times P(y_{it} = j|class = c)\big) \tag{9}$$

Where $P(y_{it} = j|class = c)$ is the probability for the individual i to choose the choice t, the alternative j conditional on their membership to the class c. This probability is calculated as follows:

$$P(y_{it} = j \mid \text{class} = \text{c}) = \frac{exp\big(\alpha_c + \beta_c' X_{ijt}\big)}{\sum_{j=1}^{J} exp\big(\alpha_c + \beta_c' X_{ijt}\big)} \tag{10}$$

$P(class = c)$ is the probability of belonging to class c, calculated as follows:

$$P(\text{class} = \text{c}) = \frac{exp(\theta_c' z_i)}{\sum_{c=1}^{C} exp(\theta_c' z_i)} \tag{11}$$

where: z_i corresponds to the choice-invariant characteristics having a potential effect on the probability of belonging to class c (e.g. geographical origin); and θ_c corresponds to the coefficients associated with the variables z_i, specific to class c.

Since each individual makes a series of T choices, the probability of choosing alternative j by individual i is:

$$P(y_i = j) = \sum_{c=1}^{C} P(\text{class} = \text{c}) \underbrace{\prod_{t=1}^{T}\big(P(y_{it} = j \mid \text{class} = \text{c})\big)}_{P_i(j|c)} \tag{12}$$

The log-likelihood function associated with the various parameters to be estimated is then defined as follows:

[10] The RPL model is estimated using 500 draws.

$$\ln L = \sum_{i=1}^{N} \ln \left(\sum_{c=1}^{C} P(\text{class} = \text{c}) \prod_{t=1}^{T} \left(P(y_{it} = j \mid \text{class} = \text{c}) \right) \right) \quad (13)$$

Due to its structure, the Latent Class model is generally considered to be an easier model to implement and to understand by decision makers, as it allows for the identification of different classes of marginal willingness-to-pay, defined according to the individual's profile as well as their respective weights in the surveyed population.

4.2.2 Deriving mean and median marginal WTP

The individual marginal Willingness to Pay for each non-monetary attribute is then calculated as follows in the case of an RPL model:

$$MWTP_{i,non\ monetary\ attribute} = -\frac{\hat{\beta}_{i,non\ monetary\ attribute}}{\hat{\beta}_{i,added\ cost}} \quad (14)$$

In the case of a Latent Class model, the calculation of the individual marginal willingness-to-pay for each non-monetary attribute is calculated in the same way after calculating the coefficients of the different attributes $\hat{\beta}_i$, as follows:

$$\hat{\beta}_i = \sum_{c=1}^{C} \hat{\pi}_{ic}^{*} \hat{\beta}_c \quad (15)$$

with

$$\hat{\pi}_{ic}^{*} = \frac{\hat{\pi}_{ic} \hat{P}_i(j|c)}{\sum_{c=1}^{C} \hat{\pi}_{ic} \hat{P}_i(j|c)} \quad (16)$$

The unweighted individual marginal willingness-to-pay ($MWTP_i$) for the non-monetary attributes are calculated via equation (14). They are then weighted to compute willingness-to-pay statistics that are representative of the population. The weighted mean marginal WTP are calculated as follow:

$$\overline{MWTP} = \frac{1}{N} \sum_{i=1}^{N} \omega_i MWTP_i \quad (17)$$

Where ω_i is the post-stratification weight for individual i derived from a raking algorithm that corrects for differences between target population quotas and achieved sample quotas. The mean marginal WTP (and the median marginal WTP) by country are calculated from pooled data according to the respondents belonging to the different countries.

5 Results

5.1 Valuing a reduction in asthma severity in adults and children

This section presents the results of the estimation of the mean and median willingness to pay of asthmatic adults and parents of asthmatic children for a reduction in asthma severity in the context of a double bounded dichotomous choice. The econometric methods associated to these estimates is presented in detail in section 4.1.

5.1.1 Main results

The parametric estimation results of model (1) for asthmatic adults are presented in Table 5.1. Column (1) shows the baseline estimation results. Baseline asthma severity has a positive and statistically significant effect on the joint probabilities to choose the reduced severity options. Asthmatics who have a mild plus or moderate form of asthma are willing to pay more than those who have a very mild or mild asthma. Moreover, asthmatics who have moderate plus or severe asthma are willing to pay even more for a reduced severity than those having a mild plus or moderate asthma. Consistent with expectations, the additional cost of choosing the reduced severity option has a negative and statistically significant effect. The spike variable equals 0.04 and is statistically different from zero. In other words, the average probability that people are indifferent to the valued item is 4% for the estimation sample.

For an average reduction (one step) in asthma severity the mean WTP equals USD PPP[11] 529 per year over 10 years and the median WTP equals USD 200 per year over 10 years. For adult with mild asthma, mean WTP equals USD 382 per year and median WTP equals USD 127 per year. For adults with mild plus or moderate asthma, mean WTP equals USD 594 per year and median WTP equals USD 227 per year. Finally, for adults with moderate plus or severe asthma, mean WTP equals USD 895 per year and median WTP equals USD 408 per year. Table C.1 provides the estimation results where all baseline severity levels are included as regressors. Results are consistent with the baseline model. However, given the small number of respondents with severe asthma, there is not enough statistical power to properly test the influence of severe asthma on WTP responses.

These results are robust to alternative methodological choices. Column (2) shows the estimation results when a log-logistic distribution of the errors is assumed, while column (3) assumes a log-normal distribution. Column (4) shows the estimation results when country dummies interacted with post-stratification weights are not included as regressors. Column (5) excludes the possibility of a spike at zero. All columns show a positive impact of baseline asthma severity and a negative impact of cost on the joint probabilities to choose the reduced severity option that is statistically different from zero. All columns report similar WTP estimates. The mean WTP varies from USD 529 to USD 615 per year and the median WTP varies from USD 175 to USD 205. The largest deviation from the baseline is when a log-normal distribution is assumed but this deviation is not economically large. Dropping the spike variable reduces the absolute value of all coefficients.

[11] All the dollar amount mentioned in this paper are PPP adjusted. For simplicity, USD PPP will be written as USD.

Table 5.1. Main parametric estimations of WTP to reduce asthma severity in adults

	Spike				No spike
	Weibull	Log-logistic	Log-normal	Without weight	Weibull
	(1)	(2)	(3)	(4)	(5)
Has mild plus or moderate asthma (0/1)	0.308***	0.462***	0.298***	0.308***	0.297***
	(0.054)	(0.082)	(0.049)	(0.054)	(0.054)
Has moderate plus or severe asthma (0/1)	0.619***	0.811***	0.470***	0.622***	0.612***
	(0.116)	(0.164)	(0.095)	(0.116)	(0.116)
Log(Cost)	-0.530***	-0.706***	-0.404***	-0.531***	-0.513***
	(0.012)	(0.017)	(0.009)	(0.012)	(0.014)
Spike	0.043***	0.028***	0.022***	0.043***	
	(0.003)	(0.002)	(0.002)	(0.003)	
Observations	2 194	2 194	2 194	2 194	2 194
Country dummies	No	No	No	Yes	No
Country dummies x weights	Yes	Yes	Yes	No	Yes
Log-likelihood	-3 218	-3 222	-3 231	-3 210	-2 979
LR statistics	81	76	83	96	77
AIC	6 457	6 466	6 484	6 440	5 981
BIC	6 520	6 529	6 547	6 497	6 044
WTP (USD per year over 10 years)					
Mean WTP (truncated at the maximum bid with adjustment)	529	601	615	535	538
Median WTP (mean of median)	200	175	169	205	196

Note: Signif. codes: '***' 0.001 '**' 0.01 '*' 0.05 '+' 0.1 ' ' 1. The baseline estimation corresponds to a maximum likelihood estimation of the joint probabilities assuming a Weibull distribution with a spike configuration. All columns exclude very slow respondents as well as speeders. Base group: mild asthmatic, American, aged 18-29, male with low and medium education. The intercept, country dummies and country dummies interacted with the sampling weight are included as regressors but not reported in the table for clarity.

The parametric estimation results of model (1) for parents of an asthmatic child are presented in Table 5.2. Column (1) shows the baseline estimation results, which are very similar to what is found for asthmatic adults. Overall, for an average reduction in child asthma severity the mean WTP equals USD 948 per year over 10 years and the median WTP equals USD 416 per year over 10 years. The mean WTP for a reduction in child asthma severity is 1.8 times the mean WTP for a reduction in adult asthma severity while the median WTP is twice as high for child asthma severity as for adult asthma severity. This difference between children and adults is similar to what is found in the Value of Statistical Life (VSL) literature (OECD, 2012[40]), where results from the United States and Europe indicate that VSL for children can be as high as a factor of 2 greater than that of their parents/adults (US EPA, 2003[41]; OECD, 2010[42]).

For parents of a child with mild asthma, mean WTP equals USD 707 per year and median WTP equals USD 245 per year (Figure 5.1). For parents of a child with mild plus or moderate asthma, mean WTP equals USD 1 056 per year and median WTP equals USD 481 per year. Finally, for parents of a child with moderate plus or severe asthma, mean WTP equals USD 1 330 per year and median WTP equals USD 726 per year.

Table C.1 provides the estimation results where all baseline severity levels are included as regressors. Results are consistent with the baseline model. However, given the small number of respondents with children with severe asthma, there is not enough statistical power to properly test the influence of severe childhood asthma on WTP responses.

Figure 5.1 compares the mean (Panel A) and median (Panel B) WTP responses for adults and parents for their asthmatic child by severity level. Both mean and median show that WTP of adults for themselves is consistently less than their WTP for their asthmatic child at all three severity categories and WTP is greater for reducing severity by one step the more severe the baseline asthma is.

As also found for adults, these results for children are robust to alternative methodological choices, as shown in Table 5.2. The mean WTP to reduce childhood asthma severity varies from USD 939 to USD 1 024 per year and the median WTP varies from USD 374 to USD 424. The largest deviation from the baseline is when a log-normal distribution is assumed but this deviation is not economically large.

To analyse the different determinants of WTP, model (3) that includes additional control variable and model (4) that includes health related controls are estimated (Table 5.3). Column (1) reports the baseline model estimated on the same sample for comparison. The main determinants of WTP to reduce asthma severity are in order of importance: having more severe asthma, having to pay medical costs out of pocket, having another chronic disease, income, being aged 30 or more and gender.

Having to pay medical costs out of pocket has a positive and statistically significant effect on the probability of choosing the reduced severity option. Therefore, some respondents did consider medical cost when choosing between baseline severity and reduced severity even if they were instructed to not think about saving these costs through using SAFETYFIRST products and to only think about the non-monetary benefits to them and the rest of their family from them having less severe asthma. The impact of this anticipation is explored in more detailed in Section 5.1.4.

Figure 5.1. Mean and Median WTP for a reduction in asthma severity in adults and children



Table 5.2. Main parametric estimations of WTP to reduce asthma severity in children

	Spike				No spike
	Weibull	Log-logistic	Log-normal	Without weight	Weibull
	(1)	(2)	(3)	(4)	(5)
Child has mild plus or moderate asthma (0/1)	0.302***	0.346**	0.202**	0.320***	0.292***
	(0.078)	(0.109)	(0.065)	(0.077)	(0.078)
Child has moderate plus or severe asthma (0/1)	0.486**	0.616**	0.346**	0.518**	0.473**
	(0.174)	(0.227)	(0.134)	(0.173)	(0.174)
Log(Cost)	-0.447***	-0.569***	-0.330***	-0.445***	-0.395***
	(0.015)	(0.020)	(0.010)	(0.015)	(0.017)
Spike	0.050***	0.038***	0.030***	0.051***	
	(0.005)	(0.004)	(0.004)	(0.005)	
Observations	1 339	1 339	1 339	1 339	1 339
Country dummies	No	No	No	Yes	No
Country dummies x sample weights	Yes	Yes	Yes	No	Yes
Log-likelihood	-1 808	-1 794	-1 791	-1 817	-1 660
LR statistics	65	63	63	48	62
AIC	3 637	3 610	3 604	3 653	3 343
BIC	3 695	3 668	3 661	3 705	3 400
WTP (USD per year over 10 years)					
Mean WTP (truncated at the maximum bid with adjustment)	948	991	1 024	939	1 005
Median WTP (mean of median)	416	374	380	404	424

Note: Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '+' 0.1 ' ' 1. The baseline estimation corresponds to a maximum likelihood estimation of the joint probabilities assuming a Weibull distribution with a spike configuration. All columns exclude very slow respondents as well as speeders. Base group: mild asthmatic child, American, male with non-asthmatic parent. Country dummies and country dummies interacted with the sampling weight are included as regressors but not reported in the table for clarity.

WTP is correlated with other factors. Asthmatics who are diagnosed with other chronic disease state higher willingness to pay than asthmatics who have no other chronic disease. This is consistent with expectations. Asthmatics aged 30 or above stated a lower WTP than asthmatics aged 18-29. This could be related to the quality-of-life impact of asthma that can be less important at different stages of life. For example, asthmatics aged 30 might be less physically active than asthmatics aged 18-29. Female respondents stated a lower willingness to pay than male respondents, conditional on income level. Asthmatics with higher income and higher education stated higher WTP, other things equal. Respondents who did not provide income stated lower WTP. This could be either because they did not report their low income or they had less interest in the survey and in the proposed risk reduction.[12] Finally, perceived health status, having had a positive diagnosis of COVID-19 and a relative who had COVID-19 have no statistically significant impact on WTP.

[12] Including the missing income dummy has no impact on the estimated parameters as shown by Table C.2 even if it is negative and statistically significant.

Table 5.3. The determinants of WTP to reduce asthma severity in adults

	Basic	Basic + controls	Basic + controls + health	
	Odds ratios	Odds ratios	Odds ratios	Marginal effect (USD per year)
	(1)	(2)	(3)	(4)
Has mild plus or moderate asthma (0/1)	0.308***	0.253***	0.210***	+148
	(0.054)	(0.055)	(0.056)	
Has moderate plus or severe asthma (0/1)	0.619***	0.634***	0.555***	+480
	(0.116)	(0.117)	(0.120)	
Female (0/1)		-0.154**	-0.154**	-116
		(0.054)	(0.055)	
Aged 30-44 (0/1)		-0.176*	-0.183*	-152
		(0.076)	(0.077)	
Aged 45-59 (0/1)		-0.290***	-0.287***	-225
		(0.077)	(0.078)	
Aged 60+ (0/1)		-0.218*	-0.229*	-185
		(0.089)	(0.090)	
Log(Income)		0.245***	0.244***	+28[a]
		(0.040)	(0.041)	
Missing income (0/1)		-0.327***	-0.323***	-208
		(0.092)	(0.091)	
High education (0/1)		0.123*	0.127*	+96
		(0.057)	(0.058)	
Health expenditure out of my pocket (0/1)			0.195*	+161
			(0.095)	
Health perceived below average (0/1)			-0.037	-27
			(0.067)	
Health perceived above average (0/1)			0.049	+38
			(0.064)	
Not diagnosed with chronic diseases (0/1)			-0.220***	-157
			(0.060)	
Was diagnosed with COVID-19 (0/1)			0.068	+52
			(0.060)	
Relative was diagnosed with COVID-19 (0/1)			0.065	+49
			(0.053)	
Log(Cost)	-0.530***	-0.538***	-0.541***	
	(0.012)	(0.012)	(0.013)	
Spike	0.043***	0.041***	0.041***	
	(0.003)	(0.003)	(0.003)	
Observations	2 194	2 194	2 194	
Country dummies x sample weights	Yes	Yes	Yes	
Log-likelihood	-3 218	-3 170	-3 159	
LR statistics	81	177	198	
AIC	6 457	6 376	6 366	
BIC	6 520	6 478	6 503	
Mean WTP truncated at the maximum bid with adjustment (USD per year over 10 years)	529	551	555	
Median WTP (USD per year over 10 years)	200	225	230	

Note: Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '+' 0.1 ' ' 1. The baseline estimation corresponds to a maximum likelihood estimation of the joint probabilities assuming a Weibull distribution with a spike configuration. All columns exclude very slow respondents as well as speeders. Base group: mild asthmatic, American, aged 18-29, male with low and medium education, health perceived as average compared to other people of the same age and gender. Country dummies and country dummies interacted with the sampling weight are included as regressors but not reported in the table for clarity. [a] For income, the marginal effect equals the increase in mean WTP due to an increase of average income by USD 500 per month.

To illustrate the relative magnitude of the impact of these different factors, marginal effects on mean WTP are provided in column (4) in Table 5.3. These marginal effects are based on the results of the estimated odds ratios reported in column (3) by changing at the margin the different determinants one by one. The mean WTP for asthmatics with moderate plus or severe asthma is USD 480 per year more than what it is for adults with mild asthma. The mean WTP for adults with mild plus or moderate asthma is UDS 148 per year more than what it is for adults with mild asthma. Asthmatics who have to pay their medical costs out of their pocket are willing to pay USD 161 per year more than those who have any form of insurance (public or and private). Asthmatics who have another chronic disease are willing to pay USD 157 per year more on average. Asthmatics aged 45-59 are willing to pay USD 225 per year less than asthmatics aged 18-29. Women are willing to pay USD 116 per year less than men on average. Finally, income has a rather small impact. When income increases by USD 500 per month, mean WTP only increases by USD 28 per year. The income elasticity equals 0.3.[13]

To analyse the different determinants of WTP for reduction in childhood asthma severity, models that include additional control variables and health related controls are estimated in columns (2) and (3) in Table 5.4. Column (1) reports the baseline model estimated on the same sample for comparison. The main determinants of WTP to reduce childhood asthma severity are in order of importance: severity, presence of another chronic disease, degree of asthma control, child gender, income and child age.

To illustrate the relative magnitude of the impact of these different factors, marginal effects on mean WTP are computed in column (4) in Table 5.4 using the estimates reported in column (3). If their child has moderate plus or severe asthma, parents are willing to pay USD 325 per year more than if their child has mild asthma. If their child has mild plus or moderate asthma, parents are willing to pay USD 128 more per year than if their child has mild.[14] It is found that parents are willing to pay USD 335 per year more if their child has another chronic disease. Finally, as would be expected, if the asthma of their child is completely controlled, parents are willing to pay USD 227 per year less than if it's partially or not controlled at all.

If their child is female, parents are willing to pay USD 210 per year less than if their child is male. This apparent preference for boys health can be surprising considering that there does not seem to be any major difference in the severity of symptoms in asthmatic males when compared to asthmatic females in childhood (Almqvist et al., 2008[43]) and that baseline severity and asthma control are both explicitly controlled for in the model.

When income increases by USD 500 per month, mean WTP for a reduction in childhood asthma increases by USD 52 per year. The income elasticity equals 0.4 and is obtained by computing the percentage difference between the mean WTP when average income increases by 1% and the baseline mean WTP.[15] It is 0.1 higher than the estimated income elasticity for adult. Finally, mean WTP to reduce childhood asthma severity decreases by USD 28 per year when the age of the child increases by one year. This is not surprising as parents generally consider young children to be more fragile as their lungs have not yet fully developed.

[13] The income elasticity is obtained by computing the % difference between the mean WTP when average income increases by 1% and the baseline mean WTP.

[14] Baseline severity is not statistically significant in this extended model because of the smaller statistical power.

[15] Including the missing income dummy has no impact on the estimated parameters as shown by Table C.3 even if it is negative and statistically significant.

Table 5.4. The determinants of WTP to reduce asthma severity in children

	Basic	Basic + controls	Basic + controls + health	
	Odd ratios	Odd ratios	Odd ratios	Marginal effect (USD per year)
	(1)	(2)	(3)	(4)
Child has mild plus or moderate asthma (0/1)	0.302***	0.178*	0.104+	+128
	(0.078)	(0.084)	(0.087)	
Child has moderate plus or severe asthma (0/1)	0.486**	0.359*	0.244	+325
	(0.174)	(0.177)	(0.182)	
Child asthma is completely controlled (0/1)		-0.187*	-0.177**	-227
		(0.080)	(0.081)	
Female child (0/1)		-0.182*	-0.168*	-210
		(0.076)	(0.076)	
Child age		-0.021**	-0.022**	-28
		(0.008)	(0.008)	
Asthmatic parent (0/1)		0.000	-0.042	-53
		(0.078)	(0.079)	
Log(Income)		0.337***	0.339***	+52a
		(0.058)	(0.058)	
Missing income (0/1)		-0.505***	-0.493**	-496
		(0.158)	(0.158)	
Health expenditure out of my pocket (0/1)			-0.057	-70
			(0.141)	
Child health perceived below average (0/1)			0.174	+234
			(0.112)	
Child health perceived above average (0/1)			-0.028	-35
			(0.084)	
Child diagnosed with other chronic diseases (0/1)			0.290***	+335
			(0.095)	
Log(Cost)	-0.447***	-0.457***	-0.459***	
	(0.015)	(0.015)	(0.016)	
Spike	0.050***	0.047***	0.046***	
	(0.005)	(0.005)	(0.005)	
Observations	1 339	1 339	1 339	
Country dummies x sample weights	Yes	Yes	Yes	
Log-likelihood	-1 808	-1 780	-1 770	
LR statistics	65	121	134	
AIC	3 637	3 594	3 588	
BIC	3 695	3 682	3 698	
Mean WTP truncated at the maximum bid with adjustment (USD per year over 10 years)	948	994	1 001	
Median WTP (USD per year over 10 years)	416	501	513	

Note: Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '+' 0.1 ' ' 1. The baseline estimation corresponds to a maximum likelihood estimation of the joint probabilities assuming a Weibull distribution with a spike configuration. All columns exclude very slow respondents as well as speeders. Base group: mild asthmatic child, American, male with non-asthmatic parent, child health perceived as average compared to other children of the same age and gender. Country dummies interacted with the sampling weight are included as regressors but not reported in the table for clarity. [a] For income, the marginal effect equals the increase in mean WTP due to an increase of average income by USD 500 per month.

5.1.2 Country-level estimates

Mean and median WTP at the country level are reported in Table 5.5. They are computed from individual WTP derived from the estimation of model (1) reported in column (1) in Table 5.1 for adult asthma severity and column (1) in Table 5.2 for childhood asthma severity.

The mean WTP for a one-step reduction in adult asthma severity varies from USD 429 per year in Canada to USD 685 per year in Czech Republic. The median WTP varies from USD 150 per year in the Canada to USD 280 in Czech Republic.

Table 5.5. Country-level estimates of WTP to reduce asthma severity

	Mean WTP		Median WTP	
USD per year over 10 years for	Reduction in *adult* asthma severity	Reduction in *childhood* asthma severity	Reduction in *adult* asthma severity	Reduction in *childhood* asthma severity
Canada	429	840	150	331
Czech Republic	685	1 080	280	495
France	438	775	153	302
Poland	632	1 130	252	534
Sweden	471	756	168	294
United Kingdom	445	743	158	267
United States	587	1 317	227	694

Note: Mean and median WTP at the country level are reported in Table 5.7. They are computed from individual WTP derived from the estimations of model (1) reported in column (1) in Table 5.1 for adult asthma severity and column (1) in Table 5.2 for childhood asthma severity. Mean WTP is truncated at the maximum bid with adjustment and median WTP is computed as the mean of individual medians.

As a robustness check, model (1) is estimated for each country taken separately. Results are provided in Table C.4 for adult asthma severity. For all countries, adults having mild plus or moderate asthma are more likely to choose the reduced severity option. However, the coefficient is not statistically significant in Czech Republic, Sweden and Poland. For all countries, adults having a moderate plus or severe asthma have the highest WTP to reduced asthma severity though the coefficient is not statistically different from zero for Czech Republic and Poland. The largest difference in WTP from mild asthma and WTP from mild plus or moderate asthma is found for the United Kingdom, Canada and the United States. The largest difference in WTP from mild asthma and WTP from moderate plus or severe asthma is found for, Canada, Sweden and the United Kingdom. In all countries, the cost for the reduced risk option has a negative effect on the probability to choose the reduced severity option that is statistically different from zero. Cost sensitivity is smallest in the United Kingdom and highest in Czech Republic. The spike at zero varies from 2.3% in Czech Republic to 6.9% in the United Kingdom. The small median WTP value compared to the mean WTP value for the United Kingdom, France and Sweden is consistent with the high share of respondents who are indifferent to the valued item, the spike at zero.

The mean and median WTP derived from these separate regressions are highly similar to the values obtained via the estimation of the pooled model showing the high robustness of the baseline results presented in Table 5.5. The largest difference compared to the baseline is USD 55 per year less for Canada and USD 61 per year more for the United States. The mean WTP for a one-step reduction in childhood asthma severity varies from USD 743 per year in the United Kingdom to USD 1 130 per year in Poland. The median WTP varies from USD 267 per year in the United Kingdom to USD 694 in the United States.

As a robustness check, model (1) is estimated for each country taken separately for childhood asthma severity. Results are provided in Table C.5. Overall, WTP increases with baseline asthma severity. However, the corresponding coefficients are not always statistically different from zero because of the few numbers of parents of an asthmatic child surveyed in each country. In all countries, the cost for the reduced childhood asthma severity option has a statistically significant negative effect on the probability of choosing the reduced risk option. Cost sensitivity is smallest in the United States and highest in Czech Republic. The spike at zero varies from 3.4% in Czech Republic to 6% in Sweden and the United Kingdom. The mean and median WTP derived from these separate regressions are very similar to the

values obtained via the estimation of the pooled model, which is evidence for the robustness of the results. The largest difference compared to the baseline is USD 172 per year less for the United States and USD 95 per year more for Poland.

Unsurprisingly, the mean WTP to reduce childhood asthma severity is positively correlated with the mean WTP to reduce adult asthma severity as illustrated in Figure 5.2. Compared to other countries, parents of an asthmatic child in the United States exhibit a relatively higher premium for reduced asthma severity than adults for a reduction of their own asthma severity. Figure 5.2 reveals two groups of countries. The first group consists of Canada, France, the United Kingdom and Sweden that exhibit lower WTP values. The second group consists of the United States, Poland and Czech Republic where respondents' choices led to higher WTP values.

Figure 5.2. WTP to reduce adult and childhood asthma severity by country



Note: Mean WTP derived from the parametric estimations reported in Table 5.5.

The potential drivers of cross-country differences in WTP are illustrated using only WTP for a reduction in adult asthma severity since it is highly correlated with WTP for a reduction in childhood asthma severity. At the country level, mean WTP to reduce asthma severity is positively correlated with the effectiveness of health systems, which are proxied by the rates of preventable and treatable causes of mortality[16] (Figure 5.3), while is it weakly negatively correlated with GDP per capita and uncorrelated with medical cost burden (Figure 5.4). Medical cost burden is measured by the ratio between domestic private health expenditure per capita (including prepayment to voluntary health insurance and directly payment to healthcare providers) and median income. That WTP is mostly correlated with the efficiency of the health system in the country of residence of respondents is consistent with the strong impact of having another chronic disease on WTP at the level of individuals.

[16] These indicators are used notably by OECD and European Union (OECD and European Union, 2022[51]).

Figure 5.3. WTP to reduce adult asthma severity and effectiveness of health system



Note: Mean WTP derived from the parametric estimations reported in Table 5.5.
Source: Data on preventable and treatable causes of mortality come from OECD (2019[44]), "Avoidable mortality (preventable and treatable)", in Health at a Glance 2019: OECD Indicators, OECD Publishing, Paris, https://doi.org/10.1787/3b4fdbf2-en.

Figure 5.4. WTP to reduce adult asthma severity, GDP per capita and medical cost burden



Note: Mean WTP derived from the parametric estimations reported in Table 5.5.
Source: GDP per capita in 2019, PPP (constant 2017 international USD) comes from the World Bank. Data on domestic private health expenditure per capita come from the World Health Organization Global Health Expenditure database. Data on equivalised income are taken from OECD Income Distribution Database.

5.1.3 Additional robustness checks

The baseline estimation results for adult asthma severity are also highly robust to different screening choices as shown in Table 5.6. Basically, problematic (termed "poor" in the text and Table 5.6) answers to debriefing questions leading to underestimates of WTP are balanced by poor responses leading to overestimates. Thus, when adding the number of poor answers to debriefing questions that are non-directional, overestimating and underestimating in column (2), the mean WTP to reduce adult asthma severity is only USD 65 per year less than the baseline while the median WTP is only USD 26 per year more than the baseline. The number of poor non-directional debriefs has a negative and statistically significant impact on WTP. The number of poor overestimating debriefs has a statistically positive impact on WTP, as expected. However, the number of poor underestimating debriefs also has a positive impact (though not highly statistically significant). When removing asthmatics who responded poorly to more than

two non-directional debriefs in column (3) (1.5%), the mean WTP is USD 3 per year less than the baseline while the median WTP is the same as the baseline. When removing asthmatics who responded poorly to more than 3 overestimation debriefs in column (4) (2%), the mean WTP is USD 10 per year less than the baseline while the median WTP is USD 5 per year less than the baseline. Finally, when removing asthmatics who responded poorly to more than two underestimation debriefs in column (5) (4.3%), the mean WTP is USD 67 less than the baseline while the median WTP is USD 2 per year more than the baseline. In Column (4) and (5), the signs of the deviation from the baseline are consistent with the expected direction due to the poor responses with the exception of the mean WTP when removing respondents with more than 3 underestimation debriefs. This could be explained by the mean WTP being more sensitive than the median WTP to outliers that are high values of individual WTP.

Table 5.6. Estimations of WTP to reduce asthma severity in adults including debriefing controls

	Basic	Basic + debrief counts	Only respondents with less than 3 non-directional	Only respondents with less than 4 overestimations	Only respondents with less than 3 underestimations
	(1)	(2)	(3)	(4)	(5)
Has mild plus or moderate asthma (0/1)	0.308***	0.211***	0.317***	0.296***	0.294***
	(0.054)	(0.055)	(0.054)	(0.054)	(0.055)
Has moderate plus or severe asthma (0/1)	0.619***	0.502***	0.638***	0.568***	0.646***
	(0.116)	(0.117)	(0.118)	(0.117)	(0.119)
Number of poor non directional debriefs		-0.146***			
		(0.037)			
Number of poor overestimating debriefs		0.233***			
		(0.029)			
Number of poor underestimating debriefs		0.074*			
		(0.034)			
Log(Cost)	-0.530***	-0.541***	-0.533***	-0.533***	-0.523***
	(0.012)	(0.013)	(0.012)	(0.012)	(0.013)
Spike	0.043***	0.041***	0.043***	0.043***	0.043***
	(0.003)	(0.003)	(0.003)	(0.003)	(0.003)
Observations	2 194	2 194	2 160	2 150	2 100
Country dummies x sample weights	Yes	Yes	Yes	Yes	Yes
Log-likelihood	-3 218	-3 175	-3 165	-3 155	-3 074
LR statistics	81	166	85	77	78
AIC	6 457	6 378	6 351	6 332	6 171
BIC	6 520	6 458	6 414	6 395	6 233
WTP (USD per year over 10 years)					
Mean WTP (truncated at the maximum bid with adjustment)	529	464	526	519	462
Median WTP (mean of median)	200	226	200	195	202

Note: Signif. codes: '***' 0.001 '**' 0.01 '*' 0.05 '+' 0.1 ' ' 1. The baseline estimation corresponds to a maximum likelihood estimation of the joint probabilities assuming a Weibull distribution with a spike configuration. All columns exclude very slow respondents as well as speeders. Base group: mild asthmatic, American, aged 18-29, male with low and medium education. Country dummies and country dummies interacted with the sampling weight are included as regressors but not reported in the table for clarity.

The baseline estimation results for childhood asthma severity are also highly robust to different screening choices as shown in Table 5.7. However, estimates of WTP for childhood asthma severity are more sensitive to screening choice in absolute terms than the corresponding estimates for adult asthma. This might be due to the lower number of observations (1 339) for childhood asthma severity compared to the 2 194 observations for adult asthma severity. When adding the number of poor answers to debriefing questions that are non-directional, overestimating and underestimating in column (2), the mean WTP to reduce adult asthma severity is USD 49 per year more than the baseline while the median WTP is USD 90 per year more than the baseline. Similar to the results for adult asthma severity, the number of poor non-directional debriefs has a negative and statistically significant impact on WTP whereas the number of poor overestimating debriefs and the number of poor underestimating debriefs both have a statistically positive impact on WTP.

Table 5.7. Estimations of WTP to reduce asthma severity in children including debriefing controls

	Basic	Basic + debrief counts	Only respondents with less than 3 non-directional	Only respondents with less than 4 overestimations	Only respondents with less than 3 underestimations
	(1)	(2)	(3)	(4)	(5)
Child has mild plus or moderate asthma (0/1)	0.302***	0.236**	0.307***	0.350***	0.313***
	(0.078)	(0.079)	(0.078)	(0.083)	(0.080)
Child has moderate plus or severe asthma (0/1)	0.486**	0.357*	0.539**	0.400*	0.495**
	(0.174)	(0.176)	(0.178)	(0.196)	(0.181)
Number of poor non directional debriefs		-0.197***			
		(0.043)			
Number of poor overestimating debriefs		0.178***			
		(0.034)			
Number of poor underestimating debriefs		0.105*			
		(0.048)			
Log(Cost)	-0.447***	-0.456***	-0.446***	-0.462***	-0.446***
	(0.015)	(0.016)	(0.015)	(0.017)	(0.016)
Spike	0.050***	0.047***	0.050***	0.048***	0.050***
	(0.005)	(0.005)	(0.005)	(0.005)	(0.005)
Observations	1 339	1 339	1 301	1 126	1 274
Country dummies x sample weights	Yes	Yes	Yes	Yes	Yes
Log-likelihood	-1 808	-1 782	-1 760	-1 533	-1 711
LR statistics	65	116	65	60	62
AIC	3 637	3 593	3 542	3 088	3 444
BIC	3 695	3 666	3 599	3 144	3 501
WTP (USD per year over 10 years)					
Mean WTP (truncated at the maximum bid with adjustment)	948	997	949	865	958
Median WTP (mean of median)	416	506	417	366	425

Note: Signif. codes: '***' 0.001 '**' 0.01 '*' 0.05 '+' 0.1 ' ' 1. The baseline estimation corresponds to a maximum likelihood estimation of the joint probabilities assuming a Weibull distribution with a spike configuration. All columns exclude very slow respondents as well as speeders. Base group: mild asthmatic child, American, male with non-asthmatic parent. Country dummies and country dummies interacted with the sampling weight are included as regressors but not reported in the table for clarity.

When removing parents of an asthmatic child (2.8%) who responded poorly to more than two non-directional debriefs in column (3), the mean WTP is USD 1 per year more than the baseline while the median WTP is USD 1 per year more than the baseline. When removing parents of an asthmatic child (15.9%) who responded poorly to more than three overestimation debriefs in column (4), the mean WTP is USD 83 per year less than the baseline while the median WTP is USD 50 per year less than the baseline. Finally, when removing parents of an asthmatic child (4.9%) who responded poorly to more than two underestimation debriefs in column (5), the mean WTP is USD 10 per year more than the baseline while the median WTP is USD 9 per year more than the baseline. In Column (4) and (5), the signs of the deviation from the baseline are consistent with the expected direction due to the poor responses.

Overall, mean and median WTP obtained with these different screening approaches have the same order of magnitude as the baseline approach both for adult and childhood asthma severity. Furthermore, the estimated coefficients are highly similar to the corresponding baseline regression results.

5.1.4 The impact of anticipated medical cost savings

Despite asking respondents to focus only on non-monetary benefits, around 35% of the asthmatic adult respondents and 39% of parents of an asthmatic child thought they could save on medical cost by choosing the reduced severity option. This share is highest in the United States (53% and 59%) where the share of income dedicated to domestic private health expenditure is also the highest (Table A.8).

To investigate the impact of such anticipations on WTP, a model (1) with an additional dummy variable equal to 1 if the respondent thought he or she could save on medical cost was estimated. Results are presented in Table C.6 for adult asthma and in Table C.7 for childhood asthma. The coefficients of the dummy variable are high and statistically different from zero. They are also positive, indicating that people who thought they could save on medical cost also state a higher WTP.

For adult asthma, mean WTP equals USD 397 per year if it is assumed that no respondent thought they could save on medical cost when choosing the SAFETYFIRST products while mean WTP equals USD 845 per year if it is assumed that all respondents thought they could save on medical cost. This difference of USD 448 per year is economically significant. Mean WTP values by country depending on respondents' assumption on medical cost are provided in Table 5.8. In all countries, mean WTP is twice as much if it is assumed that all respondents thought they could save on medical cost.

For childhood asthma, mean WTP equals USD 758 per year if it is assumed that no respondent thought they could save on medical cost when choosing the SAFETYFIRST products while mean WTP equals USD 1 293 per year if it is assumed that all respondents thought they could save on medical cost. This difference of USD 535 per year is also economically significant. Mean WTP values by country depending on respondents' assumption on medical cost are provided in Table 5.8. In all countries, mean WTP is 1.7 time higher if it is assumed that all respondents thought they could save on medical cost.

Table 5.8. Mean WTP by country depending on anticipation of medical cost savings

USD PPP per year	Adult asthma			Childhood asthma		
	No saving	Saving	Difference	No saving	Saving	Difference
Canada	320	703	383	659	1 141	482
Czech Republic	557	1 136	579	893	1 502	609
France	318	697	379	604	1 052	448
Poland	466	972	506	899	1 511	612
Sweden	365	787	422	617	1 074	457
United Kingdom	340	739	399	618	1 078	460
United States	399	849	450	1 019	1 695	676

5.2 Valuing a reduction in the risk of developing asthma

This section presents the results of the estimation of the mean and median willingness to pay of non-asthmatic adults and parents of non-asthmatic children for a marginal reduction in the probability of developing asthma in the context of a discrete choice experiment. The econometric methods associated with these estimates are presented in detail in section 4.2.

5.2.1 Non-asthmatic adults

Estimates are first conducted for all countries (Canada, Czech Republic, France, Poland, Sweden, United Kingdom, United States) for two alternative specifications. The first specification includes mild, moderate, and severe asthma risks as attributes (see. equation (4) in section 4.2) and the second specification includes total risk (see equation (5) in section 4.2)[17]. Following the recommendations of Scarpa and Thiene (2005[45]), the data indicates that the optimal number of classes is 3 for the LCM estimates for these two specifications. The heterogeneity of preferences for RPL and LCM estimates is explained via the countries where the respondents live.

The estimations are conducted using various models including MNL, RPL and LCM. For the two specifications, the highest goodness of fit across the various models, measured by McFadden's pseudo-R2, is obtained using the 3-class latent class model. For specification 1, the McFadden's pseudo-R^2 is equal to 0.048 for the MNL model, 0.233 for the RPL model and 0.365 for the 3-class LCM model. For specification 2, the McFadden's pseudo-R^2 is equal to 0.044 for the MNL model, 0.188 for the RPL model and 0.363 for the 3-class LCM model. Therefore, this paper presents the estimation results for the 3-class latent class model (Table 5.9).

In the case of specification 1 with the three levels of severity, the coefficient associated with a risk reduction of 1 in 1 000 of moderate asthma for the first class does not have the expected positive sign, which could be linked to difficulties in responding to the different choices presented during the DCE. Among the respondents who indicated that it was very difficult for them to make their choices for the DCE, the proportion of people with a low level of education is higher. Notably, many Czech respondents reported that making these choices was difficult. Therefore, a second analysis was performed from the previous data excluding non-asthmatic Czech adults to obtain more reliable estimates (Table 5.10).

[17] After dropping people who are very slow respondents, speeders, who failed the 2 probability tests and who did not take any of the attributes into account during the DCE.

Table 5.9. Estimates of the LCM model for the two specifications for all countries

	Specification 1			Specification 2		
Attribute	**Class 1 (28.8% of sample)**	**Class 2 (37.1% of sample)**	**Class 3 (34.1% of sample)**	**Class 1 (28.6% of sample)**	**Class 2 (38.0% of sample)**	**Class 3 (33.4% of sample)**
ASC	2.3032*** (0.2347)	-3.6319*** (0.1537)	-1.9945*** (0.1135)	2.9951*** (0.1818)	-3.7526*** (0.0858)	-1.6984*** (0.0777)
Mild asthma risk	0.1097*** (0.0193)	0.0515*** (0.0132)	0.1151*** (0.0058)			
Moderate asthma risk	-0.0542* (0.0315)	0.0528* (0.0309)	0.0964*** (0.0151)			
Severe asthma risk	-0.0639 (0.0580)	0.1690*** (0.0337)	-0.0082 (0.0172)			
Total risk of asthma				0.0922*** (0.0185)	0.0503*** (0.0094)	0.1239*** (0.0044)
Added cost	-0.0131*** (0.0012)	-0.0308*** (0.0010)	-0.0005 (0.0004)	-0.0130*** (0.0009)	-0.0299*** (0.0007)	-0.0016*** (0.0003)
	θ_c in class probability model					
United States	-0.2290** (0.0982)	-0.0388 (0.1012)	Ref.	-0.2230** (0.0982)	0.0116 (0.0984)	Ref.
Canada	0.4260*** (0.1326)	0.2973** (0.1350)	Ref.	0.4317*** (0.1334)	0.2898** (0.1349)	Ref.
Czech Republic	-0.8206*** (0.1522)	-0.8083*** (0.1475)	Ref.	-0.8188*** (0.1483)	-0.7932*** (0.1452)	Ref.
France	0.0861 (0.1383)	0.4558*** (0.1329)	Ref.	0.0966 (0.1392)	0.4560*** (0.1330)	Ref.
Poland	-0.6697*** (0.1436)	0.0021 (0.1298)	Ref.	-0.6594*** (0.1440)	-0.0081 (0.1298)	Ref.
Sweden	0.1753 (0.1352)	0.2207 (0.1353)	Ref.	(0.1813) (0.1361)	0.2198 (0.1351)	Ref.
United Kingdom	0.9734*** (0.1384)	0.6312*** (0.1436)	Ref.	0.9787*** (0.1395)	0.6188*** (0.1439)	Ref.
Pseudo-R^2	0.365			0.363		
AIC / N	1.398			1.401		
Number of observations (N)	5 384			5 384		

Notes: * p < 0.1 ; **p < 0.05 ; ***p < 0.01. Standard errors in parentheses.

Table 5.10. Estimates of the LCM model excluding non-asthmatic adults from the Czech Republic

	Specification 1			Specification 2		
Attribute	**Class 1 (30.1% of sample)**	**Class 2 (40.3% of sample)**	**Class 3 (29.7% of sample)**	**Class 1 (29.7% of sample)**	**Class 2 (41.0% of sample)**	**Class 3 (29.3% of sample)**
ASC	2.5024*** (0.2711)	-3.3327*** (0.1388)	-1.3637*** (0.1280)	2.9701*** (0.1758)	-3.6035*** (0.1191)	-1.2957*** (0.1165)
Mild asthma risk	0.1354*** (0.0225)	0.0735*** (0.0124)	0.1449*** (0.0069)			
Moderate asthma risk	0.0183 (0.0354)	0.1118*** (0.0292)	0.1728*** (0.0175)			
Severe asthma risk	0.0396 (0.0676)	0.2070*** (0.0324)	0.0597*** (0.0204)			
Total risk of asthma				0.1180*** (0.0171)	0.0558*** (0.0010)	0.1453*** (0.0064)
Added cost	-0.0187*** (0.0015)	-0.0309*** (0.0010)	-0.0012** (0.0005)	-0.0180*** (0.0014)	-0.0289*** (0.0008)	-0.0013*** (0.0004)
			θ_c in class probability model			
United States	-0.1888* (0.0988)	0.0431 (0.1007)	Ref.	-0.1935* (0.0990)	0.0826 (0.1009)	Ref.
Canada	0.4358*** (0.1341)	0.3099** (0.1348)	Ref.	0.4395*** (0.1348)	0.2943** (0.1346)	Ref.
France	0.1092 (0.1398)	0.4667*** (0.1333)	Ref.	0.1136 (0.1410)	0.4606*** (0.1334)	Ref.
Poland	-0.6640*** (0.1449)	0.0178 (0.1297)	Ref.	-0.6554*** (0.1457)	0.0012 (0.1298)	Ref.
Sweden	0.1930 (0.1369)	0.2308* (0.1357)	Ref.	0.1951 (0.1377)	0.2274* (0.1354)	Ref.
United Kingdom	0.9884*** (0.1401)	0.6267*** (0.1443)	Ref.	0.9933*** (0.1412)	0.6163*** (0.1447)	Ref.
Pseudo-R^2	0.379			0.378		
AIC / N	1.367			1 369		
Number of observations (N)	4 764			4 764		

Notes: * p < 0.1 ; **p < 0.05 ; ***p < 0.01. Standard errors in parentheses.

Respondents belonging to the first class, for the two specifications, give a positive and significant value to the ASC (*Alternative Specific Constant*) indicating that on average the individuals of this class prefer the status quo (keep using standard products instead of SAFETYFIRST products). Respondents from the United Kingdom have a higher probability of belonging to this class than respondents from the other countries. Conversely, the Poles have a smaller probability of belonging to this class.[18]

Individuals belonging to the 2nd and 3rd classes state a negative value to the ASC that is they get positive utility from the use of SAFETYFIRST products. For these two classes, individuals give a positive and

[18] This result is consistent with the fact that British respondents have the highest percentage of people who consistently chose the status quo that is not choosing SAFETYFIST products in their 5 choices (33.1% for adults, 24.9% for the parents of non-asthmatic children). The Polish respondents are the ones with the lowest percentage of status quo after respondents from the Czech Republic (14% for adults, 15% for the parents of non-asthmatic children).

significant value (at the 1% level of risk) to all probability reductions. The disutility associated with the additional cost is less important in the 3rd class. In the case of the first specification, the utility associated with a reduction in the risk varies depending on whether the individuals belong to the 2nd or the 3rd class. It is found that individuals in the 2nd class get a greater utility from a marginal reduction in the probability of developing severe asthma compared to moderate or mild asthma. Conversely, individuals in the 3rd class get a greater utility from a marginal reduction in the probability of developing moderate asthma compared to mild or severe asthma. From a theoretical point of view, there is no reason that the coefficient associated with severe asthma must be higher than the coefficient associated with moderate asthma (and that this latter one must be higher than the coefficient for mild asthma). Indeed, these asthma outcomes are not certain but can occur with different probabilities ordered as follow: Probability(severe asthma) < Probability(moderate asthma) < Probability(mild asthma). When making their choices respondents combine the probabilities and the levels of asthma. Consequently, the respondents can value and rank the probability reductions differently, depending on how they consider these two dimensions of the risk. Finally, there is not a "right" and a "wrong" class.

5.2.2 Parents of non-asthmatic children

Regarding parents of non-asthmatic children, the model is estimated for all countries excluding respondents from Czech Republic, as above. Three classes of respondents emerge from the estimation (Table 5.11). Nevertheless, compared to non-asthmatic adults, the distribution of the parents of non-asthmatic children is different over the 3 groups: their proportion is lower in the class with a positive ASC (-8 points) and higher in the class which the ASC is negative and with the highest disutility for additional costs for the non-asthmatic adults (+6.9 points).

As in the case of non-asthmatic adults, parents in the 3rd class get greater utility from a marginal reduction in the probability of developing moderate asthma compared to mild or severe asthma. Moreover, the values of these different coefficients are higher in the case of parents choosing for their children relative to choosing for themselves. Interestingly, parents belonging to the 2nd class focus, at the 5% level of risk, only on the marginal reduction in the probability of developing mild asthma.

5.2.3 Mean and median marginal willingness to pay (mean and median MWTP)

The mean marginal WTPs are calculated starting from equation (17) (see section 4.2) for the 3-class latent class model using the estimates displayed in Table 5.10 and Table 5.11 and the sampling weights.

The mean WTP for a risk reduction of 1 in 1 000 over 10 years equals USD 28 per year for non-asthmatic adults and USD 43 for non-asthmatic child (Figure 5.5). The mean marginal WTP for a reduction in moderate asthma risk (USD 37 per year, for non-asthmatic adult) is greater than the mean marginal WTP for a reduction in mild asthma risk (USD 32 per year, for non-asthmatic adult), which is greater than the mean marginal WTP for a reduction in severe asthma risk (USD 16 per year, for non-asthmatic adult).

The median WTP for a risk reduction of 1 in 1 000 over 10 years equals USD 5.2 per year for adult asthma and USD 7.4 for childhood asthma (Figure 5.6). The median marginal WTP for a reduction in severe asthma (USD 6.2 per year, for non-asthmatic adult) is greater than the median marginal WTP for a reduction in mild asthma risk (USD 5.9 per year, for non-asthmatic adult), which is greater than the median marginal WTP for a reduction in moderate asthma risk (USD 3.5 per year, for non-asthmatic adult). The important difference between mean and median values is due to the fact that the distribution of the individual MWTP is asymmetric with high maximum values.

Table 5.11. Estimates of the LCM model excluding parents of non-asthmatic children from the Czech Republic

	Specification 1			Specification 2		
Attributs	**Class 1 (22.1% of sample)**	**Class 2 (41.2% of sample)**	**Class 3 (36.6% of sample)**	**Class 1 (22.1% of sample)**	**Class 2 (42.9% of sample)**	**Class 3 (35.1% of sample)**
ASC	3.1328*** (0.6620)	-2.7699*** (0.1793)	-1.2444*** (0.3261)	3.7227*** (0.4665)	-2.6135*** (0.1351)	-1.3536*** (0.3433)
Mild asthma risk	0.0863* (0.0510)	0.0769*** (0.0146)	0.1917*** (0.0143)			
Moderate asthma risk	0.0190 (0.0907)	0.0674* (0.0372)	0.3071*** (0.0399)			
Severe asthma risk	-0.0950 (0.1671)	0.0582 (0.0456)	0.1015** (0.0411)			
Total risk of asthma				0.0950** (0.0432)	0.0805*** (0.0126)	0.1862*** (0.0122)
Added cost	-0.0097*** (0.0032)	-0.0211*** (0.0015)	0.0004 (0.0009)	-0.0110*** (0.0031)	-0.0204*** (0.0011)	0.0021*** (0.0006)
	θ_c in class probability model					
United States	-0.3447* (0.2044)	Ref.	0.3063 (0.1870)	-0.3747* (0.2015)	Ref.	0.2584 (0.1791)
Canada	-0.3987 (0.2841)	Ref.	-0.9441*** (0.2628)	-0.3871 (0.2820)	Ref.	-0.9408*** (0.2619)
France	-0.3681 (0.2832)	Ref.	-0.4230* (0.2555)	-0.4560 (0.2786)	Ref.	-0.6194** (0.2488)
Poland	-0.0637** (0.2599)	Ref.	-0.4169* (0.2182)	-0.6338** (0.2579)	Ref.	-0.4254** (0.2165)
Sweden	-0.1851 (0.2841)	Ref.	-0.3278 (0.2491)	-0.1828 (0.2816)	Ref.	-0.3319 (0.2466)
United Kingdom	0.0572 (0.2681)	Ref.	-0.5397** (0.2510)	0.0724 (0.2660)	Ref.	-0.5311** (0.2494)
Pseudo-R^2	0.357			0.355		
AIC / N	1.422			1.423		
Number of observations (N)	1 308			1 308		

Notes: * p < 0.1 ; **p < 0.05 ; ***p < 0.01. Standard errors in parentheses.

The marginal WTPs for a risk reduction of 1 in 1000 for the parents of non-asthmatic children are systematically greater than those of non-asthmatic adults, in terms of mean and median values (Figure 5.5 and Figure 5.6). That the valuation of health risk reduction in children exceeds the valuation of health risk reduction in adults is also observed for asthma severity and also in the VSL literature. The same is observed of median marginal WTP for a reduction in asthma risk, although the differences between adults and children are smaller than for mean WTPs. For the mean values, the very high MWTP are due to the existence of very high values for the parents of non-asthmatic children compared to the sample of non-asthmatic adults. Therefore, the median is more robust than the mean to extreme values.

Figure 5.5. Mean Marginal Willingness to Pay for 1 in 1 000 reduction in the risk to develop adult and childhood asthma



Note: Mean WTP is the weighted average of individual WTP where the weight equals to the sampling weight used to correct for the differences between the sample and the target population. Parents of non-asthmatic children were asked their WTP for a reduction in the risk that their youngest non-asthmatic child develops asthma.

Figure 5.6. Median Marginal Willingness to Pay for 1 in 1 000 reduction in the risk to develop adult and childhood asthma



Note: Median WTP is the median of individual WTP multiplied with the sampling weight used to correct for the differences between the sample and the target population. Parents of non-asthmatic children were asked their WTP for a reduction in the risk that their youngest non-asthmatic child develops asthma.

Finally, to measure how WTP vary with income, the income elasticity is estimated as follows. Logged unweighted individual WTP are regressed on logged income, a dummy for missing income and interactions between country dummies and the sampling weight. For non-asthmatic adults, the income elasticity equals 0.08 for mild asthma, 0.18 for moderate asthma, 0.12 for severe asthma and 0.07 for total risk. For parents of non-asthmatic children, the income elasticity equals 0.10 for mild asthma, 0.14 for moderate asthma, 0.08 for severe asthma and 0.06 for total risk. These income elasticities are much lower than those estimated for reducing severity in asthmatics.

5.2.4 Country-level estimates

Mean marginal WTPs for adult asthma risk is provided for each country in Figure 5.7. The mean WTP for reduction in total adult asthma risk by 1 in 1 000 varies between USD 20 and USD 37 per year. The analysis by country shows that adults without asthma from Canada, France and Sweden have very similar mean marginal WTP for each level of severity. Respondents from the United Kingdom stated the lowest mean values as opposed to respondents from Poland. One plausible explanation for the high value found in Poland is that it is the country with the largest share of young respondents aged 18-29 (23.4% versus 15.3% for the average surveyed country). An analysis of mean marginal WTP by age group indicates a higher value for non-asthmatic adults aged from 18 to 29, regardless of the severity considered. Another potential explanation could be that Poles are willing to pay relatively more to avoid asthma because they have a relatively less efficient health system as measured by treatable causes of mortality per 100 000

population compared to the other countries of the sample. However, this hypothesis is not tested in the paper.

For all countries, the marginal WTPs for a reduced risk of moderate asthma is higher than for a reduced risk of severe asthma.

Mean marginal WTPs for childhood asthma risk by country are shown in Figure 5.8. The mean WTP for reduction in total childhood asthma risk by 1 in 1 000 varies between USD 35 and USD 61. Respondents from Canada stated the lowest mean values. The largest mean WTP for childhood asthma risk is found in the United States followed by Poland.

For non-asthmatic adults, median WTP for a reduction of 1 in 1 000 in total asthma risk per year over 10 years are very similar across countries ranging from USD 5.2 for Canada to USD 5.4 for the United States, Poland and the United Kingdom (Figure 5.9). The exception is France with a lower median value equal to USD 3.9 per year. For parents of non-asthmatic children, Canada has the lowest median marginal WTP for the total risk (USD 5.9 per year), while the United States has the highest one (USD 9.4 per year) (Figure 5.10).

In contrast to mean WTP, the median WTP to reduce the risk of moderate asthma is smaller than the median WTP to reduce the risk of severe asthma in all countries for both non-asthmatics adults and parents of non-asthmatic children. These differences are explained by high values driving the mean WTP up.

Figure 5.7. Mean Marginal Willingness to Pay for non-asthmatic adults by country



Figure 5.8. Mean Marginal Willingness to Pay of parents of non-asthmatic children for a 1 in 1 000 risk reduction in the risk that their child develops asthma



Figure 5.9. Median Marginal Willingness to Pay for non-asthmatic adults by country



Figure 5.10. Median Marginal Willingness to Pay of parents of non-asthmatic children for a 1 in 1 000 risk reduction in the risk that their child develops asthma



5.2.5 Additional robustness checks

Some respondents indicated that they thought they would save on medical bills by choosing SAFETYFIRST products while other did not. The impact of such consideration is analysed here. Despite the instruction provided in the questionnaire to not take into account medical cost saving, about 25% of the adult respondents (resp. 31% of parents) declared that they considered this effect when making their choices. This proportion ranges from 13.9% in the United Kingdom to 35.8% in the United States. In the case of parents, it ranges from 19.5% in Sweden to 42.6% in the United States (Table A.9).

Thinking about saving on medical bills has a significant effect on the WTP estimates. If a respondent considered that buying SAFETYFIRST products would reduce their medical bills, their probability of being in the class of people who want to pay the most is higher while their probability of belonging to the class of people who do not want to pay is lower. Consequently, the mean and median values for the marginal WTP vary in a significant way between respondents considering or not these effects during their choices (Table 5.12). Respondents who thought they would save on their medical bills are willing to pay USD 20 per year more on average than respondents who did not think they would for a 1 in 1 000 reduction in total asthma risk.

Regarding the WTP of non-asthmatic adults, the effect of having an asthmatic child or having a non-asthmatic child or having no child, was tested for the LCM model based on the 3 classes for the two specifications (three levels of severity or total risk) (Table 5.13). The results indicate that adults without children have a higher probability of belonging to the class of people who do not want to pay and to the class of people who want to pay a small amount. Conversely, having a child decreases these respective probabilities and this phenomenon is more pronounced for adults with asthmatic children.

Table 5.12. Marginal WTP for reduced asthma risk by stance on medical cost saving for asthmatic adults

Did you think that by reducing the risk of getting asthma you also reduced your medical bills?				
MWTP (USD PPP per year)	Mean		Median	
	NO	YES	NO	YES
Mild	27.4	50.1	5.7	6.7
Moderate	30.2	59.5	3.2	6.7
Severe	14.1	24.4	5.5	9.6
Total	23.7	43.4	5.0	5.6

Note: Non-asthmatic adults, all countries without Czech Republic.

Table 5.13. Estimates of the LCM model taking into account child status

	Specification 1			Specification 2		
Attribute	**Class 1 (30.0% of sample)**	**Class 2 (40.3% of sample)**	**Class 3 (29.7% of sample)**	**Class 1 (29.6% of sample)**	**Class 2 (41.0% of sample)**	**Class 3 (29.4% of sample)**
ASC	2.5467*** (0.2759)	-3.3307*** (0.1404)	-1.3684*** (0.1278)	2.9892*** (0.1787)	-3.5942*** (0.1207)	-1.2992 *** (0.1157)
Mild asthma risk	0.1361*** (0.0229)	0.0732*** (0.0124)	0.1447*** (0.0069)			
Moderate asthma risk	0.0168 (0.0356)	0.1093*** (0.0293)	0.1721*** (0.0174)			
Severe asthma risk	0.0475 (0.0683)	0.2022*** (0.0325)	0.0597*** (0.0205)			
Total risk of asthma				0.1171*** (0.0172)	0.0562*** (0.0100)	0.1453*** (0.0063)
Added cost	- 0.0185*** (0.0015)	- 0.0308*** (0.0010)	- 0.0012** (0.0005)	-0.0178*** (0.0014)	-0.0290*** (0.0008)	-0.0014*** (0.0004)
	θ_c in class probability model					
No child	0.1418*** (0.0497)	0.4099*** (0.0560)	Ref.	0.1402*** (0.0501)	0.4368*** (0.0570)	Ref.
Asthmatic child	-0.6539*** (0.1788)	-0.3687** (0.1657)	Ref.	-0.6560*** (0.1807)	-0.3410** (0.1659)	Ref.
No asthmatic child	-0.4057*** (0.0924)	-0.3332*** (0.0900)	Ref.	-0.4049*** (0.0929)	-0.3321*** (0.0900)	Ref.
Pseudo-R^2	0.376			0.375		
AIC / N	1.372			1.374		
Number of observations (N)	4 764			4 764		

Notes: * p < 0.1 ; **p < 0.05 ; ***p < 0.01. Standard errors in parentheses.

6 Recommended values for asthma severity and risk for policy analysis

6.1 Recommended WTP values for a one-step reduction in asthma severity

Recommend mean WTP values for a one-step reduction in adult asthma severity and childhood asthma severity by country in both USD PPP and local currencies are provided in Table 6.1. These values are based on the baseline estimation strategy presented in Section 5.1.1 that is robust to various sensitivity tests. Recommended WTP values are also provided by baseline severity level. Recommend median WTP values for a one-step reduction in adult asthma severity and childhood asthma severity by country in both USD PPP and local currencies are provided in Table D.1 of Annex D.

6.2 Recommended values of a statistical case of asthma

Recommended mean values of a statistical case of adult and childhood asthma by country in both USD PPP and national currencies are provided in Table 6.2. VSC are obtained by dividing mean marginal willingness to pay values per year provided in Figure 5.7 and Figure 5.8 by 1 in 1 000 and multiplying the result by 10 that corresponds to the number of years of payment and reduced risk of developing asthma. Estimates for Czech Republic cannot be provided given the high share of respondents who could not provide informed preferences. Recommended median values of a statistical case of adult and childhood asthma by country in both USD PPP and national currencies are provided in Table D.2 of Annex D.

6.3 Comparison with previous stated preference and cost of illness studies

It is worth comparing the results of the present analysis with previous stated preferences and COI studies. Comparing the results of the present study valuing WTP for half a step reduction in asthma severity and previous studies that most exclusively focus on WTP for an asthma cure is not straightforward. Nevertheless, there are two ways to compare the results of the present studies with findings in the literature. First, WTP estimates for an asthma cure can be compared to WTP for a very mild asthma, which is the asthma severity level closest to a cure. Table E.1 shows that WTP values estimated in the present studies are in the same order of magnitude as WTP values estimated in previous studies ranging from USD 381 to USD 6 969 for adult asthma and ranging from USD 705 to USD 10 330 for childhood asthma depending on the baseline severity. However, estimates from the present study tend to be smaller probably because the asthma is not completely cured. Notably, available estimates of COI that include medical cost and lost earnings are larger than the disutility of adult and childhood asthma valued in the present paper.

Table 6.1. Recommended mean WTP values for a one-step reduction in asthma severity by surveyed country

USD PPP per year	Adult asthma	Adult mild asthma	Adult mild plus or moderate asthma	Adult moderate plus or severe asthma	Childhood asthma	Childhood mild asthma	Childhood mild plus or moderate asthma	Childhood moderate plus or severe asthma
Canada	430	320	500	760	840	640	970	1 200
Czech Republic	690	500	760	1 130	1 080	820	1 200	1 520
France	440	310	490	760	780	560	850	1 080
Poland	630	450	700	1 040	1 130	870	1 300	1 610
Sweden	770	340	540	820	760	560	850	1 080
United Kingdom	450	320	510	780	740	560	860	1 090
United States	590	410	640	960	1 300	940	1 380	1 720

Local currency per year	Adult asthma	Adult mild asthma	Adult moderate asthma	Adult severe asthma	Childhood asthma	Childhood mild asthma	Childhood mild plus or moderate asthma	Childhood moderate plus or severe asthma
Canada (CAD)	550	410	640	970	1 080	820	1 240	1 540
Czech Republic (CZK)	8 300	6 000	9 200	12 700	13 100	9 900	14 500	18 400
France (EUR)	330	230	370	570	580	420	630	800
Poland (PLN)	1 000	700	1 200	1 700	1 900	1 400	2 200	2 700
Sweden (SEK)	7 300	3 200	5 100	7 700	7 200	5 300	8 000	10 200
United Kingdom (GBP)	340	240	380	580	550	420	640	810
United States (USD)	590	410	640	960	1 300	940	1 380	1 720

Note: Values are rounded for clarity. The conversions are done using Purchasing Power Parities for actual individual consumption of 2019 since it was used to convert bid levels across countries. Data comes from the OECD Dataset: PPPs and exchange rates as of January 2022.

Table 6.2. Recommended mean values of a statistical case of asthma by surveyed country

	USD PPP		National currency	
Country	Adult asthma	Childhood asthma	Adult asthma	Childhood asthma
Canada (CAD)	270 000	350 000	350 000	450 000
France (EUR)	260 000	360 000	190 000	270 000
Poland (PLN)	370 000	470 000	620 000	780 000
Sweden (SEK)	270 000	420 000	2 550 000	3 960 000
United Kingdom (GBP)	200 000	370 000	150 000	280 000
United States (USD)	330 000	610 000	330 000	610 000

Note: Values are rounded at the ten thousand for clarity. The conversions are done using Purchasing Power Parities for actual individual consumption of 2019 since it was used to convert bid levels across countries. Data comes from the OECD Dataset: PPPs and exchange rates as of January 2022.

The second way to compare estimates is to compute the WTP equivalent for a reduction of severity from severe asthma to mild asthma in USD2022 derived from the present studies with values derived from the estimates of Zillich et al. (2002[20]) and Dickie and Messman (2004[18]). Similarly, the estimates reported in the present study and in previous studies are of similar order of magnitude (Table E.1). Comparing the values of a statistical case of asthma reported in the present study with the previous literature is not straightforward either.

Table E.2 shows that there is a large variation across studies. Only one stated preference study, Priez and Jeanrenaud (1999[11]), estimated the value of a statistical case of chronic bronchitis in 1999. Their value, when transferred over time using equation (19) that is when the growth in GDP per capita and in prices is taken into account, is equal to USD 21 355, more than ten times smaller than the value elicited in the present study. The other studies focus on chronic bronchitis or more generally chronic lung disease and are based on small- scale surveys implemented in the early 1990s. Transferring the value over time results in a value of a statistical case equal to USD_{2022} 1 016 000 for Viscusi et al. (1991[12]) and USD_{2022} 3 099 000 for Krupnick and Cropper (1992[13]), which are 3 to 10 times larger than the value elicited in the present study. These much larger values are likely due to the small samples and to the risk-risk trade-off method where respondents choose among different pairs of death risk and chronic bronchitis risk. Finally, present discounted value of the lifetime COI estimates including both medical cost and lost earnings reported by Belova et al. (2020[14]) are 10 times smaller than the value of a statistical case of adult and childhood asthma estimated in the present paper.

6.4 Strengths and weaknesses of results

This study provides new, useful and internationally validated estimates of WTP for several asthma endpoints for seven OECD countries using an original, state of the art stated preference survey. The study makes available for the first time in a consistent framework WTP estimates for a large panel of asthma endpoints: adult asthma risk, adult asthma severity, childhood asthma risk and childhood asthma severity. In addition, the present study provides values of a statistical case of asthma that does not rely on a value of statistical life estimate unlike previous studies relying on risk-risk trade-offs. The survey was implemented through an online tool to samples selected to be demographically representative of each country's population. Using various validity and robustness checks, the survey performs well and as intended. For all countries except Czech Republic in the case of the asthma risk valuation, the coefficients for variables explaining variations in WTP have signs that are consistent with expectations. In all countries, the cost for the reduced risk or severity option has a statistically significant negative effect on the probability

to choose the reduced risk or severity option. Baseline estimation results are robust to various methodological choices that are extensively tested in the paper.

Despite these numerous strengths, the study has several potential weaknesses. First, some respondents did not comply with the instruction to think only about non-monetary benefits when responding to the survey. Some thought they could save on their medical bills by choosing the reduced risk or severity option. Therefore, the mean WTP values reported in Section 6.1 and 6.2 cover not only the disutility associated with getting asthma or having a more severe asthma but also partially cover anticipated saving on medical expenditures. Mean WTP for a one-step reduction in asthma severity is twice as large (around USD 448 per year more) when respondents anticipated they could save on medical costs (Table 5.8). Mean WTP for a 1 in 1 000 risk reduction in developing asthma is also twice as large (around USD 20 per year more) when respondents anticipated they could save on medical cost (Table 5.12). If socioeconomic analysis practitioners wish to monetise only the disutility of asthma, then they should use the WTP estimates from respondents who did not think about medical cost savings.

Although the samples come close to the target quotas on gender, education and age for each country, samples of asthmatic adults and samples of parents of an asthmatic child exhibit higher deviation from the target quotas. Given the mode of administration of the survey and the reduced size of these samples, this result is not surprising. However, using post-stratification weights as additional regressors allowed for the control of these sampling deviations.

While the study significantly expands the number of WTP estimates for asthma risk and severity available for policy analysis, many countries are, of course, excluded. Countries for which a country-specific value is not provided in the current paper would need to use a benefit transfer method based on best practices.[19] In the absence of benefit transfer guidance specific to the health effects covered by the SWACHE project, it is recommended as a starting point that non-surveyed countries use the value estimated for a surveyed country from Table 6.1 and from Table 6.2 that shares similar characteristics such as income, age and public health care systems.

6.5 Using these recommended values in policy analysis

6.5.1 Using the value of a statistical case of asthma in cost benefit analysis

The estimates of a value of statistical case should be used in cost-benefit analyses addressing proposed regulations of chemicals or other pollutants that influence asthma. Presented here is the recommended use.

Assume a policy is appraised over T years in country c. Compared to the status quo, this policy is estimated to lead to a reduction of SCA_{ct} statistical cases of adult asthma and to a reduction of SCC_{ct} statistical cases of childhood asthma in country c in year t. The discounted benefits of the policy in terms of avoided asthma should be computed as follows:

$$Discounted\ benefits_c = \sum_{t=0}^{T} \frac{VSCA_{ct} \times SCA_{ct} + VSCC_{ct} \times SCC_{ct}}{(1+k_c)^t} \quad (18)$$

where k_c is the discount rate used in country c[20], $VSCA_{ct}$ is the recommended value of a statistical case of adult asthma and $VSCC_{ct}$ is the recommended value of a statistical of childhood asthma in country c in year t. $VSCA_{ct}$ and $VSCC_{ct}$ are based on the recommended values $VSCA_{c,2022}$ and $VSCC_{c,2022}$ reported in USD PPP in Table 6.2 and should reflect increase in prices and in GDP per capita over time such that:

[19] The OECD will publish benefit transfer guidance that can be applied to the SWACHE project.

[20] Note that the discount rate can also varies over time but generally it changes over long time period.

$$VSCA_{ct} = VSCA_{c,2022} \times PPP_{c,2019} \times \left(1 + \%\Delta P_{c,2022-t}\right) \times \left(1 + \%\Delta Y_{c,2022-t}\right)^{\beta} \quad (19)$$

$$VSCC_{ct} = VSCC_{c,2022} \times PPP_{c,2019} \times \left(1 + \%\Delta P_{c,2022-t}\right) \times \left(1 + \%\Delta Y_{c,2022-t}\right)^{\beta} \quad (20)$$

where $PPP_{c,2019}$ is Purchasing Power Parities for actual individual consumption in national currency per USD for the 2019 that was used to convert bid levels in the survey, $\%\Delta P_{c,2022-t}$ is the increase in consumer price index from 2022 to year t, $\%\Delta Y_{c,2022-t}$ is GDP per capita growth from 2022 to year t and β is the income elasticity.

An example for a fictional policy that reduces the number of statistical cases of adult asthma by 1 000 every year in France for 2022-2025 is provided in Table 6.3 for illustration purpose.[21] Based on a VSC of USD 260 000 in 2022, the discounted benefits of the policy over the 4 years equals EUR$_{2022}$ 767 million.

Finally, the discounted costs of the policy should be subtracted from these discounted benefits to compute the net present value of the policy.

Table 6.3. Measuring the benefits of policy intervention in France: an illustrative example using the value of a statistical case of adult asthma

		2022	2023	2024	2025
GDP per capita, volume in USD, at constant PPP (USD$_{2015}$)		43 081	43 258	43 676	43 929
GDP per capita growth since 2022 ($\%\Delta Y_{c,2022-t}$)			0.40%	1.40%	2.00%
Consumer Price Index (2015)		112	114[b]	116[b]	118[b]
Consumer Price Index growth since 2022 ($\%\Delta P_{c,2022-t}$)			1.80%	3.60%	5.40%
PPP for actual individual consumption ($PPP_{c,2019}$)		0.75			
Value of a Statistical Case of Adult Asthma ($VSCA$)	(USD$_{2022}$ PPP thousand)	260			
	(EUR$_{2022}$ thousand)	194			
	(EUR thousand)	194	197	201	204
Annual statistical cases of adult asthma avoided (SCA_{ct})		1 000	1 000	1 000	1 000
Discounted annual benefits (EUR$_{2022}$ thousand)		193 704	192 409	191 138	189 767
Discount rate		2.5%	2.5%	2.5%	2.5%
Discounted benefits (EUR$_{2022}$ thousand)		767 018			

Note: This illustrative example assumes a fictional policy that would reduce the number of statistical cases of asthma by 1 000 every year in France from 2022 to 2025. GDP per capita projections for 2022-2024 are provided by the OECD Economic Outlook (2022[46]). GDP per capita for 2025 is computed by the authors based on the linear fit of 2022-2024 values over time. Consumer Price Index data for 2022 comes from the OECD Dataset: Consumer price indices (CPIs) as of January 2022. [b] a 2% increase per year is assumed for the Consumer Price Index for 2023-2025 and is not an OECD forecast. PPP for actual individual consumption data is for year 2019 as used to convert bid levels across countries and comes from the OECD Dataset: PPPs and exchange rates as of January 2022. The discount rate comes from Quinet (2013[47]) and is what is used in France for short assessment period for which there is no systemic risk in the implementation of the policy. The income elasticity equals 0.07 as estimated for total adult asthma risk in this paper.

6.5.2 Using the WTP value for reduced asthma severity in cost benefit analysis

Similar to the WTP for the reduction of asthma risk, WTP for the reduction in asthma severity can be used in cost benefit analysis. Suppose a risk management option or a policy reduce leads to a quantified number of severity steps in a given population of asthmatics. There are two potential scenarios. Either the reduction of severity is quantified for each baseline severity or more likely, only the number of severity reductions for

[21] For clarity, only adult asthma is considered in the illustrative example.

the average baseline severity is available. In the former case, discounted benefits should be computed as follows:

$$\begin{aligned} Discounted\ benefits_c &= \sum_{t=0}^{T} \frac{1}{(1+k_c)^t} \big(\overline{WTP}_{mild,ct} \times RS_{mild,ct} \\ &+ \overline{WTP}_{mildplusmoderate,ct} \times RS_{mildplusmoderate,ct} \\ &+ \overline{WTP}_{moderateplussevere,ct} \times RS_{moderateplussevere,ct}\big) \end{aligned} \quad (21)$$

Where $\overline{WTP}_{baselineseverity,ct}$ is the mean WTP for going from baseline asthma severity to half a step lower in country c in year t, $RS_{baselineseverity,ct}$ is the number of asthmatics people whose asthma severity is reduced by half a step from the baseline asthma severity for one year due to the policy intervention in country c in year t and k_c is the discount rate used in country c.

In most cases, data are scarcer. Then, the discounted benefits can be estimated as follows:

$$Discounted\ benefits_c = \sum_{t=0}^{T} \frac{\overline{WTP}_{ct} \times RS_{ct}}{(1+k_c)^t} \quad (22)$$

Where $\overline{WTP}_{ct}$ is the mean WTP for going from baseline asthma severity to half a step lower, RS_{ct} is the number of asthmatics people whose asthma severity is reduced by half a step for one year regardless on their current asthma severity due to the policy intervention in country c in year t and k_c is the discount rate used in country c.

$\overline{WTP}_{baselineseverity,ct}$ and $\overline{WTP}_{ct}$ are based on the recommended values $\overline{WTP}_{baselineseverity,c2022}$ and $\overline{WTP}_{c2022}$ reported in USD PPP in Table 6.1 and should reflect increase in prices and in GDP per capita over time such that:

$$\overline{WTP}_{ct} = \overline{WTP}_{c2022} \times\ PPP_{c,2019} \times \left(1 + \%\Delta P_{c,2022-t}\right) \times \left(1 + \%\Delta Y_{c,2022-t}\right)^{\beta} \quad (23)$$

where $PPP_{c,2019}$ is Purchasing Power Parities for actual individual consumption in national currency per USD for the 2019 that was used to convert bid levels in the survey, $\%\Delta P_{c,2022-t}$ is the increase in consumer price index from 2022 to year t, $\%\Delta Y_{c,2022-t}$ is GDP per capita growth from 2022 to year t and β is the income elasticity. An illustrative example for a fictional policy that increases the number of asthmatics people whose asthma severity is reduced by half a step for one year by 1 000 every year in France for 2022-2025 is provided in Table 6.4 for illustration purpose.[22] Based on a mean WTP of USD 440 in 2022, the discounted benefits of the policy over the 4 years equals EUR_{2022} 1.3 million.

[22] For clarity, only asthmatic adults are considered in the illustrative example.

Table 6.4. Measuring the benefits of policy intervention in France: an illustrative example using the mean WTP to reduce adult asthma severity by half a step

Year		2022	2023	2024	2025
GDP per capita, volume in USD, at constant PPP (USD_{2015})		43 081	43 258	43 676	43 929[a]
GDP per capita growth since 2022 ($\%\Delta Y_{c,2022-t}$)			0.40%	1.40%	2.00%
Consumer Price Index (2015)		112	114[b]	116[b]	118[b]
Consumer Price Index growth since 2022 ($\%\Delta P_{c,2022-t}$)			1.80%	3.60%	5.40%
PPP for actual individual consumption ($PPP_{c,2019}$)		0.75			
Mean WTP to reduce asthma severity by half a step ($\overline{WTP}_{ct}$)	(USD_{2022} PPP)	440			
	(EUR_{2022})	328			
	(EUR)	328	334	340	346
Annual number of asthmatics people whose asthma severity is reduced by half a step for one year (RS_{ct})		1 000	1 000	1 000	1 000
Discounted annual benefits (EUR_{2022} thousand)		328	326	324	323
Discount rate		2.5%[c]	2.5%	2.5%	2.5%
Discounted benefits (EUR_{2022} thousand)		1 300			

Note: This illustrative example assumes a fictional policy that would reduce the number of statistical cases of asthma by 1 000 every year in France from 2022 to 2025. GDP per capita projections for 2022-2024 are provided by the OECD Economic Outlook (2022[46]). [a]GDP per capita for 2025 is computed by the authors based on the linear fit of 2022-2024 values over time and is not an OECD forecast. Consumer Price Index data for 2022 comes from the OECD Dataset: Consumer price indices (CPIs) as of January 2022. [b] a 2% increase per year is assumed for the Consumer Price Index for 2023-2025 and is not an OECD forecast. PPP for actual individual consumption data is for year 2019 as used to convert bid levels across countries and comes from the OECD Dataset: PPPs and exchange rates as of January 2022. [c]The discount rate comes from Quinet (2013[47]) and is what is used in France for short assessment period for which there is no systemic risk in the implementation of the policy. The income elasticity equals 0.3 as estimated for total adult asthma risk in this paper.

7 Conclusion

Asthma is a non-curable long-term condition affecting children and adults. Asthmatics experience symptoms such as cough, wheeze, shortness of breath and chest tightness. Depending on its severity, asthma can prevent normal outdoor activities, require routine medication and sometimes oxygen intake. Severe asthma can require emergency room visits and hospitalisation.

Previous valuation work does not provide internationally comparable WTP values for asthma risk and severity for adults and children. To fill this gap, the SWACHE asthma survey asks what asthmatics are willing to pay to reduce their asthma severity and or the asthma severity of their youngest child e.g. from severe to moderate, moving away from previous valuation efforts estimating WTP for an unrealistic cure of asthma. Further, the survey asks people who do not have asthma what they are willing to pay to reduce their risk of getting it. Finally, the survey asks parents what they are willing to pay to reduce: i) the severity of the asthma of their youngest asthmatic child, and ii) the risk that their youngest non-asthmatic child gets it., without relying on the value of statistical life.

The survey was implemented in seven countries. In each of these countries, a sample of at least 1 600 respondents (1 200 non-asthmatic adults, 300 asthmatic adults and 190 parents of asthmatic children) representative of the general population was collected and analysed empirically.

The WTP for reducing adult asthma severity equals USD 529 per year on average and varies from USD_{2022} 429 per year in Canada to USD_{2022} 685 per year in Czech Republic. The WTP for reducing asthma severity in children is higher at USD_{2022} 948 per year on average and varies from USD_{2022} 743 in Sweden to USD_{2022} 1 310 in the United States. The Value of a Statistical Case of adult asthma varies from USD_{2022} 200 000 in the United Kingdom to USD_{2022} 370 000 in Poland. The Value of a Statistical Case of childhood asthma varies from USD_{2022} 350 000 in Canada to USD_{2022} 610 000 in the United States.

The mean WTP for reduced asthma severity estimated in this paper are of similar magnitude as the mean WTP estimated in previous work. The mean value of a statistical case of asthma estimated differ significantly from the values of a statistical case of other chronic lung diseases estimated in previous studies. The results show that, for the United States, relying exclusively on COI estimates underestimates the benefit of avoiding an adult asthma case by around USD_{2022} 285 000 and a childhood asthma case by around USD_{2022} 554 000.

The present paper provides recommended values for asthma severity and risk and offers guidance on how to use these values in policy analysis. Further work should offer comprehensive benefit transfer guidance to estimate what values countries that were not included in the survey should use in policy analysis.

References

Alberini, A. (2017), "Measuring the economic value of the effects of chemicals on ecological systems and human health", *OECD Environment Working Papers*, No. 116, OECD Publishing, Paris, https://doi.org/10.1787/9dc90f8d-en. [2]

Almqvist, C. et al. (2008), "Impact of gender on asthma in childhood and adolescence: a GA2LEN review.", *Allergy*, Vol. 63/1, pp. 47-57. [43]

Bateman, I., I. Langford and A. Jones (2001), "Bound and path effects in multiple-bound dichotomous choice contingent valuation", *Resource and Energy Economics*, Vol. 23/3, pp. 191-213. [34]

Belova, A. et al. (2020), "Estimating Lifetime Cost of Illness. An Application to Asthma.", *Ann Am Thorac Soc.*, PMID: 32931705., pp. 1558-1569, https://doi.org/10.1513/AnnalsATS.201910-729OC. [14]

BenMAP (2022), "Environmental Benefits Mapping and Analysis Program Community Edition User's Manual". [22]

Blumenschein, K. and M. Johannesson (1998), "Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma", *Annals of Allergy, Asthma & Immunology*, Vol. 80/(2), pp. 189-194. [19]

Carson, R. and W. Hanemann (2005), *Contingent valuation*, Elsevier B.V. [35]

Centers for Disease Control and Prevention (2020), "Most recent national asthma data", https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm. [28]

Delmas, M. et al. (2021), "Revue des Maladies Respiratoires", Vol. 38/8, pp. 797-806. [49]

Dickie, M. and V. Messman (2004), "Parental altruism and the value of avoiding acute illness: are kids worth more than parents?", *Journal of Environmental Economics and Management*, Vol. 48/3, pp. 1146-1174. [18]

Eurostat (2022), "Mean age of women at childbirth and at birth of first child", https://ec.europa.eu/eurostat/databrowser/product/view/DEMO_FIND. [29]

Global Burden of Disease Collaborative Network (2021), "Global Burden of Disease Study 2019 Results.", *Seattle, United States: Institute for Health Metrics and Evaluation (IHME)*. [3]

Greene, W. and D. Hensher (2003), "A latent class model for discrete choice analysis: contrasts with mixed logit", *Transportation Research Part B*, Vol. 37/8, pp. 681-698. [39]

Hensher, D. and W. Greene (2003), "The Mixed Logit model: The state of practice", *Transportation*, Vol. 30/2, pp. 133-176. [38]

Jaakkola, J. and M. Jaakkola (2006), "Professional cleaning and asthma", *Current opinion in allergy and clinical immunology*, Vol. 6/(2), pp. 85-90. [7]

Kriström, B. (1997), "Spike Models in Contingent Valuation", *American Journal of Agricultural Economics*, Vol. 79/3, pp. 1013-1023. [36]

Krupnick, A. and M. Cropper (1992), "The effect of information on health risk valuations", *Journal of Risk and Uncertainty*, Vol. 5, pp. 29-48. [13]

Lancsar, E. et al. (2007), "Using discrete choice experiments to investigate subject preferences for preventive asthma medication.", *Respirology*, Vol. 12/1, pp. 127-136. [15]

Lloyd, A. et al. (2007), "Patient preferences for asthma therapy: a discrete choice experiment.", *Primary Care Respiratory Journal*, Vol. 16/4, pp. 241-248. [16]

Manski, C. and S. Lerman (1977), "The estimation of choice probabilities from choice based samples", *Econometrica: Journal of the Econometric Society*, pp. 1977-1988. [48]

McFadden, D. (1974), "Conditional Logit Analysis of Qualitative Choice Behavior", *In P. Zarembka (ed.), Frontiers in Econometrics. Academic Press: New York*, pp. 105-142. [37]

Medina-Ramon, M. et al. (2005), "Asthma, chronic bronchitis, and exposure to irritant agents in occupational domestic cleaning: a nested case-control study", *Occupational and environmental medicine,*, Vol. 62/(9), pp. 598-606. [6]

Mitchell, N. (2014), "The changing landscape of technology and its effect on online survey data collection - White paper", *Survey Sampling International*, Retriewed from, https://docplayer.net/21618373-White-paper-the-changing-landscape-of-technology-and-its-effect-on-online-survey-data-collection-by-nicole-mitchell-knowledge-specialist-june-2014.html. [32]

Mourato, S. and G. Shreedhar (2021), "Conducting economic valuation surveys during extreme events", *OECD Environment Working Papers*, No. 187, OECD Publishing, Paris, https://doi.org/10.1787/85477cd9-en. [24]

Navrud, S. (2018), "Assessing the economic valuation of the benefits of regulating chemicals: Lessons learned from five case studies", *OECD Environment Working Papers*, No. 136, OECD Publishing, Paris, https://doi.org/10.1787/9a061350-en. [1]

Nielsen, G. et al. (2007), "Do indoor chemicals promote development of airway allergy?", *Indoor air*, Vol. 17/(3), pp. 236-255. [8]

O'conor, R. and G. Blomquist (1997), "Measurement of consumer-patient preferences using a hybrid contingent valuation method.", *Journal of Health Economics*, Vol. 16/6, pp. 667-683. [17]

OECD (2022), "OECD Economic Outlook,", *OECD Publishing, Paris*, Vol. Volume 2022/Issue 2, https://doi.org/10.1787/f6da2159-en. [46]

OECD (2020), "Education at a glance: Educational attainment and labour-force status (Edition 2020)", *OECD Education Statistics* (database), https://doi.org/10.1787/eeab6253-en (accessed on 26 August 2022). [27]

OECD (2019), "Avoidable mortality (preventable and treatable)", *in Health at a Glance 2019: OECD Indicators, OECD Publishing, Paris*, https://doi.org/10.1787/3b4fdbf2-en. [44]

OECD (2012), "Mortality Risk Valuation in Environment, Health and Transport Policies", *OECD Publishing, Paris*, https://doi.org/10.1787/9789264130807-en. [40]

OECD (2010), "Valuing Environment-Related Health Impacts - with special emphasis on children (VERHI-Children)", *Final report, OECD, Paris*. [42]

OECD and European Union (2022), "Health at a Glance: Europe 2022: State of Health in the EU Cycle", *OECD Publishing, Paris*, https://doi.org/10.1787/507433b0-en. [51]

Priez, F. and C. Jeanrenaud (1999), "Human costs of chronic bronchitis in Switzerland", *Univ. de Neuchâtel Institut de recherches économiques et régionales*. [11]

Quinet, E. (2013), "Prise en compte du développement durable dans l'évaluation des projets: Un point de vue français", *International Transport Forum Discussion Papers, OECD Publishing, Paris*, Vol. No. 2013/31, https://doi.org/10.1787/5jz40rn70xf1-fr. [47]

Quirce, S. and P. Barranco (2010), "Cleaning agents and asthma", *Journal of Investigational Allergology and Clinical Immunology*, Vol. 20/(7), pp. 542-550. [9]

Rao, K., T. Wells and T. Luo (2014), "Speeders in a multi-mode (mobile and online) survey", *MRA'S ALERT! MAGAZINE*, Vol. Fourth Quarter. [33]

Rosenman, K. et al. (2003), "Cleaning products and work-related asthma", *Journal of Occupational and Environmental Medicine*, pp. 556-563. [5]

Scarpa, R. and M. Thiene (2005), "Destination Choice Models for Rock Climbing in the Northeastern Alps: A Latent-Class Approach Based on Intensity of Preferences", *Land Economics*, Vol. 81/3, pp. 426-444. [45]

Śliwczyński, A. et al. (2015), "Epidemiology of asthma in Poland in urban and rural areas, based on provided health care services", *Pneumonol Alergol Pol*, Vol. 83/3, pp. 178-187, https://doi.org/10.5603/PiAP.2015.002. [50]

Smith, D. et al. (1997), "A national estimate of the economic costs of asthma", *American journal of respiratory and critical care medicine*, Vol. 156/3, pp. 787-793. [21]

Survey Sampling International (2013), "Speeding (SSI POV)", *Retrieved from ttp://www.surveysampling.com/ssi-media/Corporate/POVs-2012/Speeding_POV*. [31]

The Global Asthma Network (2022), "The Global Asthma Report", *Int J Tuberc Lung Dis*, Vol. 26, pp. 1-102, https://doi.org/10.5588/ijtld.22.1010. [4]

United Nations Statistics Division (2022), "Live births by age of father", *Demographic Statistics Database*, http://data.un.org/Data.aspx?d=POP&f=tableCode%3a270. [30]

United Nations Statistics Division (2021), "Population by age, sex and urban/rural residence", *Demographic Statistics Database*. [26]

US EPA (2003), "Children's Health Valuation Handbook", *US. EPA, Washington, DC*, http://yosemite1.epa.gov/ee/epa/eed.nsf/3cdbd09d7c867d9785256c9200548b12/6ed3736d44c87a4a85256dc1004da4ac/$FILE/handbook1030.pdf. [41]

Viscusi, W., W. Magat and J. Huber (1991), "Pricing environmental health risks: survey assessments of risk-risk and risk-dollar trade-offs for chronic bronchitis", *Journal of Environmental economics and management*, Vol. 21/1, pp. 32-51. [12]

Winer, R. et al. (2012), "Asthma incidence among children and adults: findings from the Behavioral Risk Factor Surveillance system asthma call-back survey—United States, 2006–2008.", *Journal of Asthma*, Vol. 49/1, pp. 16-22. [23]

World Bank (2019), "World Bank staff estimates based on age/sex distributions of United Nations Population Division's World Population Prospects: 2019 Revision". [25]

Zillich, A. et al. (2002), "Assessment of the relationship between measures of disease severity, quality of life, and willingness to pay in asthma", *Pharmacoeconomics*, Vol. 20/(4), pp. 257-265. [20]

Zock, J., D. Vizcaya and N. Le Moual (2010), "Update on asthma and cleaners", *Current opinion in allergy and clinical immunology*, Vol. 10/(2), p. 114. [10]

Annex A. Additional descriptive statistics

Table A.1. Statistics for key demographics for asthmatic adults by country

	Canada	Czech Rep.	France	Poland	Sweden	UK	US
Age 18-29	23%	24%	25%	26%	26%	24%	13%
Age 30-44	35%	37%	32%	35%	30%	32%	42%
Age 45-59	21%	24%	27%	22%	30%	29%	24%
Age 60+	21%	15%	16%	17%	14%	16%	20%
Low and medium education	52%	72%	49%	58%	60%	42%	42%
High education	48%	28%	51%	42%	40%	58%	58%
Male	36%	52%	53%	45%	44%	47%	45%
Female	63%	48%	47%	55%	56%	52%	55%
Non binary and other	0.3%	0%	0.7%	0.7%	0%	0.9%	0.3%

Table A.2. Statistics for key demographics for parents of an asthmatic child by country

	Canada	Czech Rep.	France	Poland	Sweden	UK	US
Age 18-29	19%	28%	27%	26%	29%	12%	10%
Age 30-44	62%	51%	46%	51%	46%	55%	75%
Age 45-59	18%	20%	25%	21%	24%	32%	14%
Age 60+	1.6%	1.6%	2.1%	2.1%	0.5%	1.0%	0.5%
Low and medium education	47%	65%	48%	48%	49%	41%	17%
High education	53%	35%	52%	52%	51%	59%	83%
Male	42%	63%	56%	38%	58%	51%	63%
Female	57%	38%	44%	61%	42%	49%	38%
Non binary and other	0.5%	0%	0%	1.1%	0%	0%	0%

Table A.3. Status of children for non-asthmatic adults by country

	% sample	No child under 18	Child with asthma	Child without asthma
Canada	15.8%	76.8%	6.1%	17.1%
Czech Rep.	11.5%	61.5%	5.2%	33.4%
France	15.2%	69.6%	5.9%	24.6%
Poland	14.5%	60.5%	4.6%	34.9%
Sweden	14.7%	76.2%	5.2%	18.7%
United Kingdom	15.2%	73.7%	6.3%	19.9%
United States	13.0%	72.8%	4.3%	22.9%
All countries	N = 5 384	70.5%	5.4%	24.0%

Table A.4. Statistics for key demographics for non-asthmatic adults by country

	Canada	Czech Rep.	France	Poland	Sweden	UK	US
Age 18-29	11.90%	16.80%	11.60%	23.40%	11.90%	18.90%	12.80%
Age 30-44	32.30%	32.40%	26.30%	34.00%	24.00%	24.90%	21.70%
Age 45-59	29.00%	31.50%	31.70%	25.40%	32.20%	31.90%	36.30%
Age 60+	26.90%	19.40%	30.40%	17.20%	32.00%	24.30%	29.20%
Low-education	2.60%	21.90%	4.20%	2.00%	5.40%	2.70%	0.30%
Medium education	45.70%	47.70%	41.70%	52.60%	48.40%	44.90%	52.30%
High education	51.70%	30.30%	54.20%	45.30%	46.20%	52.40%	47.40%
Male	42.00%	50.80%	52.10%	52.50%	46.50%	48.10%	43.20%
Female	57.60%	49.20%	47.60%	46.60%	53.20%	51.30%	56.40%
Non binary and other	0.30%	0.00%	0.40%	0.90%	0.30%	0.60%	0.40%

Table A.5. Status of parents of the non-asthmatic children by country

	Canada	Czech Republic	France	Poland	Sweden	United Kingdom	United States	All countries
% sample	10.8%	15.9%	14.6%	20.6%	12.2%	13.2%	12.7%	N = 1 556
Non-asthmatic parent	88.7%	83.9%	90.7%	88.2%	82.6%	82.9%	86.8%	86.4%

Table A.6. Statistics for key demographics for parents of a non-asthmatic child by country

	Canada	Czech Rep.	France	Poland	Sweden	UK	US
Age 18-29	6.0%	13.3%	11.5%	19.3%	11.1%	18.5%	10.7%
Age 30-44	61.9%	55.2%	52.0%	54.5%	45.3%	49.3%	50.3%
Age 45-59	31.0%	28.6%	32.2%	23.1%	38.4%	28.8%	32.5%
Age 60+	1.2%	2.8%	4.4%	3.1%	5.3%	3.4%	6.6%
Low-education	0.0%	18.1%	1.3%	1.9%	4.2%	3.4%	0.5%
Medium education	36.3%	48.8%	40.1%	50.2%	42.1%	34.6%	40.1%
High education	63.7%	33.1%	58.6%	48.0%	53.7%	62.0%	59.4%
Male	35.1%	50.0%	48.9%	44.5%	43.2%	50.7%	45.7%
Female	64.9%	50.0%	50.7%	55.5%	56.8%	49.0%	53.8%
Non binary and other	0.0%	0.0%	0.4%	0.0%	0.0%	0.0%	0.5%

Table A.7. Share of serial status quo for non-asthmatic adults and parents of the non-asthmatic children by country

	Canada	Czech Republic	France	Poland	Sweden	United Kingdom	United States	All countries
Non-asthmatic adults	26.3%	11.6%	19.6%	14.0%	22.8%	33.1%	20.1%	21.5%
Parents of non-asthmatic children	20.2%	13.3%	15.9%	15.0%	19.5%	24.9%	19.3%	17.8%

Table A.8. Share of asthmatic adults and parents of an asthmatic child who thought they could save on medical cost by reducing asthma severity

	Canada	Czech Republic	France	Poland	Sweden	UK	United States	Total
Asthmatic adults	28%	30%	37%	27%	42%	28%	53%	35%
Parents of an asthmatic child	37%	33%	42%	37%	31%	31%	59%	39%

Table A.9. Proportion of respondents considering that a risk reduction of getting asthma leads to a reduction of their medical bills

	Canada	France	Poland	Sweden	United Kingdom	United States	Total
Share of adults who thought about saving on medical bills	25.4%	26.7%	33.6%	18.0%	13.9%	35.8%	25.3%
Share of parents who thought about saving on medical bills	34.5%	22.0%	39.6%	19.5%	26.3%	42.6%	31.4%

Note: Non-asthmatic adults, all countries without Czech Republic.

Annex B. Core principles of survey analysis

Detect potentially problematic responses

1. Generate a dummy variable for people failing the probability test
2. Speeder management: Generate one dummy variable for *survey* speeders and one dummy for *valuation* speeder. A respondent taking less than 48% of the median time is a speeder (ISS definition). Median values should be country specific to account for difference in languages that impact reading time.
3. Generate two dummies variable for distracted respondents: respondents who took an abnormally long time to respond:
   a. 48% longer than the median *survey* time,
   b. 48% longer than the median *valuation* time.
4. Optional. Generate a dummy variable for straightliners: when survey respondents give identical (or nearly identical) answers to items in a battery of questions using the same response scale. Note that there should not be any of them in the data sent by the internet panel provider.
5. Optional. Generate a dummy variable for respondents having incoherent answers:
   a. E.g. mismatch between the number of children, number of people in the household, or year of youngest child
6. Generate a dummy variable for unrealistic max WTP in open-ended question
7. Generate a dummy variable for probability test failers
8. Generate a dummy variable for protesters. This varies between endpoints. For example, in the asthma survey, people who disagree with the description of asthma provided in the survey or who are very doubtful that the information provided by the survey is correct or who thought they could just lower consumption of cleaning products can be considered as protesters.
9. Generate a dummy variable for respondents stating high co-benefits
10. Generate a dummy variable for consequentiality (real life debrief)
11. Optional. Read written responses to open ended questions to detect potentially problematic responses
12. Optional. Compute number of problematic responses to debriefing:
    a. that could overestimate WTP
    b. that could underestimate WTP
    c. that could go in either direction or a non-directional

Screen out problematic responses

- Baseline:
  - Exclude survey and valuation speeder (reinforced compared to Ipsos)
  - Exclude straightliners (already done by Ipsos)
  - Exclude respondents who fail the probability test (not applicable for IQ loss)
  - Keep pilot respondents if the survey design is the same even if parameters (such as bid levels) changed except if the changes are significant
  - Keep co-benefiters
  - Keep protesters to have a conservative estimate
  - Keep distracted respondents
  - Variations to perform as robustness checks:
- Optional robustness: stricter screening
  - Exclude survey and valuation speeder (same as option A)
  - Exclude straightliners (same as option A)
  - Exclude respondents who fail the probability test (same as option A)
  - Keep pilot respondents if the survey design is the same even if parameters (such as bid levels) changed (same as option A)
  - Keep co-benefiters (same as option A)
  - Exclude protesters because no does not mean true zero
  - Exclude distracted respondents
  - Exclude pilot respondents if pilot parameters differ too much (case of VLBW)
- Optional: exclude respondents that took more than 12h to complete the survey

Provide information on the sample of respondents

1. Compute summary statistics to describe the screened sample
   - Put main descriptive in body of text
   - And other e.g. country level in the appendix
2. Check that achieved quotas (age, education, location, gender) and income distribution in the screened sample are consistent with available population statistics (target quotas) at the country level (from OECD.Stat and Eurostat).
3. For each country separately, compute post-stratification weights to reweight later the observations through an iterative proportional fitting procedure (raking algorithm) using the following strata:
   - Gender × Age: (1) males aged 18-24; (2) males aged 25-34; (3) males aged 35-39; (4) males aged 40-44; (5) males aged 45-65; (6) females aged 18-24; (7) females aged 25-34; (8) females aged 35-39; (9) females aged 40-44.
   - Educational level: (1) low, (2) medium, and (3) high
   - Geographic region: country-specific NUTS 2 regions
4. It is important to consider the efficiency of the weights, such that ideally the overall weighting efficiency remains above a certain value to avoid any significant impact on the

effective sample sizes obtained and, consequently, on the statistical power of the analyses conducted. Weighting efficiency can be further improved by collapsing weighting cells and capping weights at each of the steps to reduce the impact on the variance of the final weights. At the end of each iteration of the algorithm, any weights larger than 3.0 or lower than 1/3 should be automatically set to equal this cap.

Analyse responses to the valuation questions after baseline screening

1. Compute the DBDC response matrix for both the pooled dataset and each country of the dataset
2. Scope analysis:
   - Verify that the share of yes response decreases with the cost to be paid
   - Verify that the share of yes response increases with the risk reduction offered
3. Analyse written (open-ended) questions:
   - Use examples to illustrate the thinking of respondents if they were asked why they made their choice
   - Optional. Check consistency between OE and DBDC responses
4. As a preliminary step, regress SBDC (response to first dichotomous choice) on income, bid amount, baseline risk (if relevant) and risk reduction using a logit model
5. Optional. Try to find determinants of no-no and yes-yes responses using responses to debriefing questions

Compute harmonised variables

1. Compute continuous income level in USD PPP[23] based on unequivalised income range selected by the respondents:
   - Average of each interval
   - 0.5 lowest interval and 1.5 highest interval
2. Predict missing income using the following strategy
   - Generate the following dummies
     - Missing income dummy equal to 1 if the respondent did not provide income information
     - Couple dummy equals 1 if the respondent is married or have a partner
     - Employed dummy equals 1 if the respondent is in one of the following situations:
       - employed full-time
       - self employed
       - military
       - Own business manager

[23] This is OECD standard. PPS is the technical term used by Eurostat for the common currency in which national accounts aggregates are expressed when adjusted for price level differences using PPPs. Thus, PPPs can be interpreted as the exchange rate of the PPS against the euro.

  - Part time dummy equals 1 if the respondent is employed part time
  - Retired dummy equals 1 if the respondent is retired
  - Replace employed and part time dummies by 0 if they are missing
  - Replace retired dummy by 1 if it is missing and the person is aged 60 or more or by 0 if it is missing and the person is younger than 60 years old.
- For each surveyed country separately, run the OLS regression of log(income) on age dummies, high education dummy, female dummy, couple dummy, number of persons in the household, employed dummy, part time dummy and retired dummy. For surveys targeting couples planning to have children, do not include couple dummy nor retired dummy that are naturally omitted since perfectly colinear.
- Predict income based on the regressions
- Replace missing income with predicted value in the main dataset

3. Compute one dummy variable for each age category
4. Compute a variable for education using Ipsos's low, medium and high category (directly available)
5. For all countries except the United States, compute bid level in USD PPP equivalent using OECD data on PPP for actual individual consumption. Because of rounding after currency conversion, respondents in non-US countries had bid levels that are slightly different than the bid levels seen by US respondents. Reconverting actual bid levels to USD PPP equivalent allows to obtain a more precise bid amount.

Apply a standard specification

1. Baseline:
   - All surveys: intercept, female, age, kids02, category dummies, log(income), missing income dummy, low, medium, high education dummies, baseline risk (if relevant), risk reduction
   - Add country dummies interacted by the post stratification weights to account for the difference between target and achieved sample quotas. This is similar to—albeit less complex than—the correction method for choice-based samples proposed by Manski and Lerman (1977[48]). Do not add country dummies to these interactions to avoid multi collinearity.
   - Add the number of children for fertility loss and VLBW
2. Robustness checks:
   - Health augmentation: own health perception, know someone having the condition, lifestyle, covid
   - Run the estimation without the missing income dummy.

Estimate average and median WTP based on DBDC

1. Estimator: DBDC or SBDC:
   - Baseline: interval-data maximum likelihood estimator using DBDC
   - Robustness check: Estimate WTP based on SB choice with logit model to compare to DB estimate
2. Distribution of the error:

- Baseline (preferred to allow comparison across endpoints): Weibull. The Weibull distribution has desirable characteristics. Specifically, this specification offers a flexible survival function which mimics other distributional forms quite well, and thanks to its shorter right tail it typically performs better than the log-normal distribution (Carson and Hanemann, 2005[35]).
- Robustness checks:
  - Non-parametric: Turnbull (e.g. Kaplan-Meier)
  - Basic parametric: normal, log normal, logistic, log logistic
  - Identify estimator with the lowest Akaike information criterion ($AIC = 2k - 2\ln\hat{L}$)

3. Spike configuration:
   - Baseline: use spike configuration (Kriström, 1997[36]; Carson and Hanemann, 2005[35]) if the spike variable is higher or equal to 5%. In other words, use spike when the average probability that people are indifferent to the valued item is higher or equal to 5%. Spike configuration can still be used if spike is lower than 5% but close to it. Spike is less likely to be relevant when people that have a priori no preference for the good are screened out by design. This is the case of the infertility and VLBW where only people planning to have a child over the next years were able to respond to the survey.
   - Robustness check: Compare estimates using spike and without using spike.
4. Compute WTP and VSC on pooled dataset based on a simple model with constant, country dummies interacted with weights and risk reduction as the only covariates using the following formulas:
   - Baseline: $\widehat{VSC} = \frac{1}{n}\sum_i \widehat{VSC_i}$ where $\widehat{VSC_i} = \widehat{WTP_i}/RR_i$ and $\widehat{WTP_i}$ is the individual mean WTP (truncated at the maximum bid with adjustment)
   - Robustness check (optional): Compute average WTP at sample mean: $\overline{\widehat{WTP}} = \widehat{b_0} + \widehat{b_1}\overline{RR} \rightarrow \widehat{VSC} = \overline{\widehat{WTP}}/\overline{RR}$
5. Compute WTP and VSC for each country based on the ***pooled*** regression estimated above. Do not use separate country-level regressions to generate country-level WTP and VSC as indicated in the previous version. Using the pooled model allows to capture the "cultural" differences between the countries (by also taking into account the fact that the sample is not perfectly representing the population in the country), by multiplying the country dummies with the weights, and using this as a coefficient to predict the values in each country. The pooled approach also increases dramatically the statistical power.
6. Perform the estimation using the standard specification defined above to test determinants of WTP:
   - Assess scope sensitivity:
     - Inference of the risk reduction coefficient
     - Optional. Estimate WTP for different risk reduction separately
   - Estimate income elasticity by simulating an increase in income by 1% for all respondents.
     - Increase income of all respondents by 1% before computing individual WTP. This relies on the same estimates derived from original data.

- Compute the new mean of the individual mean WTP (truncated at the maximum bid with adjustment)
- The elasticity is equal to this % change between this new mean and the baseline mean WTP.

- Other effects using the regressors of the specification: age, gender, etc.

Derive central value and range of VSC for pooled dataset and each country

1. Estimate central value (mean VSC) using the baseline approach. The central value should be clearly identified for regulators to choose.
2. Clearly present country-specific values as recommended values because they can be directly use in cost benefit analyses.
3. Provide pooled (all countries) mean VSC for information.
4. Provide pooled and country specific median WTP and VSC in the appendix
5. Provide an example of how the VSC can be used in CBA.
6. Compare WTP and VSC with magnitude of available WTP, QALY and Cost of Illness estimates from the literature for similar endpoints.

Prepare and share your code

1. Baseline: Prepare your code in R because it is free and more flexible (see dbchoice and dbspike packages). In contrast, only interval data ML estimators based on normal distribution are directly available for Stata (intreg, doubleb). In the long run, it is planned to make the code of the working paper publicly available.
2. Comment your code sufficiently so that a third person can run your code from scratch.
3. Share your code in shared folders.

Annex C. Additional estimations

Table C.1. Estimation of WTP to reduce asthma severity with all baseline severity levels

	Adult		Childhood	
	Odd ratios	Marginal effect (baseline = mild) USD per year	Odd ratios	Marginal effect (baseline = mild) USD per year
Has mild plus asthma (0/1)	0.083	+50	0.244*	+274
	(0.067)		(0.096)	
Has moderate asthma (0/1)	0.474***	+359	0.348***	+413
	(0.065)		(0.091)	
Has moderate plus asthma (0/1)	0.636***	+530	0.488**	+626
	(0.132)		(0.187)	
Has severe asthma (0/1)	0.573*	+460	0.488	+626
	(0.229)		(0.414)	
Log(Cost)	-0.533***		-0.447***	
	(0.012)		(0.015)	
Spike	0.042***		0.050***	
	(0.003)		(0.005)	
Observations	2 194		1 339	
Country dummies	No		No	
Country dummies x weights	Yes		Yes	
Log-likelihood	-3 204		-1 807	
LR statistics	108		66	
AIC	6 435		3 640	
BIC	6 509		3 708	
Mean WTP (USD per year over 10 years) for one-step reduction in severity				
Actual severity levels in the sample	536		949	
Assuming all respondents have mild	381		705	
Assuming all respondents have mild plus	431		979	
Assuming all respondents have moderate	740		1 118	
Assuming all respondents have moderate plus	911		1 331	
Assuming all respondents have severe	841		1 331	

Note: Signif. codes: '***' 0.001 '**' 0.01 '*' 0.05 '+' 0.1 ' ' 1. The baseline estimation corresponds to a maximum likelihood estimation of the joint probabilities assuming a Weibull distribution with a spike configuration. All columns exclude very slow respondents as well as speeders. Base group: mild asthmatic, American, aged 18-29, male with low and medium education. The intercept, country dummies and country dummies interacted with the sampling weight are included as regressors but not reported in the table for clarity.

Table C.2. The determinants of the willingness to pay to reduce adult asthma severity, without missing income dummy

Has mild plus or moderate asthma (0/1)	0.216***
	(0.056)
Has moderate plus or severe asthma (0/1)	0.575***
	(0.120)
Female (0/1)	-0.173***
	(0.120)
Aged 30-44 (0/1)	-0.181*
	(0.077)
Aged 45-59 (0/1)	-0.283***
	(0.078)
Aged 60+ (0/1)	-0.237**
	(0.090)
Log(Income)	0.245***
	(0.040)
High education (0/1)	0.125*
	(0.058)
Health expenditure out of my pocket (0/1)	0.192*
	(0.095)
Health perceived below average (0/1)	-0.048
	(0.066)
Health perceived above average (0/1)	0.049
	(0.064)
Not diagnosed with chronic diseases (0/1)	-0.220***
	(0.060)
Was diagnosed with COVID-19 (0/1)	0.077
	(0.060)
Relative was diagnosed with COVID-19 (0/1)	0.066
	(0.053)
Log(Cost)	-0.540***
	(0.012)
Spike	0.041***
	(0.003)
Observations	2 194
Country dummies x sample weights	Yes
Log-likelihood	-3 165
LR statistics	186
AIC	6 376
BIC	6 507
Mean WTP truncated at the maximum bid with adjustment (USD per year over 10 years)	554
Median WTP (USD per year over 10 years)	229

Note: Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '+' 0.1 ' ' 1. The baseline estimation corresponds to a maximum likelihood estimation of the joint probabilities assuming a Weibull distribution with a spike configuration. All columns exclude very slow respondents as well as speeders. Base group: mild asthmatic child, American, male with non-asthmatic parent. Country dummies interacted with the sampling weight are included as regressors but not reported in the table for clarity. [a] For income, the marginal effect equals the increase in mean WTP due to an increase of average income by USD 500 per month.

Table C.3. The determinants of the willingness to pay to reduce childhood asthma severity, without missing income dummy

Child has mild plus or moderate asthma (0/1)	0.190*
	(0.088)
Child has moderate plus or severe asthma (0/1)	0.378*
	(0.182)
Child asthma is completely controlled (0/1)	-0.216**
	(0.083)
Female child (0/1)	-0.171*
	(0.076)
Child age	-0.020**
	(0.008)
Asthmatic parent (0/1)	-0.024
	(0.079)
Log(Income)	0.327***
	(0.058)
Health expenditure out of my pocket (0/1)	-0.061
	(0.141)
Child health perceived as good or very good (0/1)	0.276**
	(0.094)
Child health perceived above average (0/1)	-0.114
	(0.081)
Child diagnosed with other chronic diseases (0/1)	0.326***
	(0.095)
Log(Cost)	-0.458***
	(0.016)
Spike	0.047***
	(0.005)
Observations	1 339
Country dummies x sample weights	Yes
Log-likelihood	-1 775
LR statistics	132
AIC	3 589
BIC	3 693
Mean WTP truncated at the maximum bid with adjustment (USD per year over 10 years)	1 002
Median WTP (USD per year over 10 years)	516

Note: Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '+' 0.1 ' ' 1. The baseline estimation corresponds to a maximum likelihood estimation of the joint probabilities assuming a Weibull distribution with a spike configuration. All columns exclude very slow respondents as well as speeders. Base group: mild asthmatic child, American, male with non-asthmatic parent. Country dummies interacted with the sampling weight are included as regressors but not reported in the table for clarity. [a] For income, the marginal effect equals the increase in mean WTP due to an increase of average income by USD 500 per month.

Table C.4. Country-level parametric estimations of WTP to reduced adult asthma severity

	Canada	Czech Republic	France	Poland	Sweden	United Kingdom	United States
Has mild plus or	0.426**	0.144	0.266+	0.177	0.106	0.555***	0.408**
moderate asthma (0/1)	(0.142)	(0.148)	(0.144)	(0.157)	(0.132)	(0.140)	(0.154)
Has moderate plus	1.009**	0.376	0.605*	0.506	0.719+	0.637*	0.526*
or severe asthma (0/1)	(0.331)	(0.338)	(0.308)	(0.317)	(0.393)	(0.277)	(0.260)
Log(Cost)	-0.568***	-0.593***	-0.540***	-0.560***	-0.517***	-0.465***	-0.524***
	(0.034)	(0.037)	(0.033)	(0.037)	(0.029)	(0.027)	(0.034)
Sample weight	0.372*	-0.549**	-0.168	-0.205	-0.014	-0.053	-0.112
	(0.166)	(0.201)	(0.142)	(0.238)	(0.094)	(0.172)	(0.117)
Spike	0.044***	0.023***	0.046***	0.031***	0.052***	0.069***	0.039***
	(0.009)	(0.005)	(0.010)	(0.007)	(0.010)	(0.012)	(0.008)
Observations	288	343	294	293	334	323	319
Log-likelihood	-419	-464	-441	-411	-507	-497	-451
LR statistics	22	10	8	3	4	19	11
AIC	849	937	893	831	1 025	1 004	914
BIC	867	956	911	849	1 044	1 023	933
WTP (USD per year over 10 years)							
Mean WTP (truncated at the maximum bid with adjustment)	374	672	414	608	439	492	648
Median WTP (mean of median)	150	323	154	262	148	156	259

Note: Signif. codes: '***' 0.001 '**' 0.01 '*' 0.05 '+' 0.1 ' ' 1. The baseline estimation corresponds to a maximum likelihood estimation of the joint probabilities assuming a Weibull distribution with a spike configuration. All columns exclude very slow respondents as well as speeders. Base group: mild asthmatic. Intercepts are not included in the table for clarity.

Table C.5. Country-level parametric estimations of WTP to reduced childhood asthma severity

	Canada	Czech Republic	France	Poland	Sweden	United Kingdom	United States
Has mild plus or	0.645**	0.142	0.348+	-0.093	0.244	0.647***	0.009
moderate asthma (0/1)	(0.204)	(0.213)	(0.205)	(0.216)	(0.189)	(0.196)	(0.255)
Has moderate plus	0.427	1.302+	0.824	0.360	-0.620+	0.658	0.783+
or severe asthma (0/1)	(0.383)	(0.732)	(0.601)	(0.599)	(0.355)	(0.428)	(0.463)
Log(Cost)	-0.482***	-0.485***	-0.442***	-0.439***	-0.455***	-0.438***	-0.421***
	(0.043)	(0.046)	(0.039)	(0.042)	(0.037)	(0.037)	(0.042)
Sample weight	-0.256	-0.202	-0.450**	-0.126	-0.375*	-0.400	-0.137
	(0.234)	(0.172)	(0.143)	(0.147)	(0.169)	(0.320)	(0.113)
Spike	0.044***	0.034***	0.059***	0.046***	0.060***	0.060***	0.042***
	(0.012)	(0.010)	(0.015)	(0.013)	(0.014)	(0.014)	(0.012)
Observations	188	192	192	188	193	194	192
Log-likelihood	-255	-241	-259	-247	-280	-265	-246
LR statistics	12	7	14	1	11	14	6
AIC	521	492	528	504	570	541	502
BIC	537	509	544	520	587	557	518
WTP (USD per year over 10 years)							
Mean WTP (truncated at the maximum bid with adjustment)	809	1 070	762	1 035	682	799	1 489
Median WTP (mean of median)	361	700	337	488	246	327	994

Note: Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '+' 0.1 ' ' 1. The baseline estimation corresponds to a maximum likelihood estimation of the joint probabilities assuming a Weibull distribution with a spike configuration. All columns exclude very slow respondents as well as survey and valuation speeders. Base group: mild asthmatic. Intercepts are not included in the table for clarity.

Table C.6. WTP to reduce asthma severity in adults and medical cost

	Baseline	Medical cost saving
	(1)	(2)
Has mild plus or moderate asthma (0/1)	0.308***	0.271***
	(0.054)	(0.054)
Has moderate plus or severe asthma (0/1)	0.619***	0.621***
	(0.116)	(0.117)
Thought could save on medical expenditure (0/1)		0.553***
		(0.059)
Log(Cost)	-0.530***	-0.538***
	(0.012)	(0.012)
Spike	0.043***	0.041***
	(0.003)	(0.003)
Observations	2 194	2 194
Country dummies	No	No
Country dummies x weights	Yes	Yes
Log-likelihood	-3 218	-3 170
LR statistics	81	176
AIC	6 457	6 364
BIC	6 520	6 433
WTP (USD per year over 10 years)		
Mean WTP (truncated at the maximum bid with adjustment)	529	556
Median WTP (mean of median)	200	230

Note: Signif. codes: '***' 0.001 '**' 0.01 '*' 0.05 '+' 0.1 ' ' 1. The baseline estimation corresponds to a maximum likelihood estimation of the joint probabilities assuming a Weibull distribution with a spike configuration. All columns exclude very slow respondents as well as speeders. Base group: mild asthmatic, American, aged 18-29, male with low and medium education. The intercept, country dummies and country dummies interacted with the sampling weight are included as regressors but not reported in the table for clarity.

Table C.7. WTP to reduce asthma severity in children and medical cost

	Baseline	Medical cost saving
	(1)	(2)
Child has mild plus or moderate asthma (0/1)	0.302***	0.287***
	(0.078)	(0.078)
Child has moderate plus or severe asthma (0/1)	0.486**	0.434*
	(0.174)	(0.174)
Thought could save on medical expenditure (0/1)		0.413***
		(0.081)
Log(Cost)	-0.447***	-0.451***
	(0.015)	(0.015)
Spike	0.050***	0.049***
	(0.005)	(0.005)
Observations	1 339	1 339
Country dummies	No	No
Country dummies x sample weights	Yes	Yes
Log-likelihood	-1 808	-1 794
LR statistics	65	93
AIC	3 637	3 612
BIC	3 695	3 674
WTP (USD per year over 10 years)		
Mean WTP (truncated at the maximum bid with adjustment)	948	976
Median WTP (mean of median)	416	466

Note: Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '+' 0.1 ' ' 1. The baseline estimation corresponds to a maximum likelihood estimation of the joint probabilities assuming a Weibull distribution with a spike configuration. All columns exclude very slow respondents as well as speeders. Base group: mild asthmatic child, American, male with non-asthmatic parent. Country dummies and country dummies interacted with the sampling weight are included as regressors but not reported in the table for clarity.

Annex D. Additional WTP values

Table D.1. Recommended Median WTP values for a one-step reduction in asthma severity by surveyed country

USD PPP per year	Adult asthma	Adult mild asthma	Adult mild plus or moderate asthma	Adult moderate plus or severe asthma	Childhood asthma	Childhood mild asthma	Childhood mild plus or moderate asthma	Childhood moderate plus or severe asthma
Canada	150	100	180	320	330	200	400	600
Czech Republic	280	180	320	570	500	300	580	880
France	150	100	180	320	300	170	340	510
Poland	250	160	280	500	530	330	650	980
Sweden	170	110	200	350	290	170	340	510
United Kingdom	160	100	180	330	270	160	320	490
United States	230	140	250	450	690	370	730	1 110

Country currency per year	Adult asthma	Adult mild asthma	Adult moderate asthma	Adult severe asthma	Childhood asthma	Childhood mild asthma	Childhood mild plus or moderate asthma	Childhood moderate plus or severe asthma
Canada (CAD)	190	130	230	410	420	260	510	770
Czech Republic (CZK)	3 400	2 200	3 900	6 900	6 000	3 600	7 000	10 600
France (EUR)	110	70	130	240	220	130	250	380
Poland (PLN)	400	300	500	800	900	500	1 100	1 600
Sweden (SEK)	1 600	1 000	1 900	3 300	2 700	kr.1 600	3 200	4 800
United Kingdom (GBP)	120	70	130	250	200	120	240	370
United States (USD)	230	140	250	450	690	370	730	1 110

Note: Values are rounded for clarity. The conversions are done using Purchasing Power Parities for actual individual consumption of 2019 since it was used to convert bid levels across countries. Data comes from the OECD Dataset: PPPs and exchange rates as of January 2022.

Table D.2. Recommended median values of a statistical case of asthma by surveyed country

	USD PPP		National currency	
Country	Adult asthma	Childhood asthma	Adult asthma	Childhood asthma
Canada	52 000	59 000	CAD 70 000	CAD 80 000
France	39 000	70 000	EUR 30 000	EUR 50 000
Poland	54 000	66 000	PLN 90 000	PLN 110 000
Sweden	53 000	87 000	SEK 500 000	SEK 820 000
United Kingdom	54 000	74 000	GBP 40 000	GBP 60 000
United States	54 000	94 000	USD 50 000	USD 90 000

Note: Values are rounded at the ten thousand for clarity. The conversions are done using Purchasing Power Parities for actual individual consumption of 2019 since it was used to convert bid levels across countries. Data comes from the OECD Dataset: PPPs and exchange rates as of January 2022.

Annex E. Comparison of WTP estimates with previous studies

Table E.1. WTP estimates for a reduction in asthma severity in comparable studies

Study	Type	Population	Country or group of countries	Total sample size	Reduction in severity	WTP per year derived from the study	WTP in USD_{2022} per year adjusted for GDP per capita growth and inflation
Present study	SP	Adult	7 OECD countries	2 194	Mild to very mild	USD_{2022} 381	381
Present study	SP	Adult	7 OECD countries	2 194	Mild plus to very mild	USD_{2022} 812	812
Zillich et al. (2002[19])	SP	Adult	United States	100	Complete relief from mild	USD_{2002} 1 080	1 895
Dickie and Messman (2004[16])	SP	Adult	United States	284	Complete relief from mild	USD_{2004} 1 901	3 132
Present study	SP	Adult	7 OECD countries	2 194	Moderate to very mild	USD_{2022} 1 552	1 552
Present study	SP	Adult	7 OECD countries	2 194	Moderate plus to very mild	USD_{2022} 2 463	2 463
Zillich et al. (2002[19])	SP	Adult	United States	100	Complete relief from moderate	USD_{2002} 1 572	2 758
Present study	SP	Adult	7 OECD countries	2 194	Severe to very mild	USD_{2022} 3 304	3 304
Zillich et al. (2002[19])	SP	Adult	United States	100	Complete relief from severe	USD_{2002} 3 972	6 969
Dickie and Messman (2004[16])	SP	Adult	United States	284	Complete relief from severe	USD_{2004} 3 224	5 311
O'Conor and Blomquist (1997[15])	SP	Adult	United States	146	Complete relief	USD_{1997} 1 500	3 042
Belova et al. (2020[12])	COI	Adult	United States	9 409	Complete relief	USD_{2010} 4 000[a]	5 659
Present study	SP	Child	7 OECD countries	1 339	Mild to very mild	USD_{2022} 705	705
Present study	SP	Child	7 OECD countries	1 339	Mild plus to very mild	USD_{2022} 1 684	1 684
Dickie and Messman (2004[16])	SP	Child	United States	284	Complete relief from mild	USD_{2004} 3 620	6 086
Present study	SP	Child	7 OECD countries	1 339	Moderate to very mild	USD_{2022} 2 802	2 802
Present study	SP	Child	7 OECD countries	1 339	Moderate plus to very mild	USD_{2022} 4 133	4 133
Present study	SP	Child	7 OECD countries	1 339	Severe to very mild	USD_{2022} 5 464	5 464
Dickie and Messman (2004[16])	SP	Child	United States	284	Complete relief from severe	USD_{2004} 6 144	10 330
Belova et al. (2020[12])	COI	Child	United States	9 409	Complete relief	USD_{2010} 4 200[a]	6 048
Present study	SP	Adult	7 OECD countries	2 194	Severe to mild	USD_{2022} 2 923	2 923
Zillich et al. (2002[19])	SP	Adult	United States	100	Severe to mild	USD_{2002} 3 665	6 430
Dickie and Messman (2004[16])	SP	Adult	United States	284	Severe to mild	USD_{2004} 1323	2 180

Present study	SP	Child	7 OECD countries	1 339	Severe to mild	USD_{2022} 4 759	4 759
Dickie and Messman (2004[16])	SP	Child	United States	284	Severe to mild	USD_{2004} 2 525	4 245

Note: [a] This includes medical cost and lost earnings. SP means stated preferences and COI means cost of illness. Based on the results of Table C.1 and assuming that the one-step WTP are additive, the WTP equivalent for a reduction of adult asthma severity from severe to mild estimated in the present study equals USD_{2022} 2 923 per year. Substracting WTP for a cure of mild asthma from WTP for a cure of severe asthma, it is possible to compute the WTP equivalent for a reduction of adult asthma severity from severe to mild in Zillich et al. (2002[20]) and Dickie and Messman (2004[18]). Zillich et al. (2002[20]) do not value childhood asthma severity reduction. Estimates from previous studies are transferred over time using equation (23), an income elasticity of 0.3 for adult asthma and an income elasticity of 0.4 for childhood asthma as reported in the present paper. Price indices data come from the OECD Consumer price indices (CPIs) dataset and GDP per capita data come from the OECD Economic outlook (2022[46]).

Table E.2. Value of a statistical case of asthma and other diseases in comparable studies

Study	Type	Population	Country or group of countries	Total sample size	Risk	Value of a statistical case (VSC) derived from the study	VSC in USD_{2022} adjusted for GDP per capita growth and inflation
Present study	SP	Adult	6 OECD countries	4 764	Asthma	USD_{2022} 283 000[a]	283 000
Present study	SP	Adult	United States	702	Asthma	USD_{2022} 330 000	330 000
Viscusi et al. (1991[11])	SP	Adult	United States	389	Chronic bronchitis	USD_{1991} 457 000	1 016 000
Krupnick and Cropper (1992[12])	SP	Adult	United States	578[b]	Chronic lung disease[24]	USD_{1992} 1 438 000	3 099 000
Priez and Jeanrenaud (1999[10])	SP	Adult	Switzerland	757	Chronic bronchitis	CHF_{1999} 38 500	21 355
Belova et al. (2020[12])	COI	Adult	United States	9 409	Asthma	USD_{2010} 32 925[c]	44 736
Present study	SP	Child	6 OECD countries	1 308	Asthma	USD_{2022} 430 000[a]	430 000
Present study	SP	Child	United States	197	Asthma	USD_{2022} 610 000	610 000
Belova et al. (2020[12])	COI	Child	United States	9 409	Asthma	USD_{2010} 41 267[d]	56 367

Note: [a] simple average across the 6 OECD countries reported in Table 6.2. [b] including the 389 respondents from Viscusi et al. (1991[12]). [c] Average of the present discounted value of the lifetime cost stream for an asthma case assuming a 3% discount rate for adult aged 20 and above reported by Belova et al. (2020[14]). [d] Average of the present discounted value of the lifetime cost stream for an asthma case assuming a 3% discount rate for adult aged between 0 and 19 reported by Belova et al. (2020[14]). Estimates from previous studies are transferred over time using equation (23), an income elasticity of 0.07 for adult asthma and an income elasticity of 0.1 for childhood asthma as reported in the present paper.

[24] According to the national cancer institute, chronic lung disease is a type of disorder that affects the lungs and other parts of the respiratory system. Types of chronic lung disease include asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, asbestosis, pneumonitis, and other lung conditions.

Valuing a reduction in the risk and severity of asthma

Asthma is a non-communicable and non-curable lung disease that affects 1 in 10 children and 4 in 100 adults worldwide and that is associated with an array of environmental contaminants and chemicals. Many of these hazards are subject to regulation, or may be considered for regulation, in order to reduce exposures and prevent human health risks. However, valuation estimates for a reduction in the risk and severity of asthma that can be used in cost-benefit analyses are few, particularly willingness-to-pay estimates. In particular, the available information on willingness-to-pay (WTP) to avoid asthma or reduce its severity is incomplete and does not provide estimates compatible with welfare economic theory. This paper is part of the series of large scale WTP studies resulting from the Surveys to elicit Willingness to pay to Avoid Chemicals related negative Health Effects (SWACHE) project that intends to improve the basis for doing cost benefit analyses of chemicals management options and environmental policies in general. The present paper offers values suitable for use in cost-benefit analyses of the willingness to pay for reduced severity of asthma attacks in adults and children and in reduced probability of getting asthma for these two population groups, all in the context of reducing chemical exposures, and covering populations in seven OECD countries: Canada, Czech Republic, France, Poland, Sweden, the United Kingdom and the United States. This paper applies two stated preference methods: the contingent valuation methods for eliciting willingness to pay (WTP) for reduced asthma severity and choice experiments for eliciting WTP for reduced probability of getting asthma of various severities. The context for such elicitations was a set of household products that contain fewer hazardous chemicals than what is currently available in supermarkets but are more expensive.

Asthma can be classified in five severity steps: mild, mild plus, moderate, moderate plus and severe depending on the intensity and frequency of symptoms, their impacts on the quality of life and the risk of hospitalisation and complications. The study finds that the WTP for reducing adult asthma severity by one step, e.g. from "moderate plus" to "moderate", is USD_{2022} Purchasing Power Parity-adjusted 529 per year on average The parental WTP for reducing asthma severity in their children is on average 1.8 time higher than their WTP for themselves at USD_{2022} 948 per year. WTP for a reduction in asthma severity varies between USD_{2022} PPP 430 per year for Canada and USD_{2022} PPP 770 per year for Sweden for adult asthma, and between USD_{2022} PPP 740 for the United Kingdom and USD_{2022} PPP 1 300 for the United States for childhood asthma. The mean Value of a Statistical Case (VSC) of adult asthma which would be applied to predictions of new cases of asthma avoided by a regulation equals USD_{2022} 280 000 while the mean VSC equals USD_{2022} 430 000. Country-specific VSC of asthma vary between USD_{2022} PPP 200 000 for the United Kingdom and USD_{2022} PPP 370 000 for Poland in the case of adult asthma and vary between USD_{2022} PPP 350 800 for Canada and USD_{2022} PPP 610 000 for the United States in the case of childhood asthma.

Recommended citation: Appéré, G., D. Dussaux, A. Krupnick and M. Travers (2023), *"Valuing a reduction in the risk and severity of asthma: A large scale multi-country stated preference approach"*, OECD Environment Working Papers, No. 218, OECD Publishing, Paris, https://doi.org/10.1787/f289d29e-en.

The OECD SWACHE project has received the financial assistance of the European Union. The views expressed herein can in no way be taken to reflect the official opinion of the European Union.

For more information:

https://oe.cd/SWACHE

@OECD_ENV

OECD Environment

OECD
BETTER POLICIES FOR BETTER LIVES